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CHAPTER I 
 
INTRODUCTION 
 
The Insulin Resistance Epidemic 
Obesity and insulin resistance 
Starting at various points during the middle of the 20th century, humans got progressively 
fatter. In 1960, when the Center for Disease Control first started collecting data on obesity rates, 
just 13% of adults were obese (Body Mass Index > 30 kg/m2) (1). The most recent National 
Health and Nutrition Examination Survey indicates that 40% of adults in the United States are 
now obese (2). This rapid rise in obesity rates has occurred not only in the United States but also 
worldwide (3). Perhaps even more concerning is that obesity has become a pediatric disorder, as 
19% of children under the age of 18 are obese (2). Obesity has clearly reached pandemic 
proportions. The causes of obesity are multi-faceted. While obesity certainly has a strong 
heritable component, genetics alone cannot explain the rapid rise in obesity in the span of less 
than a generation. Clearly, changes in environmental exposures have contributed to the recent 
rise in obesity rates. Excessive caloric intake, sedentary lifestyle, changes in dietary composition, 
reduced sleep duration and quality (4), antibiotic treatment (5), anti-psychotic medications (6), 
and chronic psychological stress (7) all contribute to the development of obesity. Obesity has 
detrimental effects on health. It increases the risk of developing Type II diabetes, cardiovascular 
disease, many forms of cancer, Alzheimer’s disease, asthma, arthritis, and chronic pain (8).  
Substantial biomedical research efforts have been focused on determining how obesity increases 
risk for these diseases. One potential driver of obesity-associated comorbidities is insulin 
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resistance. The expansion of adipose tissue, especially in visceral locations, is strongly 
associated with impaired responsiveness to the effects of insulin (9–11).  It is important to note 
that about 30% of obese individuals have normal insulin sensitivity and ~15% of normal weight 
individuals are insulin resistant (12). These findings highlight the importance of abdominal 
adiposity, rather than body weight, in promoting insulin resistance. Regardless, obese individuals 
are more likely to develop insulin resistance, a condition that afflicts nearly 1 out of 3 adults in 
the United States (13). 
 
Insulin action and insulin resistance 
Insulin is an anabolic hormone that is involved in many physiological processes. Nearly 
every cell type in the body expresses the insulin receptor (14) and is sensitive to insulin’s effects. 
The focus of this Dissertation is on the glucose-lowering and vascular effects of insulin. The 
effects of insulin on lipid (15, 16) and protein (17) metabolism, energy balance (18), cognition 
(19), reproduction (20), the sympathetic nervous system (21), immune function (22), 
mitogenicity (23) and electrolyte homeostasis (24) have been reviewed elsewhere.  
The most well known effect of insulin is to lower blood glucose. This is achieved by 
suppression of hepatic glucose production and stimulation of glucose disposal into peripheral 
tissues. When tissues become resistant to insulin, its hypoglycemic effects become less potent. 
Namely, insulin resistance results in an impaired ability of insulin to suppress hepatic glucose 
production and to promote peripheral glucose disposal. The impact of insulin resistance – 
enhanced hepatic glucose production and reduced peripheral glucose uptake – is hyperglycemia. 
There are several different types of insulin resistance. While most forms are pathological, 
others are temporary responses to normal physiological conditions. For instance, insulin 
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resistance develops during pregnancy to meet fetal metabolic needs and also as a response to 
long-term fasting (25).  Pathophysiological insulin resistance is observed in obesity, polycystic 
ovarian syndrome (26) severe inflammatory conditions such as sepsis (27), and other rare 
endocrinological disorders (28). While the focus of this Dissertation will be on obesity-induced 
insulin resistance, it is important to consider molecular similarities between various insulin 
resistant states as they may elucidate important underlying mechanisms of insulin resistance. 
 
The deleterious impact of insulin resistance on health 
 The detrimental effects of insulin resistance on health are profound. It is most well-
known for being a driver of Type 2 diabetes (29, 30). In fact, 5-10% of insulin resistant humans 
will progress to overt Type 2 diabetes within a year (31). In healthy individuals, pancreatic b 
cells can compensate for insulin resistance by secreting more insulin to restore normoglycemia 
(32). However in certain individuals, b cells fail to compensate for insulin resistance and 
hyperglycemia ensues (33). Alternatively, it has been hypothesized that prolonged 
hyperinsulinemia drives insulin resistance by desensitizing tissues to the effects of insulin (34).  
Regardless, insulin resistance leads to the development of hyperglycemia and Type 2 diabetes, 
which afflicts nearly 10% of people in the United States (13).  Prolonged Type 2 diabetes and 
hyperglycemia increase risk for cardiovascular disease, blindness, kidney failure, and limb 
amputation (35).  
Insulin resistance is not only a disorder of glucose metabolism. More broadly, insulin 
resistance is thought to underlie the metabolic syndrome, or syndrome X as originally defined by 
Gerald Reaven (36). The metabolic syndrome is a constellation of metabolic and vascular 
abnormalities that frequently accompany obesity. It is defined as the co-occurrence of abdominal 
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adiposity, glucose intolerance, low concentrations of high-density lipoprotein, increased plasma 
triglyceride levels, hypertension, and elevated levels of proinflammatory and prothrombotic 
factors. As insulin resistance can contribute to these lipid, vascular and inflammatory 
abnormalities (37), it is a major independent risk factor for cardiovascular disease (38, 39).  
Insulin resistance and the metabolic syndrome have also been linked to other seemingly disparate 
diseases such as cancer (40) and Alzheimer’s disease (41). It is clear, then, that the metabolic and 
vascular chaos resulting from obesity-induced insulin resistance has severely detrimental impacts 
on health. Given the pervasive nature of insulin resistance, it is difficult to estimate its economic 
burden. The total direct and indirect costs of Type 2 diabetes are estimated to be $245 billion, 
(42), and those of cardiovascular disease are $316 billion (43). Needless to say, insulin resistance 
is a major driver of chronic disease and a serious economic drain on the health care system. 
Thus, reducing the burden of insulin resistance is a major public health goal. 
 
Skeletal Muscle Insulin Resistance 
Why study muscle insulin resistance? 
Insulin stimulates glucose uptake, oxidation, and storage in skeletal muscle. Skeletal 
muscle comprises the majority of insulin sensitive tissue by mass. Following an oral glucose 
load, as during a meal, 26% of the ingested glucose is taken up by skeletal muscle (44). This 
value is ~85% during hyperinsulinemic-euglycemic clamps (insulin clamps)* (45). Skeletal 
muscle is the largest glucose storage depot in the body, as it stores roughly 80% of total body 
glycogen (46). Given its major role in removing glucose from the circulation, skeletal muscle 
insulin action is a key contributor to maintenance of normoglycemia. As such, skeletal muscle 
                                               
*Hyperinsulinemic-euglycemic clamps involve a continuous intravenous insulin infusion to achieve 
physiological hyperinsulinemia. Exogenous glucose is also infused to maintain euglycemia. The rate at 
which glucose must be infused to maintain euglycemia is an indicator of steady-state insulin action. 
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insulin resistance is a major site of obesity-induced insulin resistance (47) and a central defect in 
the progression of Type 2 diabetes (48). Furthermore, skeletal muscle insulin resistance appears 
to precede the development of hepatic insulin resistance (49, 50), underscoring its importance to 
the earliest stages of Type 2 diabetes.  
Lifestyle modifications that induce weight loss reverse insulin resistance and prevent the 
development of Type 2 diabetes (51, 52). However, lifestyle modifications are ineffective due to 
low adherence. In the absence of lifestyle modifications, it is important to have therapies that can 
treat or reverse skeletal muscle insulin resistance. Such drugs may be able to reverse the 
metabolic syndrome and its associated comorbidities. Thiazolidinediones, a class of drugs that 
act as agonists of peroxisome-proliferator-activated receptor-g, have direct and indirect insulin-
sensitizing effects on adipose tissue and skeletal muscle, respectively. While these drugs do 
prevent Type 2 diabetes in individuals with impaired glucose tolerance, they do not reduce 
cardiovascular events and actually increase heart failure incidence (53).  Thus, better insulin-
sensitizing drugs are needed to prevent Type 2 diabetes and its comorbidities. It is interesting to 
speculate whether drugs specifically targeting skeletal muscle insulin resistance, which is an 
early defect in the pathogenesis of Type 2 diabetes, may be more effective in reducing Type 2 
diabetes-associated cardiovascular events.  In order to design pharmaceuticals with direct 
insulin-sensitizing effects on skeletal muscle, it is imperative to understand the molecular 
etiology of skeletal muscle insulin resistance.  
 
What causes muscle insulin resistance? 
Since obesity-induced skeletal muscle insulin resistance was first described by 
Rabinowitz and Zierler in 1962 (47), the mechanism by which skeletal  muscle becomes resistant 
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to insulin has been studied extensively. The vast majority of these studies have explored 
potential defects at the myocellular level. In order to fully appreciate the cellular mechanisms of 
skeletal muscle insulin resistance, it is important to understand skeletal muscle insulin action 
during normal physiological conditions. The initiating event of myocellular insulin action is the 
binding of insulin in the interstitial fluid to the insulin receptor on the surface of myocytes. 
Receptors for insulin are formed from homo or heterodimerization of the two insulin receptor 
isoforms, insulin receptor A and B (54). Additionally, insulin – insulin-like growth factor 1 
hybrid receptors can also bind insulin (54). Binding of insulin to these receptors activates the 
phosphatidylinositol-3-kinase / protein kinase B pathway (PI3K/Akt) pathway (Reviewed in Ref 
54). Briefly, insulin binding to the insulin receptor activates the receptor tyrosine kinase which 
then phosphorylates both the insulin receptor itself and the insulin receptor substrate (IRS) 
proteins. Subsequently, PI3K is activated through binding to phosphorylated IRS proteins. 
Activated PI3K then phosphorylates phosphatidylinositol bisphosphate to generate 
phosphatidylonisotol trisphosphate (PIP3) at the plasma membrane. Increased plasma membrane 
PIP3 recruits phosphoinositide-dependent kinase, which activates Akt. Akt can then 
phosphorylate a number of downstream targets including Akt substrate of 160kDa (AS160), 
mechanistic target of rapamycin (mTOR), and glycogen synthase kinase-3b (GSK-3b). The 
cellular results of insulin signaling, as they relate to glucose disposal, include 1) translocation 
and insertion of glucose transporter type 4 (Glut4) into the plasma membrane thereby enhancing 
glucose transport (56) 2) increased activity of hexokinase II which phosphorylates glucose and 
traps it inside of the cell (57) and 3) activation of GSK-3b which promotes glycogen storage. In 
summary, insulin promotes myocyte glucose transport, intracellular phosphorylation and 
utilization through PI3K/Akt signaling events. 
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Defects in insulin-stimulated glucose transport (58, 59), intracellular phosphorylation (60, 
61),  oxidation (62, 63), and glycogen synthesis (64, 65) have been observed in the setting of 
insulin resistance and Type 2 diabetes. For decades, investigators have searched for molecular 
explanations for these impairments.  Obesity-induced insulin resistance and Type 2 diabetes have 
been associated with defects in the insulin-stimulated PI3K/Akt signaling pathway (66). This 
reduction in insulin signaling may be caused by antagonistic signaling from other cascades, 
altered subcellular distribution of signaling proteins, or single nucleotide polymorphisms (66).  
It is clear that defects at the level of the muscle cell are associated with obesity-induced 
skeletal muscle insulin resistance. Many investigators have wondered what molecular aspects of 
obesity cause these defects in insulin signaling. This question in particular has been studied 
extensively. Some of the more prominent hypotheses for defective insulin signaling include 1) 
accumulation of toxic lipid species (67) 2) low-grade inflammation (68) 3) mitochondrial 
dysfunction and excess generation of reactive oxygen species (69) or 4) extracellular matrix 
(ECM) accumulation and integrin activation (70). Each of these processes are induced by obesity 
and antagonize PI3K/Akt signaling by activating signaling cascades such as protein kinase C 
(PKC), c-Jun, N-terminal kinases (JNK), and IkB kinase (IKK) (55). 
Thus far, I have focused on the myocellular aspects of insulin action and insulin 
resistance. An equally important, yet underappreciated, aspect of skeletal muscle insulin action is 
the vascular delivery of glucose and insulin to the surface of myocytes. Before the myocytes can 
respond to insulin or transport glucose, these molecules must travel from the portal circulation to 
the muscle microcirculation. In fact, the delivery of glucose and insulin are rate-limiting to 
insulin-stimulated glucose uptake (71–73). These aspects of insulin action highlight the 
inseparable nature of microvascular function and metabolism. The vascular regulation of insulin 
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action must be studied in intact organisms because the influence of the vasculature is eliminated 
in experiments utilizing isolated tissues or cells in culture. As I discuss below, the journey of 
insulin and glucose from their initial entry into the portal circulation to their final destination at 
the surface of the myocyte is complex and subject to many levels of regulation.  
 
The Journey of Insulin and Glucose from the Portal Circulation to Skeletal Muscle 
In order to put the delivery of insulin and glucose to skeletal muscle into the context of 
whole-body physiology, I will first describe how these molecules reach the muscle 
microcirculation following an oral glucose challenge. 
 
Glucose-stimulated insulin secretion 
Insulin is stored in b cells which reside in islets of the endocrine pancreas. It is stored 
vesicularly in dense granules as a hexamer and is released in response to various stimuli, most 
notably an increase in portal vein glucose concentrations. Dietary glucose is initially absorbed by 
the small intestine and transported into the portal circulation. b cells sense the rise in portal 
glucose through increased cellular glucose metabolism and respond by secreting insulin in a 
biphasic manner (74). In response to a 75g oral glucose challenge, pancreatic islets from healthy 
adults will secrete ~70 nmol of insulin with a peak secretion rate of 600 pmol/min (75).  
 
First-pass hepatic insulin and glucose extraction 
Upon secretion into the portal vein, insulin becomes monomeric and primed for 
biological activity. Insulin in the portal vein first encounters the liver where it acts through the 
insulin receptors on hepatocytes to stimulate glucose uptake and suppress glycogenolysis (76). 
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These concerted actions of insulin convert the liver from a net producer of glucose during fasting 
to a glucose consumer after feeding (77). The liver microvasculature is characterized by 
discontinuous sinusoids that allow for free access of circulating macromolecules to hepatocytes. 
As such, a significant portion of insulin secreted from b cells is extracted on the first pass 
through the liver. Liver insulin extraction is a regulated process and can range from negligible to 
75% of secreted insulin (78, 79). While the mechanisms regulating hepatic insulin clearance are 
not well understood, it has been shown that first-pass hepatic insulin extraction is reduced in 
obese subjects (80, 81). In addition to clearing a significant proportion of the secreted insulin, the 
liver also extracts roughly 33% of ingested glucose for utilization and storage as glycogen (82). 
In summary, the liver’s physical positioning makes it a crucial first-responder to the appearance 
of glucose and insulin in the portal circulation.  
 
Systemic insulin and glucose distribution 
The remaining insulin (~50%) and glucose (~67%) that survives first pass hepatic 
extraction then enter the inferior vena cava and are delivered to the right atrium of the heart. 
Deoxygenated blood carrying insulin and glucose moves through the pulmonary circulation 
before being returned to the left atrium. Very little insulin is cleared by the lung (83). After 
entering the left atrium, insulin and glucose are then distributed to the systemic and coronary 
circulation by contraction of the left ventricle. The postprandial rise in glucose and insulin 
appear to increase cardiac output without altering mean blood pressure (84). Following systemic 
distribution, insulin and glucose enter peripheral circulatory beds including those of skeletal 
muscle, adipose tissue, brain, kidney, and the digestive tract.  
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Clearance of insulin by other organs 
 As discussed above, the majority of insulin is cleared by the liver through first-pass 
metabolism. Roughly 50% of the remaining insulin that enters the peripheral circulation is then 
cleared by the kidney by both receptor and non-receptor mediated mechanisms (85). Of note, 
insulin extraction by the kidney is highly variable and its regulation is poorly understood (86). 
Following hepatic and renal clearance of insulin, ~25%, or 17.5 nmol, of the initially secreted 
insulin remains available for skeletal muscle, heart, brain, and adipose tissue. Compared to the 
liver and kidney, insulin clearance by these organs is low. This low extraction is rather 
remarkable when considering the potent effects of insulin on skeletal muscle and adipose tissue. 
It is possible that secondary messenger systems amplify insulin’s signal in these organs. The low 
clearance of insulin in skeletal muscle, adipose tissue, and brain is most likely related to the 
continuous nature of capillaries in these tissues. Continuous capillaries are comprised of 
endothelial cells adjoined by tight junctions and, thus, do not readily transport plasma proteins. 
This is in contrast to the kidney and liver which have fenestrated and discontinuous capillaries, 
respectively, which allow for freer access of plasma contents to the underlying parenchymal 
cells. 
 
Hemodynamic Actions of Insulin 
Effect of insulin on muscle blood flow 
After insulin has been distributed to the systemic circulation, it interacts with the 
endothelium of arteries and arterioles in skeletal muscle. William B Hood Jr. and colleagues first 
demonstrated an increase in muscle blood flow, as measured by microsphere deposition, during 
insulin clamps in dogs (87). Similar observations were made in humans (88). These findings 
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were extended to hypothesize that the perfusion-enhancing effects of insulin were important for 
its metabolic effects (89, 90). However, many other investigators were unable to detect an effect 
of insulin on muscle blood flow (88). As such, there has been significant controversy regarding 
the existence and physiological relevance of insulin-stimulated increases in muscle blood flow 
(91). One concern is that, in studies where insulin stimulation did produce an increase in muscle 
blood flow, these effects were only observed after prolonged administration (2-6 hours) of high 
doses of insulin (91). Furthermore, insulin increases muscle glucose uptake much more rapidly 
than it augments muscle blood flow. Thus, the physiological relevance of insulin’s effects on 
bulk muscle blood flow and their importance to muscle glucose uptake are questionable.  
 
Microvascular flow distribution 
The laboratories of Michael Clark, Eugene Barrett, and Stephen Rattigan began using 
techniques to measure microvascular flow distribution rather than bulk muscle blood flow. They 
first demonstrated that insulin increased the metabolism of 1-methylxanthanine (1-MX) across 
the rat hind limb and human forearm (92, 93). 1-MX is a substrate for xanthine oxidase, an 
enzyme expressed mostly by the endothelium of capillaries and arterioles. As such, the 
disappearance of 1-MX across the hind limb is an indicator of endothelial surface area which 
itself is an index of microvascular flow distribution. Thus, the 1-MX studies suggested that 
insulin increases the endothelial surface area available for flow. This phenomenon was termed 
capillary recruitment. That is to say, at rest there are a significant number of capillaries which are 
under-perfused. Upon insulin stimulation, flow to these capillaries is “recruited” and the 
distribution of microvascular flow is increased (Figure 1.1).  
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Figure 1.1: Insulin-stimulated capillary recruitment. Under basal conditions (left), muscle 
microvascular perfusion is low and a minority of capillaries are perfused. Upon insulin binding 
to its receptor, the endothelium produces NO causing resistance arterioles to dilate (middle). This 
vasodilation results in a recruitment of previously under-perfused capillaries (right). NO – nitric 
oxide. Image of capillary bed on left adapted from Human Anatomy & Physiology 9th Edition 
(Marieb EN & Hoehn KN). Image of capillary bed on right adapted from Addison-Wesley 
Longman, Incorporated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
 
Subsequently, these investigators utilized contrast-enhanced ultrasound to assess 
microvascular hemodynamics and flow distribution (94). With contrast-enhanced ultrasound, 
relative microvascular volume is estimated by measuring the intensity of sound waves reflected 
from 1-5µm microbubbles injected intravenously. This measurement reflects the microbubble 
distribution volume and its relationship to microvascular volume depends on the assumption that 
all microbubbles are retained intravascularly. In addition to microvascular volume, flow velocity 
can be determined by rupturing the microbubbles with a high intensity ultrasound pulse and then 
measuring the rate at which the signal recovers. As microvessels fill more slowly than larger 
conduit arteries, the slower of the microbubble recovery rates is assumed to represent 
microvascular flow velocity. Due to the limited spatial resolution of ultrasound, it is unclear 
whether the microvascular flow velocity measurement represents capillary or venous flow 
velocity, or a combination of both.  Using contrast-enhanced ultrasound, these investigators 
showed that, in human forearm muscle, 4 hours of physiological insulin infusion increases 
microvascular volume while decreasing microvascular flow velocity (93). Furthermore they 
demonstrated that insulin’s ability to increase microvascular volume occurs 1) prior to insulin-
stimulated muscle glucose uptake (95) and 2) during physiological conditions such as a mixed 
meal tolerance test (96). Furthermore, Rattigan and Clark have suggested that insulin enhances 
the proportion of microvascular flow that is distributed to “nutritive” routes which allow for 
more rapid exchange of plasma-borne molecules with the interstitial space (97).  Thus, capillary 
recruitment and more efficient microvascular flow distribution appear to be early physiological 
responses to insulin stimulation which increase the surface area for glucose and insulin 
exchange. Of note, whether increases in microbubble distribution volume represent bona fide 
capillary recruitment has been questioned. Using intravital microscopy to directly visualize 
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capillaries, David Poole and colleagues have observed that over 80% of capillaries are already 
perfused at rest (98). As such, it is unclear whether the insulin-stimulated increase in 
microbubble distribution volume represents a recruitment of capillaries or distension of other 
microvessels. The longstanding debate regarding muscle capillary recruitment is beyond the 
scope of this discussion and has been covered elsewhere (98, 99). 
 
Vasodilatory effects of insulin 
The ability of insulin to increase microvascular perfusion has been attributed to 
vasodilatory effects on both large conduits and smaller resistance vessels. Using pulse wave 
analysis, Yki-Järvinen and colleagues demonstrated that aortic compliance was increased after an 
hour of an insulin clamp (100). This suggests that insulin dilates large blood vessels. 
Additionally, other investigators have demonstrated that insulin relaxes skeletal muscle arterioles 
at physiological concentrations (101–103). Interestingly, one of these studies showed that when 
intravenous glucose infusion is used to elicit hyperinsulinemia, pre-capillary arterioles constrict 
rather than dilate (101). Furthermore, Eringa et al. did not observe a change in cremaster muscle 
arteriolar diameter with insulin stimulation alone (104). Only after inhibition of endothelin 
receptors was insulin able to induce arteriolar dilation. These findings suggest that the effects of 
insulin on vascular tone are highly dependent on the local balance of constrictors and dilators.   
While there have been relatively few studies on the effects of insulin in the venous circulation, 
there is evidence that insulin causes dilation of dorsal hand veins in humans (105, 106). In 
summary, physiological insulin levels appear to cause vasodilation at all levels of the vasculature 
under most conditions. 
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Molecular determinants of insulin’s hemodynamic effects 
The molecular effects of insulin on endothelial cells have been studied extensively in cell 
culture and to a lesser extent in vivo. Several investigators have demonstrated that the ability of 
insulin to stimulate vasodilation, capillary recruitment, or blood flow can be blocked by nitric 
oxide synthase (NOS) inhibitors (95, 102, 107). These findings suggested that nitric oxide (NO), 
the prototypical vasodilator, is involved in the dilator effects of insulin. Indeed Michael Quon 
and colleagues demonstrated that insulin stimulates NO production from human umbilical vein 
endothelial cells (HUVECs) (108). An extensive characterization of HUVECs by this group 
revealed that insulin signaling through the PI3K/Akt pathway is required for NO production 
(109). More specifically, Akt phosphorylates endothelial NOS (eNOS) at Ser1177 and activates it 
independently of classical calcium-dependent eNOS activation. Endothelial-derived NO can then 
diffuse to nearby smooth muscle cells to activate soluble guanylyl cyclase which causes smooth 
muscle relaxation through cyclic guanosine monophosphate signaling (110). As alluded to 
above, insulin also stimulates the production of endothelin-1, a vasoconstrictor (111). Insulin-
stimulated endothelin-1 production is thought to occur through a separate mitogen-activated 
protein kinase (MAPK)-dependent insulin signaling pathway (109). Thus, the vascular effects of 
insulin depend on whether the AKT-NO or MAPK-endothelin-1 signaling cascades are activated 
by insulin.  
It is important to keep in mind that much of the work on the molecular mechanisms of 
insulin action in the endothelium has been performed in cultured endothelial cells. While we 
have gained considerable understanding of insulin action from these studies, cultured endothelial 
cells are very different from vessels in vivo (see “Technical difficulties...” below for further 
discussion).  For instance, while the insulin receptor and associated insulin signaling machinery 
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is certainly present in HUVECs, bovine aortic endothelial cells, and bovine retinal capillary 
endothelial cells, it is unclear whether skeletal muscle capillary or arterial endothelial cells 
express the insulin receptor. To the best of my knowledge, this has never been shown 
definitively in vivo. These would be the cells of interest in determining insulin’s hemodynamic 
effects in skeletal muscle. 
 
Physiological Glucose Delivery to Skeletal Muscle 
Distributed control of glucose uptake 
Glucose uptake in skeletal muscle involves microvascular delivery of glucose to the 
interstitial space, transport of glucose across the plasma membrane, and finally intramyocellular 
phosphorylation (Figure 1.2) (71). Previous experiments from our laboratory have demonstrated 
that the relative importance of delivery, transport, and phosphorylation steps to muscle glucose 
uptake are context-dependent. For instance, at rest the permeability of the muscle plasma 
membrane to glucose is very low making glucose transport the main barrier to glucose uptake 
(112). Upon insulin stimulation, membrane glucose permeability is increased through the 
insertion of Glut4, and glucose delivery and phosphorylation become more limiting to glucose 
uptake (112). These findings suggested an important role for the muscle vasculature in the 
control of insulin-stimulated muscle glucose uptake. 
 
Bulk muscle blood flow and glucose uptake 
Before glucose can be taken up by muscle, it must be delivered through the vasculature to 
the interstitial space which bathes myocytes. There are several vascular parameters, both 
structural and dynamic, to consider when determining how the vasculature may control glucose  
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Figure 1.2: Barriers to muscle glucose uptake. Before glucose can be utilized, it must first be 
delivered from the plasma to the interstitial fluid (Step 1). Subsequently, glucose must be 
transported across the plasma membrane by facilitative glucose transporter such as Glut4 (Step 
2). Finally, glucose is phosphorylated by HKII and trapped intracellularly (Step 3). Yellow 
hexagons labeled with a “G” represent glucose. Red circles labeled with “P” indicate 
phosphorylation sites. Glut4 – glucose transporter type 4, HK II – hexokinase 2. Figure adapted 
from Wasserman et al. (71). 
 
 
 
 
 
 
 
 
 
  
 18 
delivery and uptake. The first is bulk muscle blood flow. If bulk flow were an important 
contributor to insulin-stimulated muscle glucose uptake, then experimentally increasing it should 
augment glucose uptake. Such studies have produced conflicting results. Two independent 
laboratories have shown that infusing either adenosine, sodium nitroprusside (SNP) or 
bradykinin during insulin clamps augments muscle blood flow but does not increase muscle 
glucose uptake in healthy or hypertensive patients (113–116). Conversely, infusing angiotensin 
II reduces muscle blood flow, but also did not alter muscle glucose uptake (117). These findings 
would seem to suggest that bulk muscle blood flow is not a major determinant of muscle insulin 
action. On the contrary, Baron and colleagues have shown that increasing bulk flow with 
methacholine enhances muscle glucose uptake and reducing bulk flow with L-NG-monomethyl 
arginine acetate, a NOS inhibitor, impairs glucose uptake (118, 119). As discussed above, insulin 
does not increase muscle blood flow unless it is administered for several hours. Thus, the role of 
bulk muscle blood flow as an independent contributor to insulin-stimulated muscle glucose 
uptake is questionable. When considering the implications of these studies for the importance of 
glucose delivery to glucose uptake, it is important to remember that changes to bulk blood flow 
do not necessarily indicate changes in glucose delivery. In fact, none of the aforementioned 
studies actually measured glucose delivery. It is possible that the interventions described above 
may have altered bulk flow without changing the distribution of flow or glucose delivery.   
 
Microvascular perfusion and glucose uptake 
As discussed previously, insulin dilates resistance arterioles and increases muscle 
microvascular volume (120). These vascular effects would be predicted to increase the 
endothelial surface area for glucose exchange and enhance glucose delivery. Perhaps due to the 
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difficulty of measuring glucose delivery, this hypothesis has not been explicitly tested. 
Furthermore, it relies on the assumption that microbubble distribution volume, as measured by 
contrast-enhanced ultrasound, reflects that of plasma, the carrier for glucose. Bergman and 
colleagues demonstrated that insulin increased the interstitial distribution volume of inulin, an 
inert ~6000 Da molecule, without altering intravascular volume (121). These data indicate that 
insulin either increased the trans-endothelial transport of inulin or directed blood flow to vessels 
that more easily equilibrate with the interstitial space. Interestingly, these effects of insulin were 
not observed in humans (122). Whether insulin also increases the interstitial distribution volume 
of glucose, a much smaller molecule (180 Da), is unknown. 
Findings from Barrett and colleagues do suggest that the microvascular effects of insulin 
are important for muscle glucose uptake. Importantly, the microvascular effects of insulin occur 
before stimulation of muscle glucose uptake (95). This temporal arrangement of events suggests 
that the vascular effects of insulin are necessary for its metabolic effects. Furthermore, treatment 
of rats with L-NG-nitroarginine methyl ester (L-NAME; NOS inhibitor) blocked the insulin-
stimulated increase in microvascular volume and, subsequently, muscle glucose uptake (95). 
Conversely, angiotensin-(1-7) [Ang-(1-7)], a peptide hormone of the renin angiotensin system, 
increases both microvascular perfusion and insulin action (123). While glucose delivery was not 
measured in these studies, these findings suggest a tight coupling between muscle microvascular 
volume and glucose uptake.  
 
Vascular architecture and glucose delivery 
In addition to hemodynamics, vascular architecture is also important for efficient glucose 
delivery. The most basic descriptor of vascular structure is the number of capillaries in a given 
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tissue. Given that capillaries are the main sites of plasma to muscle glucose exchange, capillary 
density represents the surface area available for exchange. The surface area for glucose exchange 
should correlate positively with glucose delivery and muscle insulin sensitivity. Indeed, skeletal 
muscle capillary density is positively associated with skeletal muscle insulin sensitivity (124, 
125) in humans. Previous studies from our laboratory utilized a mouse model in which vascular 
endothelial growth factor (VEGF) was deleted specifically from muscle (126). As VEGF is a 
critical pro-angiogenic factor, loss of VEGF in these mice results in a 60% reduction in muscle 
capillary density. As would be expected, these mice displayed impaired insulin-stimulated 
muscle glucose uptake as measured during an insulin clamp. When soleus muscles from these 
mice were isolated and stimulated with insulin ex vivo, glucose uptake was not impaired, 
indicating normal myocellular insulin action. In this case, muscle insulin resistance was 
generated through a reduction in capillary density rather than through a myocellular defect. 
While capillary density is positively correlated with insulin-stimulated glucose uptake, it remains 
to be determined whether this correlation is driven by glucose delivery per se. It is possible that 
changes in capillary density could alter insulin delivery or muscle metabolism. Finally, an 
understudied aspect of vascular structure that may contribute to glucose delivery is the topology 
of microvascular networks. That is to say, certain spatial arrangements and connectivity patterns 
of arteries, capillaries and venules may minimize diffusion distances and allow for the most 
efficient delivery of glucose (127).  
 
Endothelial glucose permeability and interstitial glucose dispersion 
A final consideration in the delivery of glucose to muscle is the permeability of the 
endothelium and the interstitial space to glucose. Glucose is a small (~7Å) hydrophilic molecule 
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and, as such, is thought to either a) diffuse passively through inter-endothelial junctions (128) or 
b) be transported by endothelial Glut1 (129). Despite the small size of glucose compared to the 
width of inter-endothelial junctions (~50Å), basal muscle interstitial glucose is ~60-70% of 
plasma glucose in humans (130, 131). There appears to be species differences in the trans-
endothelial glucose gradient as plasma and interstitial glucose concentrations are more similar in 
rats (132). When insulin was infused into these rats, muscle interstitial glucose fell to a greater 
extent than did plasma glucose, indicating that it increased the trans-endothelial glucose gradient 
(132). Whether the dynamics of trans-endothelial glucose transport constitute a significant 
barrier to muscle glucose uptake is unclear. Another aspect of glucose delivery is the movement 
of glucose within the interstitial space. The muscle interstitial space is a hydrogel consisting of 
various ECM proteins and glycosaminoglycans such as hyaluronan (133). It is possible that the 
interstitial milieu may hinder the access of interstitial glucose to GLUTs located on the surface 
of the myocyte. Whether the interstitial ECM constitutes a significant barrier to muscle glucose 
uptake is unknown. 
In summary, glucose delivery is an important regulator of insulin-stimulated muscle 
glucose uptake. While the physiological relevance of total muscle blood flow to glucose uptake 
is questionable, it appears that insulin induces a more efficient distribution of flow. These 
hemodynamic effects of insulin may contribute to muscle glucose uptake. The contributions of 
microvascular network topology, trans-endothelial glucose transport, and interstitial glucose 
dispersion as barriers to glucose uptake warrant further investigation. Furthermore, future studies 
of glucose delivery would be improved by measuring interstitial glucose levels using interstitial 
sampling methods or intravital imaging techniques.    
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Physiological Insulin Delivery to Skeletal Muscle 
The trans-endothelial insulin gradient 
The hypothesis that insulin delivery may be limiting to peripheral insulin action was first 
proposed by Reubin Andres and colleagues (134). These investigators noticed that, during a 
continuous insulin infusion intended to produce hyperinsulinemia, plasma insulin levels peaked 
almost instantaneously whereas it took considerably longer for glucose utilization to reach its 
maximum. These findings suggested that there was a disconnect between plasma insulin and 
insulin action in the periphery. Using compartmental modeling, these investigators described an 
interstitial compartment with which plasma insulin equilibrated slowly that was important for 
peripheral glucose utilization. They hypothesized that lower permeability of some tissue vascular 
beds may impede insulin’s delivery to this interstitial compartment. A few years earlier, Eugenio 
Rasio and colleagues had observed that, following an intravenous glucose bolus, insulin 
appeared rapidly in the hepatic lymph, indicating extensive insulin clearance by the liver (135). 
However, the amount of insulin in the lymph draining the leg was much lower and its appearance 
less rapid. Assuming that the majority of leg lymph drains skeletal muscle, these findings suggest 
a relatively low extraction of insulin by muscle. Consistent with this observation, Richard 
Bergman and colleagues measured a considerable gradient between plasma and thoracic duct 
insulin following an intravenous glucose bolus (136). Direct measurements of muscle interstitial 
insulin concentrations by microdialysis confirmed that levels of insulin in the plasma were 
roughly twofold higher than in the interstitial space (137). In summary, these early studies 
demonstrated that plasma insulin equilibrates slowly with the muscle interstitial space. Based on 
these findings, investigators hypothesized that the low permeability microvasculature of skeletal 
muscle may restrict insulin’s access to muscle.  
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The endothelium is rate-limiting for muscle insulin action 
While measuring the dynamics of lymph insulin appearance, Richard Bergman and 
Jerrold Olefsky’s groups noticed that the kinetics of muscle insulin action were strongly 
correlated with its appearance in the lymph (72, 138). Namely, the timing of insulin-stimulated 
insulin receptor kinase activity (138) and glucose disposal (72, 138) is the same as insulin 
appearance in the lymph. This suggested that the movement of insulin across the endothelium is 
rate-limiting to muscle insulin action. To more directly test this hypothesis, Bergman and 
colleagues injected insulin directly into the muscle interstitial space, thereby bypassing the 
endothelial barrier (73). In contrast to the slow increase in glucose uptake caused by 
intravenously administered insulin, intramuscular insulin injection stimulated maximal glucose 
uptake within 10 minutes. This finding was strong evidence that the rate-limiting step to muscle 
insulin action is the trans-endothelial transport of insulin.  
 
Characteristics of muscle capillary endothelium 
The capillary endothelium comprises roughly 85% of all endothelial surface area (139). 
As such, capillary networks provide a vast surface area for fluid and solute exchange between the 
plasma and the underlying tissue parenchyma. The endothelium lining capillaries forms a semi-
permeable barrier which limits trans-capillary exchange. The properties of this barrier depend on 
the tissue in which it is located. There are 3 main types of capillary endothelia: discontinuous, 
fenestrated, and continuous (140). Discontinuous endothelia are characterized by large distances 
(~100 nm) between adjacent endothelial cells and allow free exchange of circulating blood cells 
and plasma constituents with the underlying tissue parenchyma. Such vessels include the 
sinusoids of the liver and bone marrow. Fenestrated endothelium, as found in the kidney, contain 
 24 
pores ranging from 6-15nm in diameter. While fenestrated endothelia are relatively impermeable 
to cells, they do allow free exchange of large plasma proteins. Finally, continuous endothelia, as 
found in the muscle, adipose tissue, and brain are comprised of endothelial cells adjoined by 
either zona occludens (brain) or macula occludens (adipose, skeletal muscle) inter-endothelial 
junctions. The capillary inter-endothelial junctions in these tissues range from <1nm in brain to 
~2-5nm in skeletal muscle and do not leak plasma proteins. These characteristics of muscle 
capillaries are in agreement with the findings discussed above which showed that the 
endothelium restricts insulin’s access to muscle. Given that insulin’s diameter is ~3nm and inter-
endothelial junctions range from ~2-5nm, it is feasible that insulin may access inter-endothelial 
junctions. Another consideration is that the glycocalyx, a layer of negatively charged 
glycoproteins that extrudes from the luminal endothelial surface, may sterically hinder insulin’s 
access to the inter-endothelial junction. Furthermore, as insulin is negatively charged at 
physiological pH, the glycocalyx may impede trans-endothelial insulin efflux through charge 
selectivity. In summary, the muscle capillary endothelium presents barriers to trans-endothelial 
insulin transport. Whether insulin is able to access inter-endothelial junctions is unclear from 
structural considerations alone.     
 
Endothelial transport mechanisms 
In addition to passive movement through inter-endothelial junctions, macromolecules can 
also be actively transported by endothelial cells. Using electron microscopy, George Palade and 
colleagues observed that the very thin endothelium of muscle capillaries contain vesicles, termed 
plasmalemmal vesicles or caveolae, that span roughly 70nm in diameter. (141). These vesicles 
can contribute to molecular exchange by either 1) fusing to form transient trans-endothelial 
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channels which allow for passive movement of plasma constituents to the interstitial space (142, 
143) or 2) actively transport macromolecules through a process termed transcytosis (144). 
Transcytosis begins with endocytosis of caveolae which are fused with the luminal endothelial 
plasma membrane and open to circulating plasma. Caveolae contain a number of receptors, 
including the insulin receptors (at least in adipocytes) (145), and thus can concentrate specific 
cargo for transport. These vesicles are internalized through a mechanism that involves dynamin-
mediated scission (146). Subsequently, the free vesicle is translocated across endothelial 
microtubules with assistance from motor proteins such as kinesin and dynein (146). Finally, the 
free vesicle utilizes soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
(SNARE) machinery to dock with the abluminal plasma membrane and release its contents into 
the interstitial space (146). Of note, there has been considerable controversy regarding the extent 
to which transcytosis, endothelial pores, or inter-endothelial junctions mediate trans-endothelial 
solute transport (Figure 1.3). The specifics of this debate are beyond the scope of this discussion 
and have been covered elsewhere (147, 148).  
 
How does insulin cross the capillary endothelium in skeletal muscle? 
In the previous sections I discussed the evidence which shows that the endothelium 
restricts insulin’s access to skeletal muscle and that there are multiple endothelial protein 
transport mechanisms. These observations led investigators to examine the molecular mechanism 
of trans-endothelial insulin transport in skeletal muscle. This issue has generated considerable 
debate over the last 30 years. Some studies have suggested that insulin is actively transported 
across the endothelium by saturable insulin receptor-mediated transcytosis whereas others have 
shown that insulin diffuses  
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Figure 1.3: Potential mechanisms of trans-endothelial insulin transport. Insulin is delivered to muscle 
capillary beds through the arterial circulation. Subsequently, insulin may be transported across the 
endothelium either by 1) receptor-mediated transcytosis 2) movement through inter-endothelial junctions 3) 
non-saturable vesicular transcytosis or 4) movement through trans-endothelial channels formed by fusion of 
endothelial vesicles. After insulin crosses the endothelium and enters the interstitial space it can bind to the 
insulin receptor on the surface of myocytes and stimulate glucose uptake.  
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passively across the endothelium (Figure 1.3). Below I will review the evidence for each 
hypothesis.  
 
Evidence that insulin moves across the endothelium by saturable insulin receptor-mediated 
transcytosis  
The notion that insulin may be trafficked across the endothelium by a receptor-mediated 
process began with the demonstration that cultured HUVECs contain insulin receptors (149). 
The expression of insulin receptors in various cultured endothelial cells has now been 
demonstrated extensively. George King and colleagues then showed that antibodies against the 
insulin receptor inhibited the movement of 125I-insulin across a monolayer of bovine retinal 
capillary endothelial cells in vitro (150). This suggested that insulin was being trafficked across 
cultured endothelial cells by an insulin receptor-mediated process. Using an ex vivo perfused 
heart preparation, Bar and colleagues demonstrated that the appearance of 125I-insulin in heart 
tissue sections could be reduced by unlabeled insulin and an antibody against the insulin receptor 
(151). These ex vivo findings indicated that in heart, which contains continuous capillaries, 
endothelial insulin receptors can control the delivery of insulin. Continuing along this line of 
investigation, Eugene Barrett and colleagues used immunohistochemistry to show that 
fluorescein isothiocyanate (FITC)-labeled insulin accumulates in the endothelium of arterioles 
and venules (152). Given that capillaries are the main sites of insulin exchange, the role of 
venular and arteriolar insulin accumulation is unclear. In the same study, these investigators also 
observed that, in the endothelium, the insulin receptor co-localized with caveolin-1, the main 
structural component of caveolae. Two separate studies in cultured endothelial cell monolayers 
showed that disrupting caveolae inhibited insulin uptake, indicating that caveolae may mediate 
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the transport of insulin (153, 154). On the contrary, Klip and colleagues found that in vitro 
endothelial insulin transport was mediated by a clathrin-dependent mechanism (155). Finally, in 
a tour de force study, Kubota et al. observed a reduction in interstitial insulin delivery in mice 
lacking endothelial insulin receptor substrate 2. These findings indicated that endothelial insulin 
signaling was necessary for insulin delivery (156). The most commonly accepted model, based 
on the studies discussed above, is that 1) insulin binds to the insulin receptor located in caveolae, 
2) caveolae are then translocated across the EC by transcytosis and 3) insulin is released in the 
interstitial space where it can then stimulate muscle glucose uptake. It is important to note that in 
none of the aforementioned studies was skeletal muscle trans-endothelial insulin transport 
measured directly in vivo.    
 
Evidence that insulin transport across the endothelium is not receptor-mediated 
To test whether trans-endothelial insulin transport were saturable in dogs, Bergman and 
colleagues infused physiological and pharmacological doses of insulin and measured its 
appearance in the lymph (157). They reasoned that if trans-endothelial insulin transport were 
saturable, then the appearance of insulin in the lymph should plateau with increasing levels of 
plasma insulin. However, they found that the appearance of insulin was not saturable even with 
very high doses of insulin. These findings indicated that insulin delivery was not saturable in 
vivo, as would be expected for a receptor-mediated process. Subsequently, Kahn and colleagues 
generated a mouse that lacked the insulin receptor in endothelial cells (158). They found that this 
mouse had normal glucose homeostasis, suggesting that the insulin receptor was not involved in 
trans-endothelial insulin transport. It should be noted, however, that this same group made a 
second endothelial-specific insulin receptor knockout mouse using a different promoter to drive 
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the endothelial expression of Cre recombinase (159). These mice displayed delayed insulin-
stimulated muscle insulin signaling and glucose uptake suggesting that the insulin receptor does 
regulate insulin delivery. In summary, there is in vivo evidence that trans-endothelial insulin 
transport is not saturable and does not require the insulin receptor. These studies are limited by 
their measurement of insulin delivery which is controlled by both perfusion and trans-endothelial 
insulin transport. Thus, it is unclear whether changes in insulin delivery are caused by altered 
muscle perfusion, trans-endothelial insulin transport, or a combination of both.   
 
Technical difficulties in assessing capillary trans-endothelial insulin transport 
Two main approaches have been used to study trans-endothelial insulin transport, both of 
which have their limitations. The first such approach is the use of techniques which measure total 
insulin delivery. Such methods include microdialysis (156), lymph sampling (157), and the 
autoradiographic approach used by Bar et al. (151). The delivery of insulin to the muscle 
interstitial space is regulated by two main factors: 1) muscle perfusion, or the surface area for 
capillary insulin exchange and 2) trans-endothelial transport. Thus, when using these techniques 
to measure total insulin delivery, it is unclear whether perturbations cause a change in perfusion, 
trans-endothelial insulin transport or both. This limitation is further complicated by the fact that 
insulin itself increases microvascular perfusion. Thus, these techniques do not directly measure 
trans-endothelial insulin transport but rather an index of insulin delivery. Another issue with 
microdialysis is temporal resolution. With microdialysis, equilibration of the interstitial fluid 
with the microdialysis probe may take up to 20 minutes (160). Thus, more rapid interstitial 
insulin dynamics may be missed. Finally, the use of lymph as a surrogate for interstitial fluid is 
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limited because lymphatic function can vary during disease conditions (161). Thus, changes in 
lymph flow may confound the relationship between interstitial fluid and lymph.  
 The majority of studies investigating trans-endothelial insulin transport have been 
performed in cultured endothelial cells in vitro. While we have gained valuable information from 
these studies, they have several limitations. The first issue is the source of endothelial cells. 
Many studies have utilized macrovascular endothelial cells such as HUVECs or bovine aortic 
endothelial cells (149, 154). Given the phenotypic heterogeneity between endothelial cells at 
different levels of the vasculature (162), it is problematic to draw conclusions about capillaries in 
vivo from cultured macrovascular endothelial cells. Some studies have utilized “microvascular” 
endothelial cells (150, 153, 155). The term microvascular refers to a range of vessels including 
arterioles, venules, and capillaries, all of which have different properties (162). Thus, the extent 
to which microvascular endothelial cells are representative of capillaries is questionable. The 
second issue with cultured endothelial cells is the organ from which they are isolated. Studies of 
trans-endothelial insulin transport have utilized endothelial cells from retina (150), aorta (152, 
154), adipose tissue (155), or lung (153). It is becoming increasingly appreciated that endothelial 
cells in different tissue beds have very different properties (163). Whether endothelial insulin 
transport in other organs is representative of skeletal muscle is unclear. To the best of our 
knowledge, there have been no studies of trans-endothelial insulin transport in endothelial cells 
isolated from skeletal muscle capillaries.  
In addition to endothelial heterogeneity, using cultured endothelial cells is problematic 
for several reasons. First, immediately upon isolation the endothelial proteome changes 
significantly. Namely, Schnitzer and colleagues analyzed the proteome of freshly cultured 
endothelial cells and endothelial membranes isolated in vivo to show that 40% of proteins 
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expressed in vitro are not expressed in vivo (164). Especially relevant to the current discussion, 
endothelial monolayers can be up to 100 times more permeable to plasma proteins than intact 
vessels (165). This makes trans-endothelial transport studies in cultured endothelial cells 
problematic. Finally, and perhaps most importantly, endothelial cells in static culture lack the 
complex milieu of the in vivo environment. In vivo, endothelial cells are in contact with one 
another, attached to a complex basement membrane, continuously exposed to shear stress from 
capillary plasma and red blood cells, and receive a myriad of biochemical signals from both the 
circulation and underlying tissue parenchyma. These features of endothelial cells in vivo are very 
difficult to replicate in vitro.  
An ideal technique for the measurement of trans-endothelial transport in skeletal muscle 
capillaries would be 1) conducted in vivo with minimal physiological perturbations 2) able to 
measure both plasma and interstitial insulin as a function of time and 3) able to account for 
perfused capillary surface area. Such a technique would require high sensitivity for the 
measurement of insulin, sufficient spatial resolution to differentiate between plasma and 
interstitial space, and adequate temporal resolution to track rapid insulin dynamics. 
The lack of methodology available for the study of trans-endothelial insulin transport was 
the impetus for Aim 1 (Chapter III). Namely, we sought to develop a technique to directly 
measure trans-endothelial insulin efflux in skeletal muscle capillaries in vivo. Furthermore, we 
wanted to use this technique to determine the mechanism of trans-endothelial insulin efflux in 
skeletal muscle capillaries in vivo (Aim 2, Chapter IV). 
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Interstitial movement of insulin 
A final consideration in the delivery of insulin to the insulin receptor located on the 
surface of myocytes is the movement of insulin within the interstitial space. As discussed above, 
this space is replete with glycosaminoglycans which may sterically hinder insulin’s access to the 
myocyte. As of yet, it is unknown whether interstitial ECM proteins form a major barrier to the 
movement of insulin in the interstitium. Additionally, myofibers contain deep invaginations 
known as t-tubules, which contain insulin receptors (166). Lauritzen and colleagues used an 
elegant microscopy approach to demonstrate that it takes ~10 minutes for insulin to diffuse from 
the surface of the myocyte to deep within the t-tubules (167). Thus, the t-tubular space appears to 
be a barrier to muscle insulin action.  
  
Glucose and Insulin Delivery in Insulin Resistance 
The notion that glucose and insulin delivery regulate muscle insulin action raised the 
intriguing possibility that these processes may contribute to insulin resistance.  Below I will 
discuss the evidence that microvascular dysfunction contributes to muscle insulin resistance. 
 
Muscle microvascular dysfunction accompany obesity and insulin resistance  
Given that insulin stimulates muscle perfusion, it was reasonable to hypothesize that 
impairments in insulin’s vasodilatory effects may contribute to insulin resistance. Alain Baron 
and colleagues demonstrated that the ability of insulin to stimulate leg blood flow was impaired 
in obese, insulin resistant humans (168). These findings have been supported by some (169), but 
not all (47), studies. On the other hand, several studies have shown that obese humans and 
animal models have a diminished response to endothelial-dependent vasodilators and an 
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exaggerated response to vasoconstrictors (170, 171). Interestingly, basal muscle perfusion is 
comparable between lean and obese humans (171). Furthermore, the blood flow response to 
SNP, an NO donor, is preserved in obesity, indicating that smooth muscle relaxation is not 
impaired (168). A fascinating study by Jonathan Lindner and colleagues, using contrast-
enhanced ultrasound in monkeys, showed that during the development of obesity-induced insulin 
resistance, the primary muscle vasodilatory mechanism switches to eicosanoid-based 
vasodilation as NO bioavailability declines (172). Thus, it appears that obesity results in 
alterations to the endothelial production of and response to vasoactive compounds. With respect 
to microvascular perfusion Eugene Barrett and Michael Clark’s groups have demonstrated that 
insulin-stimulated microvascular perfusion is also impaired in obese, insulin resistant humans 
and animal models (173, 174). Not only do obese subjects have a reduction in muscle 
microvascular volume, but their microvascular flow is also more heterogeneous (175). At a 
structural level, muscle capillary density is lower in obese and insulin resistant humans (124, 
176). Interestingly, we have not observed any difference in muscle capillary density between 
lean and obese mouse models (177). In summary, obesity and insulin resistance are strongly 
associated with both structural and hemodynamic vascular dysfunction. These vascular defects 
may contribute to muscle insulin resistance through a reduction in glucose and insulin delivery. 
 
Insulin resistance, endothelial dysfunction, and nitric oxide bioavailability 
 As discussed above, obesity and insulin resistance are associated with impaired 
endothelium-dependent vasodilation (Figure 1.4). Investigators studying coronary artery disease 
had also observed this phenomenon in patients at risk for developing atherosclerosis (178). They  
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Figure 1.4: Endothelial dysfunction and impaired insulin-stimulated vasodilation in 
obesity. Under basal conditions (left), muscle microvascular perfusion is low and a minority of 
capillaries are perfused. In obese subjects, insulin-stimulated NO production from the arterial 
endothelium is impaired. As such, terminal arterioles are unable to relax (middle) and 
microvascular flow distribution is reduced (right). This reduction in capillary recruitment may 
reduce the surface area for glucose and insulin exchange. NO – nitric oxide. Image of capillary 
bed adapted from Human Anatomy & Physiology 9th Edition (Marieb EN & Hoehn KN). 
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termed this impairment in endothelium-dependent vasodilation “endothelial dysfunction.” At the 
molecular level, endothelial dysfunction, or endothelial activation, is characterized by reduced  
NO bioavailability, increased production of reactive oxygen species and enhanced expression of 
inflammatory mediators (179). These molecular defects have been also been observed in the 
endothelium of insulin resistant humans and animal models (180). Most notably, obesity and 
insulin resistance are frequently associated with reduced endothelial NO bioavailability (181). 
The diminishment of endothelial NO is caused by a variety of factors including reduced 
endothelial NOS (eNOS) expression and activity, eNOS uncoupling, and enhanced scavenging 
of NO by oxidant species such as superoxide (181). An interesting study from Francis Kim and 
colleagues demonstrated that, in a mouse model of obesity, reduced aortic NO production occurs 
before the development of muscle insulin resistance. This suggests that reduced endothelial NO 
bioavailability may play a causative role in the development of muscle insulin resistance (182).  
Endothelial function is governed, in large part, by the bioavailability of nitric oxide (NO). 
In arterioles, NO produced by endothelial cells causes smooth muscle relaxation thereby 
reducing resistance to flow and increasing muscle perfusion (110). Furthermore, NO has 
complex effects on capillary barrier function. Namely, under normal, basal conditions NO 
maintains endothelial barrier function (183, 184) whereas under inflammatory conditions NO can 
produce vascular leakiness (185). Given its effects on both perfusion and capillary permeability, 
endothelial NO is well-positioned to be a key regulator of glucose and insulin delivery to muscle. 
Endothelial NO bioavailability may directly regulate muscle insulin delivery by 
modulating either muscle perfusion or trans-endothelial insulin transport. Several groups have 
demonstrated that pharmacological reduction of NO during steady-state hyperinsulinemia 
diminishes muscle perfusion and glucose uptake in both humans and rats (95, 119, 186, 187). 
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Furthermore, mice lacking eNOS display peripheral insulin resistance and impaired muscle 
perfusion (188, 189). These findings demonstrate that reduction of endothelial NO can limit 
muscle perfusion and steady-state muscle insulin action. Whether reducing NO alters trans-
endothelial insulin transport remains to be determined. 
With respect to insulin transport, Barrett and colleagues showed that NO promotes the 
uptake of FITC-labeled insulin into cultured bovine aortic endothelial cells (190). The 
implication of these findings is that NO may promote the movement of insulin across the 
endothelium. However, these studies should be interpreted with caution given the limitations of 
studying endothelial transport function in vitro discussed above. In contrast to these in vitro 
experiments, several in vivo studies have shown that inhibition or genetic deletion of NOS 
actually increases microvascular permeability (183, 184). Thus, the effect of varying endothelial 
NO levels on the movement of insulin across the skeletal muscle capillary endothelium in vivo 
remains unclear. The experiments described in Aim 4 ( Chapter VI) address the role of NO in 
insulin movement across the endothelium of skeletal muscle capillaries in vivo.  
 
Glucose delivery and insulin resistance 
 As alluded to previously, the muscle perfusion defects associated with obesity and insulin 
resistance may lead to a reduction in glucose delivery. To the best of my knowledge, insulin-
stimulated glucose delivery has not been directly measured in obese, insulin resistant humans. 
However, it has been demonstrated that the glucose permeability – surface area product, an index 
of glucose delivery, is reduced in Type II diabetes (191). Furthermore, our laboratory utilized an 
isotopic countertransport technique to show that delivery of glucose is impaired in a rat model of 
diet-induced insulin resistance (192). On the other hand, when insulin resistance was created 
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with a lipid infusion in humans, interstitial glucose delivery was actually increased during an oral 
glucose tolerance test (193). Thus, the relationship between insulin resistance and glucose 
delivery is complex and may depend on obesity, plasma lipids, glycemia, and other factors.  
If impaired glucose delivery were a component of muscle insulin resistance, one would 
expect that experimentally increasing delivery would correct insulin resistance. The majority of 
studies have shown that this is not the case. Ferrannini and colleagues showed that treating 
insulin resistant humans with either SNP or adenosine increased muscle blood flow but did not 
improve insulin sensitivity during an insulin clamp (115, 116). These findings were corroborated 
by an independent laboratory using bradykinin to augment muscle blood flow (194). 
Furthermore, studies from our laboratory demonstrated that treating obese mice acutely with 
sildenafil (a phosphodiesterase-5a inhibitor which increases NO bioavailability) or relaxin (an 
endothelium-dependent vasodilator) does not increase muscle insulin sensitivity (195, 196).  
These findings show that increasing perfusion acutely does not correct muscle insulin resistance. 
This evidence contradicts the hypothesis that impaired glucose delivery contributes to skeletal 
muscle insulin resistance. However, it is possible that the vasodilators described above, while 
increasing blood flow, did not produce efficient microvascular flow distribution or nutritive flow 
(197). It is also possible that the trans-endothelial movement of glucose or its diffusion through 
the interstitial space is restricted in obese subjects. In fact, our lab and others have shown that 
ECM components, such as collagens and hyaluronan, accumulate in the muscle of obese mice 
and humans (198–200). Thus, ECM accumulation in the interstitial space or the glycocalyx 
lining endothelial cells may restrict glucose’s movement across the endothelium or its diffusive 
capacity in the interstitial space.  
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 In contrast to the finding that acute vasodilation does not increase insulin sensitivity, our 
laboratory has found that chronic treatment of insulin resistant mice with vasodilators does 
improve muscle insulin action. Namely, treating mice with sildenafil for 12 weeks concurrently 
with high fat feeding prevented diet-induced muscle insulin resistance (195). Similarly, 3 weeks 
of relaxin treatment following 10 weeks of high fat diet restored skeletal muscle insulin 
sensitivity (196). The mechanism by which chronic vasodilator treatment improves muscle 
insulin sensitivity has yet to be determined. 
 This effect of chronic vasodilator treatment has also been observed to a certain extent in 
humans. Namely, hypertensive patients, who are frequently obese, treated with drugs that block 
the actions of angiotensin II (Ang II) have a lower incidence of Type II diabetes (201). These 
drugs, including angiotensin converting enzyme inhibitors (ACEis) and Ang II receptor blockers 
(ARBs) are vasodilators and improve endothelial function (202–205). ACEis and ARBs, in 
addition to blocking the formation and activity of Ang II, increase the formation and activity of 
Angiotensin-(1-7) [Ang-(1-7)], another peptide hormone of the renin angiotensin system (206). 
Ang-(1-7) is a vasodilatory peptide that counterbalances Ang II (206). Liu and colleagues 
showed that Ang-(1-7) causes a dose-dependent increase in insulin-stimulated microvascular 
perfusion and glucose uptake in lean mice (123). Ang-(1-7) treatment also improves glucose 
homeostasis in rodent models of obesity and insulin resistance (207–209). Whether this peptide 
may be used to specifically treat skeletal muscle insulin resistance is unknown. Furthermore, it is 
an ideal peptide to investigate mechanisms by which chronic vasodilator treatment restores 
insulin sensitivity in obese subjects. In Aim 5 (Chapter VII), I will test the hypothesis that 
chronic treatment of obese mice with Ang-(1-7) will restore muscle insulin sensitivity. 
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Insulin delivery, trans-endothelial insulin transport, and insulin resistance 
Given that obese and insulin resistant subjects display endothelial dysfunction, it is 
reasonable to hypothesize that they also have impaired muscle insulin delivery. Indeed, several 
investigators have demonstrated that the delivery of insulin to the muscle interstitial space is 
reduced in humans and animal models of insulin resistance. Using microdialysis during insulin 
clamps and glucose tolerance tests, Lönnroth and colleagues showed that the appearance of 
insulin in the interstitial space is delayed in obese, insulin resistant humans (210, 211).  These 
findings were supported by experiments utilizing animal models of obesity and insulin resistance 
(156, 212). Not all studies have arrived at the same conclusion, however. During insulin clamps 
in a cohort of obese humans, Lillioja et al. did not find any changes in the ratio of arterial to 
lymph insulin, an index of insulin delivery (213). Furthermore, lipid-induced insulin resistance in 
lean subjects does not appear to impair the access of insulin to skeletal muscle (193, 214). As 
with glucose delivery, the precise relationship between obesity, insulin resistance and insulin 
delivery is complex and further investigation is warranted.  
As discussed previously, delivery of insulin to the muscle interstitial space is a function 
of both microvascular perfusion and trans-endothelial insulin transport (Figure 1.5). Using 
microdialysis or lymph sampling, it is not possible to determine whether changes in total insulin 
delivery are due to microvascular perfusion, trans-endothelial insulin transport, or both. As of 
yet, no direct measurements of trans-endothelial insulin transport in the setting of obesity and 
insulin resistance have been made. The experiments in Aim 3 (Chapter V) are designed to test 
whether trans-endothelial insulin transport is delayed in a mouse model of obesity and insulin 
resistance.  
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Figure 1.5: Microvascular perfusion and capillary permeability to insulin control muscle 
insulin delivery. Schematic illustrating the effects of perfusion and capillary permeability on 
insulin (black pentagons) delivery to the muscle. A) In a low perfusion, low permeability state, 
there is relatively little insulin delivered to the muscle. With isolated increases in either B) 
perfusion or C) capillary permeability to insulin, insulin delivery is increased. Insulin delivery is 
enhanced even further by D) concomitant increases in both perfusion and capillary permeability. 
Of note, interstitial sampling techniques which measure muscle insulin delivery are unable to 
deconvolve the contributions of perfusion and permeability to delivery.  
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Once insulin crosses the endothelium, it must navigate the interstitial space to find insulin 
receptors on the surface of myocytes. As discussed previously, the interstitial ECM (70), t-tubule  
geometry (167), or interstitial fluid flux may alter interstitial insulin’s access to the myocyte. 
Bergman and colleagues performed a fascinating study whereby they injected insulin directly 
into the interstitial space of lean and obese dogs and measured its appearance in the lymph and 
vein (215). They found that, in obese dogs, the interstitially injected insulin was reabsorbed into 
the venous circulation whereas it had appeared mostly in the lymph in lean dogs. These findings 
raise the intriguing possibility that insulin’s dispersion within the interstitial space may 
contribute to insulin action and insulin resistance. 
 
Aims and Hypotheses 
The aims of this Dissertation are to: 
 
1. Develop a technique to directly measure trans-endothelial insulin transport in skeletal 
muscle capillaries in vivo. 
2. Test the hypothesis that trans-endothelial insulin transport occurs by a saturable, insulin 
receptor-mediated process. 
3. Investigate the effects of pharmacologically manipulating nitric oxide levels on trans-
endothelial insulin transport. 
4. Determine whether trans-endothelial insulin transport is impaired in a mouse model of 
obesity and insulin resistance. 
5. Determine the effects of treating obese mice chronically with Ang-(1-7), a vasodilatory 
peptide of the renin-angiotensin system, on skeletal muscle insulin sensitivity.  
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I hypothesize that insulin is transported across the endothelium by a saturable process that 
involves the insulin receptor and is positively regulated by NO. Furthermore, I hypothesize that 
trans-endothelial insulin transport is impaired in skeletal muscle capillaries of obese, insulin 
resistance mice. Finally, I expect that treating obese mice chronically with Ang-(1-7), a 
vasodilatory peptide of the renin-angiotensin system, will restore skeletal muscle insulin 
sensitivity by improving microvascular function. 
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CHAPTER II 
 
RESEARCH METHODS AND MATERIALS 
 
Mouse Models 
 All animal protocols were approved by the Vanderbilt Institutional Animal Care and Use 
Committee and conducted in Association for Assessment and Accreditation of Laboratory 
Animal Care-accredited facilities. C57Bl/6J mice were used for all experiments. Mice were 
housed in a temperature and humidity-controlled facility and maintained on a 12-hour light/dark 
cycle. All mice were purchased from The Jackson Laboratory with the exception of the mice 
used for intravital microscopy experiments in Chapter V, which were bred and maintained at 
Vanderbilt University. Breeding pairs housed in the Vanderbilt University mouse colony were 
fed a “breeder chow” diet (Table 2.1). Pups were weaned at 3 weeks of age, separated by sex, 
and switched to a standard chow diet (5001 Purina Laboratory Rodent Diet; Table 2.1). At 6 
weeks of age, male and female mice were fed either a chow or high fat diet (HFD; F3282 
BioServ; Table 2.1) ad libitum for 16 weeks. These mice were subsequently used for intravital 
microscopy in Chapter V. For the experiments in Chapter VII, 6 week-old male mice were 
purchased from Jackson Laboratory and either fed a chow or HFD for 11 weeks.  
 
Diet Fat (%kcal) Carbohydrate (%kcal) Protein (%kcal) 
Breeder chow 25.3% 54.9% 19.8% 
Chow 13.3% 57.9% 28.7% 
High fat 59.0% 26.0% 14.9% 
          Table 2.1. Mouse diet macronutrient composition.  
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Carotid Artery and Jugular Vein Catheterization 
 A detailed protocol describing the procedure for catheterization of the carotid artery and 
jugular vein in mice is available on the Vanderbilt Mouse Metabolic Phenotyping Center website 
(https://labnodes.vanderbilt.edu/resource/view/id/10764/community_id/1418) (216). All 
equipment and surgical spaces were sterilized prior to catheterization surgeries. Surgeries were 
performed on mice anesthetized with 2% isofluorane administered continuously through a nose 
cone.  
The intrascapular and neck regions were first shaved and sterilized with betadine and 
70% ethanol. A small vertical midline incision was made 5mm cephalic to the sternum. The left 
carotid artery was then isolated by folding back the sternomastoid muscle, removing connective 
tissue from the artery, and gently separating the artery from the vagus nerve. The cephalic end of 
the carotid artery was then ligated with silk suture. To open the artery for catheter insertion, the 
caudal end of the carotid artery was clamped with micro-serrefine and a small incision was made 
just below the cephalic ligation. Subsequently, a polyethylene catheter was inserted into the 
carotid artery and advanced to the aortic arch. Finally, the caudal end of the carotid artery was 
ligated and the catheter sampling ability was confirmed.  
To expose the right jugular vein, a second incision was made 5mm to the right of the 
midline and 2mm caudal to the first incision. Subsequently, the right jugular vein was isolated by 
blunt dissection. After ligating the cephalic end of the right jugular vein, a small incision was 
made in the vein just below the cephalic ligature. A Silastic catheter was then inserted into the 
jugular vein and the caudal end of the vein was ligated with silk suture. Finally, the sampling 
ability of the venous catheter was confirmed. 
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 In order to exteriorize the catheters, they were tunneled under the skin and through a 
small incision between the shoulder blades. The ventral incisions made for catheter insertion 
were then closed with nylon suture. The tunneled catheters were connected to the steel tubing of 
a MASAÔ, a device which allows the exteriorized catheters to protrude outwards from the 
mouse’s shoulder blades. The MASAÔ was then implanted in the incision between the mouse’s 
shoulder blades and the incision was closed with nylon suture. Finally, the patency of both 
catheters was re-confirmed and catheters were flushed with 10U/ml heparinized saline.  
Following catheterization, mice were placed in a clean cage on a heating pad. Mice were 
allowed to recover for at least 3 days following jugular vein catheterizations and at least 5 days 
following combined carotid artery and jugular vein catheterization. Recovery from 
catheterization surgeries was deemed adequate if mice lost no more than 10% of their pre-
operative body weight and if their behavior was normal.  
 
 
In Vivo Glucose Metabolism Experiments 
  
Hyperinsulinemic-euglycemic clamps (insulin clamp) 
 Insulin clamps were performed in conscious, unstressed mice as described in detail 
previously (Figure 2.1) (216). At least 5 days before experiments, carotid artery and jugular vein 
catheters were implanted for blood sampling and infusions, respectively. Mice were fasted for 5 
hours prior to starting the insulin clamp. A primed, continuous infusion of [3-3H]glucose 
(0.04µCi×min-1; Perkin Elmer) was started at t=-90 min to determine basal rates of plasma 
glucose appearance (Ra) and disappearance (Rd). Basal arterial samples were collected to 
measure glucose specific activity (t=-15 and -5 min), insulin (t=-5 min), and non-esterified fatty 
acids (NEFA; t=-15 and -5 min; average value reported). At t=0 min, continuous insulin  
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Figure 2.1 Experimental setup for the hyperinsulinemic-euglycemic clamp. A) Schematic 
depicting the jugular vein infusion and arterial sampling arrangement. Modified from: Glucose 
Clamping the Conscious Mouse (Vanderbilt MMPC 2005). B) Insulin clamp protocol. 
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(4mU×kg-1×min-1; Humulin R; Eli Lilly) and variable glucose (D50 + 50µCi[3-3H]glucose) 
infusions were initiated. For the insulin clamps in Chapter IV, we used either unlabeled insulin 
or insulin labeled with Alexa Fluor 647 to assess the bioactivity of insulin-647 (INS-647). Donor 
erythrocytes were infused throughout the insulin clamp to prevent a fall in hematocrit. From time 
t=0 to 120 min, arterial glucose was measured every 10 min and the exogenous glucose infusion 
rate (GIR) was adjusted to maintain euglycemia (130-150 mg/dl). Steady-state GIR and [3-
3H]glucose kinetics were determined from t=80 to 120 min.  During the clamp, arterial samples 
were collected for the measurement of glucose specific activity (t = 80, 90, 100, 110, 120 min),  
insulin (t=100 and 120 min) and NEFA (t=80 and 120 min; average value reported). At t=120 
min, mice received an intravenous bolus of 2[14C]deoxyglucose (2[14C]DG; 13µCi; Perkin 
Elmer) to determine the glucose metabolic index (Rg), a measure of tissue-specific glucose 
uptake (217). Blood samples were obtained at t = 2, 7, 15, 25, and 35 min after the bolus to 
measure plasma 2[14C]DG disappearance. At t = 155min, mice were sacrificed by intravenous 
injection of sodium pentobarbital. Tissues were immediately freeze-clamped and stored at -80ºC 
for biochemical analysis or incubated in 10% neutral buffered formalin followed by 70% ethanol 
for histological analysis.  
 
Insulin tolerance tests 
In Chapter IV, we performed insulin tolerance tests to assess the in vivo bioactivity of 
INS-647. Insulin tolerance tests were performed under anesthesia as to mimic the conditions of 
the in vivo imaging experiment. At least 5 days prior to the day of the study, mice had indwelling 
catheters implanted in the jugular vein for infusions of insulin, isotopic glucose tracers, and 
anesthetics (216). After a 5 hour fast, mice were anesthetized with an intravenously administered 
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ketamine / xylazine / acepromazine (KXA) cocktail (7.9/1.6/0.2 mg/kg). Booster doses of KXA 
were given as needed throughout the remainder of the study. Depth of anesthesia was ensured by 
assessing the response to a toe pinch. Basal glucose was measured (Accu-Chek Aviva) from the 
tail vein at 15 and 5 minutes prior to the start of the experiment. At t=0 min a 1U/kg bolus of 
either insulin or INS-647 together with 2[14C]DG (13µCi) was administered. Subsequently, tail 
vein glucose levels were measured at t= 3, 6, 9, 12, 15, 20, 25, and 30 min following the insulin 
bolus. Mice were euthanized by cervical dislocation immediately following the experiment and 
tissues were harvested for further analysis. The glucose disappearance rate was calculated as the 
rate of fall of glucose over the first 15 minutes of the experiment (218). 
In Chapter VI, we performed frequently sampled intravenous insulin tolerance tests in 
conscious, chronically catheterized mice to test the effects of acute L-NAME treatment on 
insulin sensitivity. At t = -15 min, mice received an intravenous bolus of either 30mg/kg L-
NAME or an equivalent volume of saline (50µL). At t = 0 min mice received a 25mU/kg 
intravenous bolus of insulin (Novolin R; Novo Nordisk) diluted in 0.1% bovine serum albumin 
(Sigma Aldrich) in 0.9% saline. Arterial whole blood glucose was measured at t = – 5, 1, 2, 3, 4, 
5, 6, 7, 8, 9, 10, and 15 min (Contour; Bayer) following the insulin bolus.  
 
Fluorescent Probes for Intravital Microscopy 
Insulin-647 synthesis and analysis 
 
The conjugation of Alexa Fluor 647 to insulin follows a modified version of a procedure 
described previously (219). Diisopropylethylamine (DIPEA, 7 mmol, 1.22 mL, 40 eq) was 
initially added to a solution of biosynthetic human insulin (BHI, 0.2 mmol, 1.16 g) dissolved in 
DMSO (15 mL).  Boc-OSu (0.445 mmol, 95.7 mg, 2.5 eq) was then dissolved in DMSO (2 mL) 
 49 
and added slowly to the BHI solution over 5 min.  After 40 min, the reaction was quenched with 
TFA (100 µL) and diluted with 0.1 N HCl (150 mL).  The reaction mixture was purified by 
reverse phase-HPLC (RP-HPLC; Waters 19x300 mm SymmetryPrep C18) using gradients of 
acetonitrile in water with 0.1% TFA. Fractions containing the desired product as determined by 
LC-MS were pooled and lyophilized to provide a white powder (647.3 mg). The calculated 
molecular weight was 6,007.8 Da, and the electrospray mass spectrometry observed average 
mass was 6,006.7 Da. This intermediate product was a BHI conjugate containing t-Boc 
protecting groups on the A1 and B29 position of BHI (A1,B29-Bis-Boc-BHI). 
To conjugate Alexa Fluor 647 to the protected BHI intermediate, Alexa Fluor 647–NHS 
ester (2 mg; Life Technologies) was dissolved in DMSO (20 µl) and added slowly to a 
dimethylformamide solution (500 µl) containing A1,B29-Bis-Boc-BHI (20 mg) and DIPEA (17 
µl, 30 Eq). The reaction mixture was wrapped in aluminum foil, agitated for 5 hours, and then 
quenched with acetic acid (200 µl), diluted with water (10 ml), and lyophilized. The Boc groups 
were removed by treatment with a mixture of TFA/water/triisopropylsilane (92:4:4, vol/vol) for 
1 hour at room temperature, and the material was then precipitated with cold diethyl ether and 
centrifuged at 2,147 x g for 5 minutes. The blue pellet was resuspended in acetonitrile/water (1:1, 
vol/vol) and purified to 98.9% by RP-HPLC (Waters 7.8 × 300 mm SymmetryPrep C18) using 
gradients of 0.01% HCl/acetonitrile in water. Fractions containing the desired product, INS-647, 
were pooled and lyophilized to provide a blue powder (8 mg). The calculated molecular weight 
was 6,646.6 Da, and the electrospray mass spectrometry observed average mass was 6,648.3 Da. 
The location of the Alexa Fluor 647 label was confirmed at the B1 position by digestion of 100 
µg of product with Glu-C endoproteinase (P6181-50UG, Sigma-Aldrich; 10 µg) and analysis of 
the fragments by LC-MS. 
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To determine the affinity of INS-647 for the insulin receptor, we used a scintillation 
proximity assay (SPA) described previously (220). Briefly, membranes were prepared from 
HEK293 cells overexpressing the human insulin receptor. Membranes were then immobilized on 
polyvinyltoluene polyethyleneimine-treated Type A wheatgerm agglutinin-coupled SPA beads 
(GE Healthcare). Subsequently the abilities of INS-647 and BHI to compete with 125I-insulin 
binding to insulin receptors were assessed. 125I-insulin binding to the SPA beads was detected 
with a scintillation counter (Perkin Elmer MicroBeta Trilux). IC50 values for unlabeled insulin 
and INS-647 binding were calculated from 4-parameter logistic non-linear regression analysis.  
IC50 values were then converted to affinity values (Ki) using the Cheng-Prussoff equation Ki = 
IC50/(1+L/Kd), where L is the concentration of radioligand used in the experiment and Kd is the 
equilibrium binding affinity for the radioligand for the human insulin receptor (0.218nM as 
determined by saturation analysis). Three independent experiments were conducted with the 
geometric mean and standard error of the mean (SEM) reported. 
 
 
Insulin and insulin-647 pharmacodynamics 
Insulin and INS-647 pharmacodynamic studies were performed in mice with indwelling 
jugular vein and carotid artery catheters. Following a 5 hour fast, mice were anesthetized with 
(7.9/1.6/0.2 mg/kg) KXA through the venous catheter and placed on a heating pad. After a 
baseline arterial blood sample was taken, mice received a 4U/kg intravenous bolus of either 
insulin or INS-647. Subsequently, arterial blood samples were collected at t = 1, 3, 5, 10, 15, and 
30 minutes following the bolus. 
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Insulin-647 stability in vivo 
 
To assess the stability of INS-647 in vivo we first injected a bolus of INS-647 into 
anesthetized mice through an indwelling jugular vein catheter. 30 minutes later, tail vein blood 
was collected into heparinized capillary microtubes. Plasma was separated from erythrocytes by 
centrifuging whole blood at 13,000 rpm for 1 minute. Plasma was then diluted 25X with 0.9% 
NaCl and the total plasma fluorescence was measured in a quartz cuvette (Sterna Cells) with a 
FluoroMax-4 Spectrofluorometer (Horiba). Samples were excited at 633nm and emission spectra 
were collected from 650-750nm. Fluorescence intensity for a sample was calculated as the 
intensity area under the curve from 650-750nm. Background fluorescence was measured in 
unlabeled mouse plasma and subtracted from samples containing INS-647. After measuring total 
fluorescence, the plasma was separated into low (<3kDa) and high (>3kDa) molecular weight 
fractions using centrifugal filters with a 3kDa cutoff (Amicon Ultra, Millipore). Fluorescence 
was then measured in the two fractions as described above, with fractionated unlabeled mouse 
plasma serving as the background. Finally, the percent of fluorescence in each fraction was 
calculated. Fluorescence in the low molecular weight fraction was interpreted as Alexa Fluor 647 
which had become separated from insulin over the course of the experiment.   
 
 
Insulin-647 photostability 
 
The rate of INS-647 photobleaching was measured in untreated glass capillary tubes on 
an LSM 780 laser scanning confocal microscope (Zeiss). INS-647 was imaged continuously for 
5 minutes using a 633nm HeNe laser with powers ranging from 348 to 435 µW. Image 
acquisition parameters (i.e. size, scan speed) were set to the same values as used during in vivo 
imaging experiments. Photomultiplier tube gain and offset were set so that the histogram of 
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intensity values was centered in the full dynamic range for each laser power. From images for 
each of the different laser powers, we calculated the exponential decay constant of intensity as a 
function of scan number (i.e. exposure time). We then calculated the percent loss of fluorescence 
per scan as a function of laser power. Finally, we set a threshold of acceptable percent loss of 
fluorescence to photobleaching (~5-8%) and then calculated the laser power necessary to stay 
below this level of photobleaching during an experiment.   
 
 
Insulin-647 emission spectrum 
 
Equimolar amounts of INS-647 or free Alexa Fluor 647 were first diluted 100x in 0.9% 
NaCl. Probe fluorescence was then measured in a quartz cuvette with a FluoroMax-4 
Spectrofluorometer. Samples were excited at 633nm and emission spectra were collected from 
650-750nm. The slit width for excitation and emission was set to 1nm and the integration time 
for the photomultiplier tube detector was 1 second.  
 
 
Fluorescent probe preparation and storage 
 
2,000,000 Da tetramethylrhodamine-dextran (rho-dex), 3,000 Da Alexa Fluor 680-
dextran, 10,000 Da Alexa Fluor 647-dextran, and Alexa Fluor 647-bovine serum albumin (BSA-
647) were all purchased from Life Technologies. Lyophilized INS-647 was solubilized in a 
buffer containing buffer 16mg/ml glycerol, 2mg/ml m-cresol, 20mM Tris-HCl and 1% Triton X-
100 to a final concentration of 1mg/ml. This is similar to the buffer used in pharmaceutical 
insulin preparations which prevents aggregation of INS-647. All other probes were dissolved in 
sterile 0.9% injectable saline to a concentration of 10mg/ml. All probes were mixed vigorously 
and sonicated in a water bath sonicator (Branson 2510) for 1 hour. Subsequently, probes were 
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centrifuged for 20 min at 13,000 rpm to remove any insoluble material. Finally, probes were 
visually inspected under a microscope to ensure that no aggregates were visible.  
 
Flow cytometry of rhodamine-6G-labeled leukocytes 
To determine the efficiency with which circulating blood cells were labeled by 
rhodamine 6G in vivo, anesthetized mice were injected with 0.2mg/kg rhodamine 6G through an 
indwelling jugular vein catheter. Blood samples were collected from an indwelling arterial 
catheter prior to, and 5 and 30 minutes following rhodamine 6G injection. Red blood cells were 
lysed with ACK lysis buffer (K D Medical). After a wash step with cold fluorescence-activated 
cell sorting (FACS) buffer (PBS, 1% FBS, 2mM EDTA), the remaining leukocytes were 
incubated in an Alexa Fluor 647-labeled anti-CD45 antibody (2.5 µg/ml; BioLegend, Cat: 
103123, Clone 30-F11) for 30 minutes at room temperature. Cells were then washed twice and 
resuspended in cold FACS buffer containing 0.2 µg/ml DAPI. Appropriate single-color controls 
were also prepared (unstained, DAPI, Rhodamine6G, and Alexa Fluor 647 only). Samples were 
injected into a 5-laser BD LSRII flow cytometer following daily Cytometer Setup and Tracking 
quality control. Samples were analyzed using FACS DiVa software version 8.  
 
 
Intravital Microscopy 
  
Gastrocnemius preparation 
 
Mice were first anesthetized with (7.9/1.6/0.2 mg/kg) KXA through an indwelling venous 
catheter and placed on a heating pad. After assuring an appropriate depth of anesthesia, hair was 
removed from the left leg with an electric razor. A small notch was made in the skin covering the 
lateral ankle. The skin was then removed from the lower leg to reveal the lateral gastrocnemius 
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(Figure 2.2A). Finally, the fascia covering the lateral gastrocnemius was carefully removed to 
uncover the fibers of the lateral gastrocnemius (Figure 2.2B). Extensive care was taken to 
minimize perturbations to the muscle fibers and to avoid severing any blood vessels. After 
preparing the lateral gastrocnemius, the mouse was transferred to the custom stage mount for 
subsequent imaging.  
 
Custom stage mount construction 
 
Stage mounts were constructed with the lid of a standard plastic 96 well plate and a 
coverglass. Briefly, a rectangular opening was cut into the 96 well plate lid with a heated scalpel. 
Then, a 22mm x 50mm #1.5 cover glass (Fisher) was sealed on top of the rectangular opening 
using nail polish and silicone medical adhesive (Factor II, Inc). A 1-200µL pipette tip was fixed 
onto the stage mount with the silicone adhesive to serve as a port for removing fluids off of the 
coverslip.  
 
 
Physiological monitoring and maintenance 
 
Body temperature was measured with a rectal probe and maintained at 37°C using a 
feedback controller system connected to an electric blanket (Harvard Apparatus). To maintain 
the hydration and physiological stability of the exposed gastrocnemius, the tissue was 
continuously irrigated with a bicarbonate-buffered physiological saline solution composed of (in 
mmol/L)132 NaCl, 4.7 KCl, 2 MgSO4, 1.2 CaCl2, and 18 NaHCO3 (221). This solution was 
maintained at 37°C and bubbled continuously with 95%N2/5%CO2 to maintain pH at 7.4. The 
saline solution was continuously circulated over the exposed tissue with a peristaltic pump 
(inflow) and a vacuum trap (outflow).  
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Figure 2.2: Method for exposing the gastrocnemius for intravital fluorescence microscopy. 
A) Image depicting the lateral gastrocnemius after the skin has been removed. B) Image showing 
the exposed gastrocnemius fibers following careful removal of the overlying fascia. 
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Selection of imaging region 
 
The quality of the gastrocnemius preparation was visualized using tissue 
autofluorescence. Light from a 120W mercury arc lamp (XCite® 120) was sent through a 
bandpass filter (Zeiss Filter Set 10; Excitation: 450-490nm, FT: 510nm, Emission: 515-565nm) 
onto the exposed gastrocnemius. With this filter, blood vessels are visible as dark structures 
against autofluorescence emanating from the tissue. First, we ensured that fibers were 
sufficiently exposed and that no hairs were in potential fields of view. After ensuring the quality 
of the preparation, 50µg rho-dex was infused into the animal. The filter set was then switched 
(Zeiss Filter Set 43 HE; Excitation: 550/25nm, FT:570nm, Emission: band pass 605/70) to 
visualize rho-dex fluorescence emanating from blood vessels. The field of view was selected 
from a capillary bed emanating from the external sural artery and based on the following criteria: 
1) the presence of a sufficient number of clearly visible capillaries 2) the absence of large vessels 
in the nearby area and 3) the absence of capillaries immediately adjacent to one another.  
 
 
Molecular efflux imaging 
 
All imaging was performed on an inverted Zeiss LSM 780 microscope (Zen software) 
with a 20X 0.8NA Plan-Apochromat air objective. For imaging of trans-endothelial molecular 
efflux (INS-647, BSA-647, dextrans), rho-dex fluorescence was excited using light from a 
561nm solid-state laser and detected on a multichannel photomultiplier tube. The near infrared 
fluorophores were excited using a helium-neon 633nm laser and emitted light was detected using 
a GaAsP detector. For both rho-dex and the near-infrared fluorophores, excitation and emission 
light were passed through an MBS 488/561/633 dichroic. A confocal pinhole was set to give an 
optical section of 8µm (+/- 4µm about the focal plane). Imaging of the rho-dex and near-infrared 
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fluorophores was performed using two-channel sequential excitation and detection to prevent 
bleed through. We switched between channels every line to minimize channel mis-registration 
due to intra-scan motion artifacts. 8-bit intensity, 1024x1024 pixel images were acquired with 
unidirectional scanning. For each time point, a 4-“slice” z-stack was acquired in each channel 
using a step size of 4µm to avoid aliasing. Photomultiplier tube detector settings were adjusted to 
maximize the dynamic range of the detector and kept constant for each given experiment to 
allow for quantitative comparisons.  
Following the selection of an imaging region but prior to administration of the probes, a 
background image was acquired. Subsequently, INS-647, 3kD dextran-680, 10kD dextran-647, 
or  BSA-647 were infused through the indwelling vein catheter and followed with a 20µl pulse 
of saline. For the experiments in Chapter III and IV, images were then acquired using the 
procedure described above at t=0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12.5, 15, 20, 30 min following 
probe injection. For mice receiving 2U/kg INS-647 in Chapter IV, images were collected every 
minute for 15 minutes. For the mice receiving 4U/kg INS-647 in Chapter V and VI, images were 
acquired every minute for 15 minutes. 
The image acquisition procedure for mice receiving 0.5U/kg or 1U/kg INS-647 was 
modified slightly in order to increase sensitivity. Namely, the laser power was doubled to image 
the low level of INS-647. In order to keep the total laser dose similar to other INS-647 imaging 
experiments, we reduced the number of scans per experiment. To do this, we acquired only 2 
slices per z-stack and reduced the number of time points at which images were collected (t= 0, 1, 
2, 3, 4, 5, 7.5, 10, 15 min following injection). Furthermore, the pixel dwell time for each scan 
was increased to enhance signal detection. 
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In vivo imaging of capillary leukocyte and platelet adhesion 
 
The gastrocnemius preparation for in vivo imaging was performed as described above. 
0.2mg/kg of rhodamine-6G (Sigma) was injected into mice and allowed to circulate for 5 
minutes to accumulate in leukocytes (222). At this time, images were acquired to determine the 
basal level of capillary leukocyte adhesion. Rhodamine-6G fluorescence was excited with light 
from a 514nm Argon laser passed through an MBS 458/514 dichroic beam splitter. Emitted light 
was passed through an open pinhole (145µm) and detected with a multichannel photomultiplier 
tube. 512x512 pixel single-plane images were acquired at 8-bit intensity depth using 
unidirectional scanning. Images were acquired continuously for a period of 2.61 minutes. To test 
if the laser illumination caused an increase in leukocyte adhesion, the gastrocnemius was either 
illuminated using the same scheme as during INS-647 imaging or not illuminated at all. 
Subsequently, a second round of rhodamine-6G imaging was performed as described above. 
Rhodamine-6G+ structures were defined as leukocytes if they were >8µm in diameter and 
platelets if they were <5µm in diameter. Leukocytes and platelets were deemed “adherent” if 
they remained in the same location along the vessel wall for >30s (223).  
 
 
Phototoxicity 
To determine whether the light exposure dose affected the efflux kinetics of INS-647, an 
experiment was performed where images were only acquired at t=0 and 30 min, thereby reducing 
the laser dose by ~87%. The fractional distribution of INS-647 in the intravascular and 
extravascular spaces was then measured at t=30min under normal INS-647 conditions and under 
the reduced light exposure conditions. 
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Intravital Microscopy Image Analysis 
 
Intravascular and extravascular spaces were segmented in raw images using a custom 
ImageJ macro (See Appendix). A mask of vascular structures in the rho-dex channel was created 
using Otsu thresholding (224). This mask was then closed (dilation then erosion) and opened 
(erosion then dilation) with mathematical morphometric techniques. We then applied a median 
filter (radius = 4 pixels) to remove any remaining noise. Object recognition was then performed 
with the ImageJ Particle Analyzer to select vessel structures that were larger than 50µm2 in area 
and having circularity from 0-0.5. The final mask of these vascular structures was then applied to 
the INS-647 channel to measure the intravascular intensity of INS-647. The mask was then 
dilated in steps of 0.5µm starting at 1µm from the capillary wall out to 3µm from the capillary 
wall to segment the interstitial spaces immediately adjacent to the capillary. The intensity of 
INS-647 was then measured in all of these extravascular segments. The contribution of INS-647 
from multiple vessels to a single interstitial segment was avoided by 1) imaging regions in which 
capillaries are not immediately adjacent to one another (i.e. >15 µm apart in most cases) and 2) 
restricting analysis of the interstitial space to 3µm from the capillary wall.  
Following the extraction of intravascular and extravascular INS-647 intensity vs. time 
profiles, a number of post-processing steps were performed. First, data were background-
subtracted using intensity values from background images collected during imaging experiments. 
Subsequently, the loss of fluorescence due to photobleaching was corrected for each scan in the 
interstitial spaces. We chose not to correct the intravascular INS-647 measurements for 
photobleaching because intravascular INS-647 is circulating through the capillary blood stream 
and therefore most likely does not reside in the field of view long enough to undergo significant 
bleaching. The intensities from the 4 slices of the z-stack were averaged to give a single value at 
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each point in time and space. At this point, the contribution of free Alexa Fluor 647 to the 
observed kinetics of INS-647 was subtracted assuming that 10% of observed fluorescence 
kinetics was due to free Alexa Fluor 647 (See Figure 3.6). Importantly, neither the 
photobleaching nor the free Alexa Fluor 647 corrections had a detectable effect on subsequent 
calculations. At the end of image processing, we obtained a 3D matrix describing the intensity of 
a given probe as a function of time after injection and distance from the capillary wall. These 
matrices were then used for endothelial transport parameter estimation as described below.    
 
Intravital Microscopy Quantification 
Model-independent analysis 
In Chapter V, the clearance of INS-647 from the plasma was analyzed by fitting the first 
5 minutes of the plasma INS-647 decay curve to a mono-exponential decay function. We decided 
to describe capillary INS-647 kinetics with mono-exponential decay as our imaging data fit this 
function better than bi-exponential decay (data not shown). The rate of trans-endothelial insulin 
efflux can be assessed by determining the rate at which insulin in the capillary equilibrates with 
the surrounding interstitial space. To measure this equilibration rate, we plotted the ratio of 
plasma to interstitial INS-647 intensity as a function of time following the INS-647 bolus. Over 
time, this ratio will decay as INS-647 leaves the plasma and enters the interstitial space. We 
quantified the gradient decay constant of the plasma/interstitial INS-647 ratio by fitting the first 5 
minutes of the decay curve to a mono-exponential decay function. 
To estimate an index of total INS-647 delivery to the muscle, we measured the mean 
INS-647 intensity in the entire extravascular space of the field of view. Extravascular INS-647 
was measured by using the capillary mask from the vascular segmentation algorithm, dilating the 
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mask by 1µm, and then inverting the mask to measure INS-647 intensity in the entire 
extravascular space. In Chapter V and VI, we calculated the baseline-subtracted area under the 
extravascular INS-647 curve using trapezoidal integration as a measure of total insulin delivery.  
 
 
Mathematical modeling 
To model molecular efflux kinetics, we initially assumed that probes move through the 
interstitial space by diffusion. Therefore, as a base model we used the diffusion equation, a 
second-order partial differential equation, to describe the movement of probes through the 
interstitial space (Equation 1). While movement of INS-647 in the interstitial space occurs in 3 
dimensions, we restricted our analysis and subsequent modeling to 1 dimension. We chose to 
make this dimensional reduction because it is not currently technically feasible to precisely 
measure the movement of INS-647 in the z-plane in a live animal. Therefore, we assume that the 
transport parameters governing INS-647 movement in 1 dimension generalize or extend to 3 
dimensions. We also assumed that probes are removed from the interstitial space by a first-order, 
concentration-dependent process (Equation 1). The initial (IC) and boundary conditions (BCs) to 
the diffusion equation are as follows: IC) Prior to administration of the INS-647 bolus (i.e. t=0), 
INS-647 intensity is 0 for all x. BC1) At points infinitely far from the capillary wall INS-647 
intensity is 0 for all t. BC2) The boundary condition describing movement of INS-647 from the 
plasma into the interstitial space was set to either a) the modified Fick equation to describe 
diffusion (Equation 2a), b) an equation describing fluid-phase transport (Equation 2b), or c) the 
Michaelis-Menten equation (Equation 2c). The diffusion equation (Equation 1) was solved with 
the aforementioned boundary and initial conditions using Laplace transforms (225) to give 
equations describing either diffusion (Equation 3a), fluid-phase transport (Equation 3b), or 
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saturable transport (Equation 3c) across the endothelium. The inputs to the equation are the 
independent variables x and t, the plasma INS-647 intensity as a function of time cp(t), and the 
adjustable parameters D, k, and P (diffusion model), D, k, kL (fluid-phase transport model), or D, 
k, Vmax and Km (Michaelis-Menten model).  
(1)  !"!# = 𝐷 !&"!'& − 𝑘𝑐 
(2a) 𝑃 ,𝑐-(𝑡) − 𝑐(0, 𝑡)3 = −𝐷 !"!#4'56 
(2b) 𝑘7𝑐-(𝑡) = −𝐷 !"!#4'56 
(2c) 𝑉9:' ";(#)<=>";(?) = −𝐷 !"!#4'56 
(3a) 𝑐(𝑥, 𝑡) = ℎ ∫ 𝑐-(𝜏)𝑒EF(#EG) HI JK(#EG) 𝑒 LM&NO(?LP) − ℎ𝐷𝑒Q'>JQ&(#EG)𝑒𝑟𝑓𝑐 T 'UVJ(#EG) + ℎV𝐷(𝑡 − 𝜏)XY 𝑑𝜏#6  
(3b) 𝑐(𝑥, 𝑡) = 𝑔 ∫ 𝑐𝑝(𝜏)𝑒EF(#EG)I JK(#EG) 𝑒 LM&NO(?LP)#6 𝑑𝜏 
(3c) 𝑐(𝑥, 𝑡) = 𝑎 ∫ ( 𝑐𝑝(𝜏)<=>𝑐𝑝(𝜏))𝑒EF(#EG)I JK(#EG) 𝑒 LM&NO(?LP)#6 𝑑𝜏 
In the above equations, c = INS-647 intensity, t = time, D = interstitial diffusion 
coefficient, x = distance from the capillary, k = interstitial removal constant, P = permeability, kL 
= the fluid-phase mass transfer coefficient, cp(t)  = plasma INS-647 intensity as a function of 
time, c(0,t) = the interstitial INS-647 intensity immediately adjacent to the abluminal side of the 
capillary wall, Vmax = the maximum rate of reaction, Km = the concentration of substrate at ½ 
Vmax, h = P/D, g = kL/D, a = Vmax/D, and t - t = the convolution integral time shift.  
To estimate these adjustable parameters, INS-647 intensity profiles were simulated from 
equations 3a-c. Parameters were estimated by minimizing the weighted sum-of-squared residuals 
between simulated and experimental measurements. Weighting was performed by dividing 
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residuals by the inverse of the intragroup standard deviation of intensity at each point in space 
and time. The effect of this scheme was to give more weight to the residuals at points where the 
confidence in the measurement was higher (i.e. low standard deviation) and vice versa. A multi-
start approach was used to generate random initial parameter estimates. A trust-region-reflective 
search algorithm was then used to minimize the weighted sum-of-squared residuals by adjusting 
the parameters. Goodness of fit between experimental and simulated measurements was 
determined by several analyses including the sum of squares of the weighted residuals and visual 
analysis of the residuals. Goodness of fit was deemed to be acceptable if the weighted sum-of-
squared residuals fell within the 95% confidence interval of the chi-square distribution for a 
certain number of degrees of freedom. Parameter estimation and goodness of fit analyses were 
performed using custom MATLAB scripts and functions (See Appendix).  
 
 
Vascular parameters 
 
Average capillary diameter was estimated using a simplified version of an algorithm 
developed by McClatchey et al. to measure mitochondrial width (226). Briefly, the rho-dex 
vascular marker channel was used to calculate the ratio of total vascular surface area to total 
vascular perimeter. This ratio approximates the radius of long cylindrical vessel segments. 
Plasma-perfused surface area was calculated from images by summing the rho-dex surface area 
for all 4 slices at a given time point.  
 
 
 
 
 64 
In Vivo Physiological Measurements 
Body composition 
 Body composition was measured using an mq10 nuclear magnetic resonance (NMR) 
analyzer. For the experiments in Chapter VII, body composition was measured at 16 weeks of 
age after 10 weeks of either chow or HFD diet and 2 weeks of either saline or Angiotensin-(1-7) 
treatment. In Chapter V, body composition was measured after 15 weeks of chow or HFD. 
Percent fat mass was calculated by dividing the absolute fat mass by the total mass measured by 
the NMR analyzer (fat mass + lean mas + free fluid mass). 
 
 
Cardiac function and blood pressure 
 Cardiac function was assessed by transthoracic echocardiography with a Sonos 5500 
system (Agilent). Parameters of cardiac function were estimated from chamber dimensions 
calculated from M-mode echocardiographic tracings. Blood pressure was measured through an 
indwelling carotid artery catheter connected to a strain-gauge transducer and a BPA-400 analyzer 
(Digi-Med). For the experiments in Chapter VII, blood pressure and heart rate were measured 
in conscious mice on the morning of insulin clamps, after approximately 2.5 hours of fasting. 
After a 15-minute acclimation period, we recorded the first five measurements taken at 10-
second intervals. The average of these blood pressure and heart rate measurements was reported. 
In Chapter VI, blood pressure was measured every minute in 5 hour-fasted mice anesthetized 
with KXA. 
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Microsphere deposition 
To assess muscle perfusion in Chapter III, we measured the deposition of intra-arterially 
administered microspheres. 100 µl of yellow 15-µm microspheres (Dye-Trak, Triton 
Technology) were injected into the carotid artery after the last sampling time point of the insulin 
clamp to measure regional blood flow to the hind limb. 5 minutes following microsphere 
administration, the hind limb (gastrocnemius, soleus, and vastus muscles) was excised, weighed 
and incubated in 1M KOH at 60°C overnight. Blue microspheres (10,000) were added to each 
sample to control for loss of microspheres during processing. The following day, samples were 
vortexed, 50°C ddH2O was added, and samples were centrifuged for 15 minutes at 2623 rpm at 
room temperature. The supernatant was then aspirated and the pellet resuspended in Triton X-
100 by sonication. This centrifugation, supernatant aspiration, resuspension sequence was 
repeated with 0.2% HCl in ethanol followed by ethanol alone. After aspirating the ethanol, 
pellets were allowed to dry overnight. To elute the dye from microspheres, pellets were 
incubated in N,N-dimethylformamide for 15 minutes. Following centrifugation for 5 min at 2623 
rpm, supernatants were added to 96 well polypropylene plates and Abs440 and Abs670 were 
measured on a spectrophotometer. Absorbance readings were converted to microsphere numbers 
based on a known standard curve from the manufacturer. Arterial microsphere mixing was 
considered adequate if the difference in the number of microspheres deposited in the left and 
right kidneys was less than 15%. 
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Plasma Analyses 
Plasma 3[3H]glucose and 2[14C]2deoxyglucose 
To measure plasma and infusate levels of the isotopic tracers, 3[3H]glucose and 
2[14C]DG, samples were first diluted twofold in 0.9% NaCl and then deproteinized by sequential 
treatment with barium hydroxide [Ba(OH)2, 0.3N] and zinc sulfate (ZnSO4, 0.3N]. Deproteinized 
plasma samples were centrifuged for 5 minutes at 13,000 rpm and 100 µl of the resulting 
supernatant was transferred to a glass vial.  For 3[3H]glucose samples, the supernatant was dried 
in a vacuum oven for 1 hour at 60°C followed by addition of 1 ml ddH2O. For 2[14C]2DG 
samples, 990 ml ddH2O was added directly to 100ul of supernatant. Finally, 10 ml of Ultima 
Gold scintillation cocktail (Perkin Elmer) was added to all vials and radioactivity was measured 
using a Tri-Carb 2900TR liquid scintillation counter (Packard). 
 
 
Plasma insulin 
 
Plasma insulin was measured by a double antibody radio-immunoassay (Milipore 
Mouse/Rat Insulin RIA, see Ref (227)). Plasma samples were diluted in a buffer containing 
50mM PBS (pH 7.4), 25mM EDTA, 0.08% sodium azide, and 1% BSA. Subsequently, 125I-
insulin and a guinea pig anti-mouse insulin antibody were added to each sample and incubated 
overnight at 4ºC. The antibody-bound 125I-insulin was separated from free 125I-insulin by adding 
a precipitating reagent containing goat anti-guinea pig IgG serum, 3% polyethylene glycol, and 
0.05% Triton X-100 in 50mM PBS, 25mM EDTA and 0.085% sodium azide. Following a 20-
minute incubation, samples were centrifuged at 2500 x g to separate free (supernatant) from 
bound (pellet) 125I-insulin. 125I radioactivity was then measured in the pellets using a Cobra II 
AutoGamma counter. Counts in the pellet were compared to a standard curve to calculate 
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unknown insulin concentrations in the plasma samples. If the percent of 125I-insulin displaced by 
the unlabeled insulin was >90 % (too concentrated) or <10% (too dilute) in any given sample, 
plasma dilutions were adjusted and the assay was repeated. 
 
Plasma non-esterified fatty acids  
Plasma non-esterified fatty acids (NEFAs) were measured using an enzymatic 
colorimetric assay (HR Series NEFA-HR(2); Wako Diagnostics). Plasma samples were collected 
into tubes pre-treated with a lipase inhibitor, tetrahydrolipstatin, to prevent NEFA degradation 
during sample collection. 5µL samples were diluted 1:2 in H2O. NEFAs were then converted to 
AcylCoAs by adding a solution containing AcylCoA synthetase, ATP, and CoA for 10 minutes 
at 37ºC. Subsequently, AcylCoAs were oxidized by adding Acyl-coenzyme A oxidase for 10 
minutes at 37ºC. This reaction generates hydrogen peroxide. In the presence of peroxidase and 
the hydrogen peroxide, 4-aminoantipyrine and 3-methyl-N-(b-hydroxyethyl)-aniline can be 
oxidatively condensed to generate a purple end product. The amount of this end product formed 
is proportional to the amount of hydrogen peroxide generated and, thus, plasma NEFA levels. 
The amount of the purple end product was measured spectrophotometrically at 560nm on a 
SpectraMax Plus spectrophotometer. Sample absorption measurements were compared to an 
oleic acid standard curve to calculate NEFA levels in the unknown plasma samples. Basal and 
clamp NEFA levels were calculated as the average NEFA levels at t = -15 and -5 min, and t = 80 
and 120 min, respectively.  
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Circulating angiotensin peptide levels  
 In Chapter VII, plasma Ang-(1-7) and Ang II levels were measured in a separate cohort 
of mice that did not undergo insulin clamps [n=6 chow-fed, vehicle; n=6 chow-fed Ang-(1-7); 
n=8 HFD, vehicle; n=8 HFD Ang-(1-7)]. Blood was collected in an EDTA tube containing a 
peptidase inhibitor to prevent degradation of Ang peptides. Plasma was separated from red blood 
cells and sent to the Hypertension Core at Wake Forest University for analysis as previously 
described (228). Briefly, plasma was homogenized in 75% ethanol/0.18M HCl and separated on 
a C18 SepPak column using high performance liquid chromatography. Radiolabeled Ang peptides 
were used to determine recovery efficiency. Following separation, Ang-(1-7) was measured by 
radioimmunoassay using a custom antibody. The minimum detectable level is 0.8 pg/tube with 
8% intra-assay coefficient of variation. Ang II was measured using a commercially available 
radioimmunoassay kit (ALPCO Diagnostics, RK-A22). The minimum detectable level is 2.5 
pg/tube with 12% intra-assay coefficient of variation. 
 
 
Tissue Analyses 
 
Tissue 2[14C]deoxyglucose accumulation 
To determine levels of 2[14C]DG and 2[14C]DG-6-phosphate (2[14C]DGP), tissues were 
first homogenized (Bullet Blender, Next Advance) in 0.5% perchloric acid to extract metabolites. 
After centrifugation at 13,000 rpm for 5 minutes, the homogenate pH was adjusted to 7.5 with 
KOH. Radioactivity was counted in one aliquot of the neutralized homogenate to determine 
tissue levels of combined 2[14C]DG and 2[14C]DGP. A separate aliquot was treated with 
Ba(OH)2 and ZnSO4 to remove 2[14C]DGP and any glycogen-incorporated radioactivity. This 
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sample was then counted to measure 2[14C]DG. The difference in radioactivity between the first 
aliquot (2[14C]DG + 2[14C]DGP) and second aliquot (2[14C]DG) is equal to 2[14C]DGP. 
 
Immunohistochemical staining  
 To determine muscle capillary density we performed CD31 staining on gastrocnemius 
sections. CD31 is an endothelial cell marker which allows for the immunohistochemical 
detection of blood vessels in tissue sections. Following insulin clamps, the gastrocnemius was 
excised, fixed in 10% neutral-buffered and embedded in paraffin. 5µm sections were cut using a 
microtome and mounted on charged slides. For CD31 staining, the Leica Bond Max IHC stainer 
was used. Epitopes were retrieved by heat-induced antigen retrieval using Epitope Retrieval 2 
solution (Leica) for 20 minutes. Slides were incubated with an anti-CD31 primary antibody 
(1:100; Dianova; see Table 2.1) for 60 minutes followed by a biotinylated anti-rat antibody 
(1:200; Vector; Table 2.1) for 15 minutes. Slides were then lightly counterstained with Mayer 
hematoxylin solution. The EnVision+HRP/DAB System (DakoCytomation) was used to produce 
localized, visible staining.  
In order to determine the level of Glut4 at the muscle sarcolemma, we performed a 
double immunostaining of Glut4 and caveolin-3 (Cav3), a sarcolemmal marker. Epitopes masked 
by formalin fixation were retrieved by incubating sections in a 10mM Tris buffer (pH 9) for 50 
minutes at 90°C. After a brief wash in phosphate-buffered saline (PBS), non-specific secondary 
antibody binding was blocked for 1 hour in 5% normal goat serum (NGS; Jackson 
ImmunoResearch) and ‘Mouse on Mouse’ blocking reagent (M.O.M.; Vector) at room 
temperature. Then, sections were incubated overnight at 4°C in rabbit anti-Glut4 (1:200; Abcam; 
Table 2.1) and mouse anti-Cav3 (1:200; Santa Cruz; Table 2.1) in 5%NGS/PBS. The next day  
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sections were washed in PBS followed by incubation in an Alexa Fluor 647 conjugated goat anti-
rabbit (1:500; Life Technologies; Table 2.1) and an Alexa Fluor 555 conjugated goat anti-mouse 
secondary antibody (1:500; Life Technologies; Table 2.1) in 5% NGS/PBS. Finally, sections 
were rinsed, mounted in 50% glycerol/H2O, cover slipped, and stored at 4°C in the dark. Control 
sections stained in the same manner as described above, but lacking primary antibodies, were 
used to demonstrate specificity of the secondary antibodies (Figure 2.3). Similarly, sections  
stained with only one primary antibody were used to ensure that secondary antibodies only 
recognized the correct primary antibody (Figure 2.3). 
 
Immunohistochemistry image acquisition and analysis 
 Following the CD31 staining, images of gastrocnemius sections were captured at 175x 
total magnification using a Nikon DS-Ri2 camera mounted on a Nikon AZ100M upright, wide-
field microscope. At least 3 images were collected per section from 3 serial sections per mouse. 
Quantification of capillary density was performed by counting CD31+ structures using a custom,  
automated macro in ImageJ (See Appendix). An investigator blind to diet and treatment 
performed all image acquisition and analyses.  
For the Glut4/Cav3 double staining, images were acquired using an inverted Zeiss LSM 
510 confocal microscope equipped with two helium-neon (HeNe) lasers (543nm and 633nm) and 
a 40X 1.3NA oil immersion Plan Neofluar objective (Zeiss). Alexa Fluor 555 was excited with 
the 543nm laser line of the HeNe laser and emitted light was collected using a 560-615nm 
bandpass emission filter. Alexa Fluor 647 was excited with the 633 nm laser line of the HeNe 
laser and emitted light was collected using a longpass 650nm filter. Sampling was performed at a 
resolution fulfilling the Nyquist criteria and with the pinhole set to give an optical section of 
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Figure 2.3 Labeling controls for Cav3/Glut4 immunofluorescence staining. Representative 
micrographs of gastrocnemius sections obtained following hyperinsulinemic-euglycemic clamps 
in high-fat fed mice. Images were obtained by confocal microscopy to demonstrate specificity of 
secondary antibodies for the appropriate primary antibody. All control sections were treated with 
both AlexaFluor555-conjugated goat anti-mouse and AlexaFluor647-conjugated goat anti-rabbit 
secondary antibodies. The left column represents sections not treated with any primary 
antibodies (no primary control). The sections in the middle and right columns were treated with 
either Cav3 or Glut4 primary antibodies, respectively; to ensure that secondary antibodies only 
recognized the correct primary antibody. 
 
 
 
 
 
 
 
 
 
 
 
CAV3 
GLUT4 
No primary 
control 
Single label 
control CAV3 
Single label 
control 
GLUT4 
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1.6µm. The two fluorophores were excited sequentially to prevent bleed-through and frame 
averaged 2 times. Photomultiplier tube detect settings were kept constant throughout imaging to 
allow for quantitative comparisons. At least 2 images were collected per section from 3 serial 
sections per mouse. All image analysis was performed using ImageJ software (NIH). Images 
were background-corrected using the rolling ball radius background subtraction method. Then, a 
mask of the sarcolemma was created by Otsu-based thresholding of the Cav3 channel. This mask 
was applied to the Glut4 (Alexa Fluor 647) channel and the mean Glut4 fluorescence intensity 
within this mask was measured. Image acquisition and data analysis was performed by an 
investigator blinded to the study design. 
 
Immunoblotting 
 
Gastrocnemius muscle samples were mechanically homogenized (Bullet Blender; Next 
Advance) in buffer containing 50mM Tris-HCl (pH 7.5), 100mM NaCl, 1mM EDTA, 1mM 
EGTA, 1% TritonX-100, 1mM DTT, 10% glycerol, and Halt Protease and Phosphatase Inhibitor 
Cocktail (Life Technologies). Samples were then centrifuged at 13,000 rpm for 20 min at 4°C. 
Homogenates were separated on SDS-PAGE gels and transferred to polyvinylidene fluoride 
membranes. Membranes were blocked with Odyssey Blocking Buffer (LI-COR) for 1 hour at 
room temperature. For the experiments in Chapter VII, membranes were probed with the 
following antibodies: phosphorylated Akt (Ser473; Cell Signaling), total Akt (Cell Signaling), 
phosphorylated AS160 (Ser588; Cell Signaling), and total AS160 (Millipore). In Chapter VI, 
membranes were probed with antibodies against total VASP (1:500; #3112; Cell Signaling), 
phosphorylated (Ser239) VASP (1:500; #3114; Cell Signaling), and GAPDH (1:1000; ab9484; 
Abcam). Primary antibodies were detected using either 800CW goat anti-rabbit (1:5000; LI- 
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Antibodies: 
 
Target Species Application Dilution Manufacturer Ref# Lot# 
pAkt (Ser473) Rabbit WB 1:0000 Cell Signaling 9271 13 
Akt Rabbit WB 1:1000 Cell Signaling 9272 25 
pAS160 
(Ser588) Rabbit WB 1:500 Cell Signaling 8730 1 
AS160 Rabbit WB 1:1000 Millipore 07-741 2455680 
GAPDH 
Mouse WB 1:1000 Abcam 9484 
GR17466
6;GR286
286-12 
800CW anti-
Rabbit IgG  Donkey WB 1:10,000 LI-COR 
926-
32213 B0228-01 
680LT anti-
Mouse IgG  Donkey WB 1:10,000 LI-COR 
926-
68022 
C50512-
02 
pVASP 
(Ser239) Rabbit WB 1:500 Cell Signaling 3114 6 
VASP Rabbit WB 1:500 Cell Signaling 3112 5 
800CW anti-
Rabbit IgG Goat WB 1:5000 LI-COR 
926-
32211 
C70620-
05 
680RD anti-
mouse IgG Goat WB 1:5000 LI-COR 
926-
68071 
C41009-
01 
CD31 Rat IHC 1:100 Dianova DIA-310 SZ31 
Rat IgG Rabbit IHC 1:200 Vector BA-4000 Z0612 
Glut4 Rabbit IF 1:200 Abcam 654-250 387864 
Cav3 Mouse IF 1:200 Santa Cruz Sc-5310 B0414 
Alexa Fluor 555 
anti-mouse Goat IF 1:500 
Molecular 
Probes A21422 1685557 
Alexa Fluor 647 
anti-rabbit Goat IF 1:500 
Molecular 
Probes A21245 1700082 
Alexa Fluor 647 
anti-mouse 
CD45 
Rat Flow 2.5µg/ml BioLegend 103123 B20144 
 
Table 2.2. List of antibodies used. WB = western blot; IHC = immunohistochemistry; IF = 
immunofluorescence. 
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COR) or 680RD goat anti-mouse (1:10,000; LI-COR) secondary antibodies.  All antibodies used 
for immunoblotting are shown in Table 2.1. Membranes were imaged with an Odyssey Imaging 
System (LI-COR) and quantified by densitometric analysis with ImageJ.  
 
Transmission electron microscopy  
Samples were processed for transmission electron microscopy and imaged in the 
Vanderbilt Cell Imaging Shared Resource – Research Electron Microscopy facility. Erythrocytes 
were initially rinsed from the circulation of anesthetized mice by infusing 0.1M cacodylate 
buffer into the vasculature through a catheter inserted into the left ventricle. Rinsing was deemed 
complete when perfusate leaking from an incision in the liver turned a pale pink color. Tissues 
were then fixed by switching the perfusate to 2.5% glutaraldehyde in 0.1M cacodylate buffer. 
The gastrocnemius was then excised and fixed for an additional 24h at 4°C. Tissues were 
subsequently postfixed with osmium tetroxide, dehydrated and embedded in Epon 812 epoxy 
resin. 70-80 nm sections were cut from embedded tissues and stained with 2% uranyl acetate and 
Reynold’s lead citrate. Sections were imaged using a Philips/FEI Technai T12 electron  
microscope. Capillaries were identified and selected for analysis at low magnification where 
endothelial ultrastructure (i.e. vesicles) is not visible. This approach prevents bias in capillary 
selection. Subsequently, 2-4 images were acquired of each capillary at high magnification 
(67,000x). 6-13 capillaries were imaged per section.  
Endothelial vesicular density was measured by applying a test point grid (ImageJ) to 
micrographs and then counting the number points residing within vesicles and within the entire 
endothelium (229). Endothelial vesicular density was calculated as the number of points within 
vesicles relative to the number of points in the endothelium as a whole. Vesicular diameter was 
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measured at the widest point of each vesicle. Endothelial vesicle localization was assessed by 
manually counting vesicles that were either facing the capillary lumen (luminal), contained 
within the endothelium (intracellular), or facing the interstitial space (abluminal). Basement 
membrane thickness was measured perpendicularly to points of intersection between a line grid 
applied to micrographs and the capillary endothelium.  
 
 
Calculations 
 
Whole-body glucose flux 
 
The rates of whole-body plasma glucose appearance (Ra) and disappearance (Rd) were 
determined from plasma 3[3H]glucose levels and calculated using non-steady state equations 
(230):  
 𝑅: = 𝐼 − 𝑉 • 𝐴 • 𝜕𝑆𝐴𝜕𝑡𝑆𝐴 																𝑅` = 𝑅: − 𝑉 • 𝜕𝐴𝜕𝑡  																           
where I is the tracer infusion rate (dpm•kg-1•min-1), Vd is the volume of distribution (dl•kg), A is 
the arterial glucose (mg•dl-1), ∂SA/∂t is the rate of change in glucose specific activity over 30 
minutes (dpm•mg-1•min-1), SA is glucose specific activity (dpm•mg-1), and ∂A/∂t is the rate of 
change in arterial glucose over 30 minutes. These equations describe the turnover of glucose in a 
single, well-mixed compartment. Arterial glucose and glucose specific activity used in the 
equations were calculated using a moving average over three consecutive time points (231). Ra 
and Rd were calculated at t= 90, 100, and 110 min and averaged. To calculate the endogenous 
rate of glucose appearance (EndoRa), the exogenous glucose infusion rate was subtracted from 
total Ra. Non-steady state equations were used for all calculations; however, steady state 
calculations gave nearly identical rates, suggesting that steady state conditions were present.  
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2[14C]deoxyglucose calculations 
 During the insulin clamps performed in Chapter VII, we measured the accumulation of 
2[14C]DG to calculate the glucose metabolic index (Rg). Rg is a measure of tissue-specific 
glucose uptake and was calculated using the following equation (217): 
 𝑅f = 2[ 𝐶jjk ]𝐷𝐺𝑃#noopq𝐴𝑈𝐶2[ 𝐶jjk ]𝐷𝐺-s:o9: • [𝑎𝑟𝑡𝑒𝑟𝑖𝑎𝑙	𝑔𝑙𝑢𝑐𝑜𝑠𝑒] 
 
where 2[14C]DGPtissue is the accumulated 2[14C]DGP in tissue (dpm•mg-1), AUC2[14C]DGplasma is 
the area under the plasma 2[14C]DG disappearance curve (dpm•ml-1•min), and [arterial glucose] 
is the average blood glucose (mmol•L-1)) from t = 120 to t = 155 min of the clamp period. For 
the insulin tolerance tests in Chapter V, we measured tissue glucose clearance using the 
following equation:  
𝐾f = 	 2[ 𝐶]	jk 𝐷𝐺𝑃#noopq∫ 2[ 𝐶	jk ]𝐷𝐺-s:o9:jz6  
 
where 2[14C]DGPtissue is the accumulated 2[14C]DGP in the tissue (dpm•g-1 tissue) and ∫ 2[ 𝐶	jk ]𝐷𝐺-s:o9:jz6  is the time-integrated 2[14C]DG activity in the plasma calculated using 
trapezoidal integration. Finally, When using 2[14C]DG during intravital microscopy experiments 
or for insulin tolerance tests in Chapters III, IV, V, and VI, we measured and reported the 
accumulation of 2[14C]DG in the gastrocnemius due to the difficulty of measuring plasma 
2[14C]DG during intravital microscopy experiments. 
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Statistics 
 
 All data are presented as mean ± SEM unless otherwise noted. All statistical analysis was 
performed using Prism (GraphPad). Outliers were detected by Grubbs’ test (a = 0.05) and 
subsequently removed. Comparisons between groups were performed using either Student’s t-
test, one-way ANOVA, two-way ANOVA, or two-way repeated measures ANOVA where 
appropriate. Dunnett’s tests (one-way ANOVA) or Bonferroni corrections (two-way ANOVA) 
were used to correct for multiple comparisons.  
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CHAPTER III 
 
DEVELOPMENT OF AN INTRAVITAL MICROSCOPY TECHNIQUE 
TO MEASURE THE RATE OF TRANS-ENDOTHELIAL INSULIN TRANSPORT 
IN SKELETAL MUSCLE CAPILLARIES IN VIVO 
 
Aims 
Methods to measure the rates of molecular efflux across the capillary endothelium in vivo 
are lacking. Cultured endothelial monolayers, especially those using macrovascular endothelial 
cells, lack several key characteristics of capillaries in a live organism. On the other hand, in vivo 
interstitial sampling is limited because the number of capillaries feeding the space from which 
sampling is performed is unknown. Therefore, such techniques do not directly measure trans-
endothelial molecular efflux but rather an index of delivery which is determined by both 
perfusion and transport. We sought to develop a method to directly measure capillary insulin 
transport that could 1) be conducted in vivo with minimal physiological perturbations, 2) 
measure the concentration of insulin in both the intravascular and adjacent interstitial spaces as a 
function of time, and 3) allow for determination of the capillary surface area feeding a given 
interstitial space. Intravital microscopy provides the necessary balance of sensitivity as well as 
spatial and temporal resolution to satisfy these criteria. Thus, the aim of Chapter III is to 
develop a quantitative intravital microscopy technique to directly measure the rate of movement 
of a fluorescently-labeled insulin probe across the endothelium in single skeletal muscle 
capillaries in vivo.   
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Results* 
Site-specific conjugation of Alexa Fluor 647 to human insulin 
 The most commonly used fluorescent insulin probes are FITC-insulin conjugates. These 
probes can contain a heterogeneous mixture of insulin conjugate species that have lower affinity 
for the insulin receptor than native insulin (232, 233). Furthermore, the fluorescence intensity of 
FITC is sensitive to pH, falling off rapidly as the pH drops below 7 (234). Because various 
intracellular compartments display a range of pH values, the fluorescence intensity of FITC does 
not reliably reflect the concentration of the insulin probe. An ideal fluorescent insulin conjugate 
for in vivo imaging would be fully bioactive, have high signal-to-noise ratio in live tissue, and be 
unaffected by the microenvironment. 
To achieve this goal, we labeled insulin in a site-specific manner with Alexa Fluor 647. 
We chose Alexa Fluor 647 because of its brightness and photostability (235), insensitivity to pH 
(234), and the lack of tissue autofluorescence in the near-infrared wavelengths. Next, we 
selectively labeled the N-terminal phenylalanine of the B chain (B1) of human insulin (Figure 
3.1). We chose this site because conjugation of various molecules to B1 has little to no effect on 
the affinity of the resulting conjugate for the insulin receptor (232). To perform this labeling, we 
first blocked the reactivity of all free amines except the B1 phenylalanine using tert-
butyloxylcarbonyl (t-boc) protection chemistry (Figure 3.1). Then we conjugated the free amine 
on the unprotected B1 phenylalanine to Alexa Fluor 647 succinimidyl ester (Figure 3.1). Finally, 
the t-boc groups were removed with trifluoroacetic acid to complete the synthesis of the B1-
Alexa Fluor 647-insulin conjugate (INS-647) (Figure 3.1). Analysis of INS-647 using HPLC- 
 
                                               
* These results have been published in: Williams IM, Valenzuela FA, Kahl SD, Ramkrishna D, Mezo AR, 
Young JD, Wells KS, Wasserman DH. Insulin exits skeletal muscle capillaries by fluid-phase transport. J 
Journal of Clinical Investigation 2018 Feb 1; 128(2):699-714. PMID: 29309051.    
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Figure 3.1: Synthesis of insulin-647,  a novel fluorescent insulin probe. A) Schematic 
depicting the chemical synthesis of INS-647. t-Boc - tert-butyloxycarbonyl, DIPEA - N,N-
Diisopropylethylamine; Boc-OSu - (Boc)succinimide ester; DMSO - dimethylsulfoxide; NHS-
AF647 - Alexa Fluor 647 NHS ester; DMF – dimethylformamide; TFA - trifluoroacetic acid; 
TIPS - triisopropylsilane.  
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mass spectrometry (LC-MS) revealed a single conjugate species (Figure 3.2A) with the 
appropriate mass (Figure 3.2, B and C).  Most importantly, INS-647 has unaltered affinity for  
the insulin receptor as determined by scintillation proximity assay-based competitive radioligand  
binding analysis (Figure 3.2D). Moreover, during a 1U/kg insulin tolerance test in vivo, INS-
647 lowered blood glucose to the same extent as unlabeled insulin (Figure 3.3, A and B) and 
fully stimulated muscle 2[14C]DG accumulation (Figure 3.3, C and D). To assess INS-647 at a 
more physiological insulin level, we performed insulin clamps with insulin and INS-647 (Figure 
3.4). During steady-state hyperinsulinemia, there was no difference in the glucose infusion rate 
required to maintain euglycemia using insulin or INS-647 (Figure 3.4, A and B). Furthermore, 
the rates of insulin-stimulated peripheral glucose disposal (Figure 3.4C) and suppression of 
endogenous glucose production (Figure 3.4D) were not different when using insulin or INS-647. 
Basal and clamp plasma insulin levels were also identical between groups (Figure 3.4E). These 
data indicate that INS-647 is fully bioactive at physiological concentrations. To determine 
whether the pharmacokinetic properties of INS-647 are similar to unlabeled insulin, we 
administered a 4U/kg intravenous bolus of either insulin or INS-647. Measurements of arterial 
plasma insulin indicated that there was no difference in arterial kinetics between insulin and INS-
647 (Figure 3.5, A and B). INS-647 is also stable in the in vivo environment, with 90% of the 
dye remaining conjugated to insulin after 30 minutes in the circulation (Figure 3.6). In 
conclusion, we have synthesized a fully bioactive, optically optimized insulin conjugate which is 
well suited for in vivo imaging and other fluorescence-based applications.  
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Figure 3.2: In vitro characterization of insulin-647. A) Analytical RP-HPLC trace of INS-647. 
B) Mass spectrum of INS-647. The labeled peaks indicate the three most abundant ions 
(M+5H)5+, (M+6H)6+, (M+7H)7+. C) The mass of INS-647 as calculated from the m/z of the 
three most abundant ions (M+5H)5+, (M+6H)6+, (M+7H)7+. The observed mass of INS-647 
(6648.33 Da) is nearly identical to that which would be predicted (6646 Da) based on calculation 
derived from the molecular weight of human insulin conjugated to Alexa Fluor 647. D) The 
affinity (Ki) of unlabeled insulin and insulin-647 for the human insulin receptor determined by 
scintillation proximity assay-based competitive radioligand binding analysis. Data are reported 
as geometric mean ± standard error of the mean from n=3 experiments. m/z - mass/charge; RP-
HPLC - reversed phase-high performance liquid chromatography. 
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Figure 3.3: Assessment of insulin-647 bioactivity by insulin tolerance test. A) Tail blood 
glucose levels following a 1 U/kg intravenous bolus of either insulin (n=5) or INS-647 (n=6) in 
anesthetized mice. B) Glucose disappearance is calculated as the rate of blood glucose decrease 
over the first 15 minutes of the experiment. C-D) Accumulation of 2[14C]deoxyglucose in 
various muscles as an index of muscle glucose uptake. A 13µCi bolus of 2[14C]deoxyglucose 
was given in conjunction with the insulin or INS-647 bolus in A. Groups were compared using 
unpaired Student’s t-test. 
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Figure 3.4: Assessment of insulin-647 bioactivity by hyperinsulinemic-euglycemic clamp. 
A) Arterial glucose levels were clamped at ~150mg/dl by variable venous infusion of 50% 
glucose in mice treated with unlabeled insulin (n=4) or insulin-647 (n=4). B) The glucose 
infusion rate (GIR) required to maintain euglycemia during hyperinsulinemia, a measure of 
insulin sensitivity. C,D) Basal and insulin-stimulated rates of peripheral glucose disposal (Rd) 
and endgoenous glucose production (endoRa) as determined by steady-state plasma levels of 
3[3H]glucose. E) Basal and clamp levels of plasma insulin during hyperinsulinemic-euglycemic 
clamps. Groups were compared using unpaired Student’s t-test. 
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Figure 3.5: Arterial dynamics of insulin-647 and unlabeled insulin. A) Arterial plasma levels 
of insulin (n=6) and insulin-647 (n=6) following a 4U/kg intravenous bolus. B) Data in A 
normalized to the insulin level at t=1 min. 
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Figure 3.6: In vivo stability of insulin-647. Percent of total plasma INS-647 fluorescence that is 
in a low molecular weight fraction (<3kD) vs. a high molecular weight fraction (>3kD) 30 
minutes after an intravenous bolus of INS-647 (n=6 mice). Fluorescence in the <3kD fraction is 
indicative of Alexa Flour 647 that is separated from INS-647 during an imaging experiment. 
Fluorescence in the >3kD fraction is intact INS-647.  
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Intravital microscopy of INS-647  
 Previous in vivo imaging examinations of skeletal muscle vascular function have used 
thin, translucent muscles such as the cremaster or spinotrapezius (221, 236). We sought to 
develop a preparation of a representative skeletal muscle that required minimal perturbations to  
the tissue. Therefore, we chose to study the lateral gastrocnemius muscle because it is a major 
site of insulin-stimulated glucose disposal. The lateral gastrocnemius fibers are exposed by 
carefully removing the overlying skin and fascia. The anesthetized mouse can then be simply 
situated on its side so that the exposed gastrocnemius is positioned against a coverslip embedded 
in a custom stage mount (Figure 3.7A). We then tested whether our gastrocnemius preparation 
induced an inflammatory response that might affect our measurements of capillary function. In 
vivo imaging of leukocytes and platelets labeled with rhodamine 6G (~90-95% labeling 
efficiency of leukocytes; Figure 3.8, A-C) revealed that very few leukocytes or platelets adhered 
to capillary walls during the course of the experiment (Figure 3.7B). Furthermore, BSA-647 did 
not leak out from gastrocnemius capillaries (Figure 3.7C) as it would during an inflammatory 
response (237). These results show that our gastrocnemius preparation maintains skeletal muscle 
capillaries in a near-physiological state.    
 To measure the rate of trans-endothelial INS-647 transport, it is imperative to be able to 
resolve the intravascular and interstitial spaces. In order to demarcate the intravascular space, we 
infused 50µg of a tetramethylrhodamine-labeled 2 megadalton dextran probe (Rho-dex) through 
an indwelling jugular vein catheter (Figure 3.9). Subsequently, the rho-dex is imaged using a 
confocal microscope (Zeiss LSM 780) to find a suitable region for imaging. After selecting a 
field of view, a 4U/kg bolus of INS-647 is injected into the mouse through the indwelling  
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Figure 3.7: A novel gastrocnemius preparation for intravital fluorescence microscopy. A) 
Schematic showing the setup and mouse preparation for intravital microscopy. The left panel 
depicts the mouse situated on the stage mount with the necessary accessories. The inset shows a 
zoomed in view of the exposed gastrocnemius fibers pressed against the coverglass and a 
diagram of the light path for confocal microscopy. The blue and green arrows indicate incident 
and emitted light, respectively. B) In vivo imaging of leukocytes and platelets stained with 
rhodamine 6G. Background-subtracted representative images show rhodamine-6G+ structures 
during a typical experiment. Blue arrowheads and blue arrows indicate adherent and non-
adherent leukocytes, respectively. Green arrows and arrowheads represent adherent and non-
adherent platelets respectively. Graphs show the number of adherent leukocytes and platelets 
before and after exposure to either no light (No scans; n=3) or the same amount of light used 
during an insulin imaging experiment (15 scans; n=4). C) Imaging of albumin to test the stability 
of capillaries in the gastrocnemius preparation. Representative images are maximum intensity 
projections showing 2 megadalton tetramethylrhodamine-dextran (top) and Alexa Fluor 647-
conjugated bovine serum albumin (bottom) at the indicated time points following fluorescent 
albumin injection. D) Insulin imaging with different light exposure doses to test for 
phototoxicity. Representative images are background-subtracted and contrast-enhanced 
maximum intensity projections showing INS-647 distribution at the indicated time points after 2 
scans (top; n=3) or after 15 scans (bottom; n=5-6). Graph shows INS-647 intensity as a function 
of distance from the capillary at the indicated time points with varying light exposure doses. 
PMT - photomultiplier tube; TMR-dex - tetramethylrhodamine dextran; BSA-647 - Alexa Fluor 
647-labeled bovine serum albumin. 
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Figure 3.8: Labeling efficiency of leukocytes in vivo with rhodamine 6G. A) Table shows the 
% of live leukocytes that are stained with rhodamine 6G at two time points following rhodamine 
6G injection (n=3 mice). B) Gating strategy for flow cytometry. In the direction of the arrows, 
debris were removed by size, doublets were deleted (2x), and dead cells were removed (DAPI). 
The remaining cells were gated for presence of CD45 to include leukocytes. C) Representative 
table showing the number and percentage of cells counted following each gating step. SSC, side 
scatter; FSC, forward scatter; A, area; H, height, R6G, rhodamine 6G. 
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Figure 3.9: Insulin-647 imaging. Representative images (maximum intensity projections) of an 
INS-647 imaging experiment. The top panel shows 2 megadalton tetramethylrhodamine-dextran 
and the bottom panel shows INS-647 at the indicated time points following INS-647 injection. 
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catheter. 3D confocal images of both rho-dex and INS-647 are acquired every minute for the first 
10 minutes and then at 12.5, 15, 20, and 30 minutes thereafter (Figure 3.9).  
Imaging parameters (i.e. laser power, sampling frequency) were chosen to minimize both 
the photobleaching of INS-647 and phototoxicity caused by irradiating live tissue with visible 
light (238). We set our imaging parameters so that photobleaching would account for at most a  
~5-8% loss in INS-647 fluorescence intensity during an experiment (Figure 3.10, A-C). 
Furthermore, the amount of light used during an INS-647 imaging experiment did not alter the 
intravascular or extravascular distribution of INS-647, (Figure 3.7D) accumulation of 2[14C]DG, 
(Figure 3.11), or leukocyte adhesion (Figure 3.7B). These findings suggest that our 
experimental imaging conditions do not induce any detectable photodamage. Finally, the 
conjugation of Alexa Fluor 647 to insulin caused a very slight red shift in its emission spectrum 
(Figure 3.10D). However, this shift was not significant enough to alter the excitation or 
detection strategy for INS-647 compared to Alexa Fluor 647. In summary, our quantitative, 
intravital image acquisition design allows us to collect spatial and temporal information 
regarding the levels of rho-dex and INS-647 in the gastrocnemius of live mice without causing 
any major perturbations to the tissue. 
 
Quantitative Image Analysis 
 To estimate endothelial transport parameters, the levels of INS-647 as a function of time 
in both intravascular and interstitial spaces must be measured. To obtain this information, we 
developed an Otsu-based (224) automated vascular and interstitial segmentation algorithm using 
ImageJ (Figure 3.12A; see Research Materials and Methods). This algorithm is used to 
generate intensity-time profiles of INS-647 in the intravascular and interstitial spaces (Figure 
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3.12B). To test the performance of our vascular segmentation algorithm we compared it against a 
manual segmentation of 192 images. We found that while our algorithm was able to capture most 
of the vascular spaces outlined manually, it overestimated the area of vascular space by ~45% 
(Figure 3.13, A and B). While this led to a slight underestimation of INS-647 levels (Figure 
3.13, C and D), it did not significantly alter any transport parameter estimates (Figure 3.13, E-
H) nor did it change model-independent efflux parameters (Figure 3.13I). Because the method 
of image segmentation did not affect the final results, we think that the benefits of automating 
image analysis (enhanced reproducibility, removal of user bias, faster processing speeds) 
outweigh the small reduction in segmentation accuracy.  
After obtaining the capillary and interstitial INS-647 curves, we sought to quantify the 
endothelial transport parameters that control the movement of INS-647 from the plasma to the 
interstitial space. The transport parameters of interest depend on the mechanism by which a 
molecule traverses the continuous endothelium. For instance, if INS-647 crosses the endothelium 
by a receptor-mediated process, as has been hypothesized for insulin (150, 239), then the 
parameters of interest are the Michaelis-Menten parameters, Km and Vmax. If instead INS-647 
leaks out of capillaries through inter-endothelial junctions, then the parameters of interest are 
either permeability of the vessel to INS-647 (diffusion), or the mass transfer coefficient (fluid-
phase transport).  
To make this determination, we fit our experimental data to 3 different mathematical 
models. As the base model, we described INS-647 movement within the interstitial space by the 
diffusion equation and assumed 1st order removal of INS-647 from this space (Figure 3.14; see 
Research Materials and Methods for extended equations). A pertinent aspect of the model is 
the boundary condition describing movement of INS-647 from the plasma to the interstitial space 
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Figure 3.10: Photostability and optical properties of insulin-647. A) The rate of decay of 
insulin-647 fluorescence as a function of incident laser power. The blue line shows the linear 
regression of these two variables and the dotted lines show the 95% confidence intervals of the 
regression. B) Percent loss of fluorescence after 60 scans, the same number of scans as during an 
insulin imaging experiment. The green lines indicate the maximum usable laser power at which 
the acceptable photobleaching rate (5%) is achieved. C) Percent loss of fluorescence per scan. D) 
Emission spectra of equimolar amounts of Alexa Fluor 647 or insulin-647 after excitation with 
633nm light. 
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Figure 3.11: Effect of varying light exposure on insulin-stimulated muscle glucose uptake. 
Accumulation of 2[14C]deoxyglucose in various tissues during insulin-647 imaging with either 2 
(n=3) exposures or 15 exposures (n=7). 
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Figure 3.12: Insulin-647 image analysis. A) General workflow for image analysis. B) 
Representative 3D plot of INS-647 intensity (z-axis) as a function of distance from the capillary 
(y-axis) and time (x-axis). 
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Figure 3.13: Performance of an automated vascular segmentation algorithm. The 
segmentation performance of an automated algorithm was compared against manual 
segmentation for all images from n=3 experiments. A) Percent of manually outlined pixels that 
were also outlined by the algorithm (True positive) and percent of pixels outlined by the 
algorithm that were not outlined by the manual segmentation (False positive). B) Total vascular 
surface area segmented by manual and automated segmentation. C,D) Difference in INS-647 
intensity as a function of C) time or D) distance from the capillary when using automated versus 
manual segmentation. E-H) Best fit model parameter estimates using manual or automated 
segmentation. I) Ratio of plasma to interstitial INS-647 intensity as a function of time following 
ins-647 injection using manual and automated segmentation. 
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Figure 3.14: Mathematical model of trans-endothelial insulin efflux. Schematic of the 
mathematical models used to estimate endothelial transport parameters. White pentagons 
represent insulin. In the plasma compartment (red/blue), insulin is shown exiting the capillary 
through interendothelial junctions or by a receptor-mediated process. The equations used to 
describe these behaviors are the diffusion equation (top), fluid-phase transport equation (middle) 
and Michaelis-Menten equation (bottom). See Research Materials and Methods for details 
regarding equations and symbols. 
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We described the boundary behavior of INS-647 with equations describing either diffusion 
(240), fluid-phase transport (241), or Michaelis-Menten kinetics. We then solved the diffusion 
equation with the different boundary conditions to generate models that described these potential 
mechanisms of INS-647 transport. Experimental data were fit to these models using weighted 
non-linear least squares regression in MATLAB. This allows us to estimate the following 
parameters: permeability for the diffusion model, mass transfer coefficient for the fluid-phase 
transport model, and Km and Vmax for the Michaelis-Menten model. All models allowed for 
estimation of the interstitial diffusion coefficient and removal constant of INS-647. Finally, the 
goodness of fit of the experimental data to the models was determined by analyzing the sum of 
the weighted residuals.  
 
Method validation 
 The rate of trans-endothelial efflux of molecules decreases with increasing molecular size 
(242). To validate our measurements and demonstrate that we can reproduce this phenomenon 
with our technique, we imaged fluorescently-labeled dextrans of sizes 3kDa and 10kDa and INS-
647, which is 6.6kDa (Figure 3.15A). Visually, one can see that the smaller molecules leak out 
of capillaries much faster than the larger ones (Figure 3.15A). Mathematical modeling showed 
that the extravasation of these probes occurred by fluid-phase transport (Figure 3.16, A-D and 
Chapter IV). Mass transfer coefficient estimates show that efflux rates decrease as probe 
molecular weight increases (Figure 3.15B). Furthermore, the kinetics of capillary / interstitial 
gradient dissipation were slower with increasing molecular weight, as predicted (Figure 3.15C). 
Therefore, we are confident in the accuracy of our measurements and our ability to resolve 
differences in trans-endothelial efflux parameters.  
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Figure 3.15: Validation of intravital fluorescence microscopy for resolving differences in 
trans-endothelial molecular efflux. A) Representative images (max intensity projections) of 
3kD dextran-Alexa Fluor 680 (n=6), INS-647 (n=6), and 10kD dextran-Alexa Fluor 647 (n=6) 
distribution at the indicated time points following injection. B) Best-fit model estimates of the 
mass transfer coefficient for the probes in A displayed as a function of molecular weight. C) 
Ratio of plasma/interstitial fluorescence intensity as a function of time following injection for the 
indicated probes. Groups were compared using ANOVA with a Bonferroni correction for 
multiple comparisons. 
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Figure 3.16: Model fit analysis of dextran imaging data. Plots show experimental data and 
“Diffusion,” “Michaelis-Menten,” or “Fluid-phase transport” model simulations for A) 3kD 
dextran-Alexa Fluor 680 and B) 10kD dextran-Alexa Fluor 647 probe. C,D) Weighted sum of 
squared residuals for each of the different model simulations as compared to the experimental 
data for C) 3kD dextran-Alexa Fluor 680 (n=6) and D) 10kD dextran-Alexa Fluor 647 (n=6). 
The number of variable parameters are indicated above the bar for each model. Param – 
parameters. 
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Discussion 
 
We have developed an intravital imaging technique to measure to the flux of insulin 
across the endothelium of individual skeletal muscle capillaries. To accomplish this, we 1) 
synthesized a fluorescent, bioactive insulin probe, 2) developed a novel gastrocnemius  
preparation 3) developed an automated vascular segmentation algorithm and 4) fit data to 
mathematical models to estimate transport parameters. Notably, our measurement of the steady-
state plasma/interstitial insulin gradient with intravital microscopy is similar to measurements  
made by both lymph sampling (157) and microdialysis (137). This observation supports the 
accuracy of our method. Our in vivo imaging technique makes major advances in other key 
areas. INS-647 is a suitable fluorescent insulin probe in that it is homogenous, fully bioactive, 
insensitive to changes in pH, photostable, and stable in the in vivo environment. This is an 
improvement over the use of FITC-insulins, which do not bind the insulin receptor with the same 
affinity as insulin, are very sensitive to changes in pH, and spectrally overlap with endogenous 
tissue fluorescence. Finally, our novel gastrocnemius preparation does not require any 
exteriorization or major manipulation of the tissue and maintains the skeletal muscle capillaries 
in a near-physiological state. 
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CHAPTER IV 
 
INSULIN EXITS SKELETAL MUSCLE CAPILLARIES BY FLUID-PHASE 
TRANSPORT 
 
 
Aims 
 As discussed in the Introduction, there is disagreement regarding the mechanism by 
which insulin is transported across the skeletal muscle capillary endothelium. The most 
commonly accepted hypothesis is that insulin is transported across the endothelium by a 
saturable, insulin receptor-mediated mechanism. However, there have been no direct 
measurements of trans-endothelial insulin transport in skeletal muscle capillaries in vivo. The 
aim of Chapter IV is to determine the mechanism of trans-endothelial insulin transport in 
skeletal muscle capillaries in vivo. To accomplish this goal, we will utilize the intravital 
microscopy technique described in Chapter III combined with mathematical modeling and 
pharmacological interventions. 
 
 
Results* 
 
Mathematical modeling: Trans-endothelial INS-647 transport data are best described by a 
fluid-phase transport model 
 To determine the mechanism by which insulin transits the endothelium, we initially fit 
our experimental INS-647 imaging data (Figure 4.1A) to models describing either diffusion, 
fluid-phase transport, or Michaelis-Menten kinetics. Both visual (Figure 4.1, B-D) and residual 
                                               
*These results have been published in: Williams IM, Valenzuela FA, Kahl SD, Ramkrishna D, Mezo AR, 
Young JD, Wells KS, Wasserman DH. Insulin exits skeletal muscle capillaries by fluid-phase transport. J 
Journal of Clinical Investigation 2018 Feb 1; 128(2):699-714. PMID: 29309051. 
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(Figure 4.1E) analysis of best-fit model simulations revealed that INS-647 transport kinetics fit 
the fluid-phase transport and Michaelis-Menten models better than the diffusion model. 
Therefore, we rejected the diffusion model. We then compared the fluid-phase transport model to 
the Michaelis-Menten model. The INS-647 imaging data fit the fluid-phase transport model 
slightly better than the Michaelis-Menten model (weighted sum of squared residuals: 81.6 fluid-
phase transport vs. 88.0 Michaelis-Menten). Furthermore, the fluid-phase transport model 
contains one less variable parameter than the Michaelis-Menten model. Finally, the estimate of 
the Michaelis constant, Km, (226 intensity units; Figure 4.2) is twofold higher than INS-647 
levels ever reach in the capillary plasma. This indicates that the Michaelis-Menten model 
essentially predicts a linear relationship between capillary INS-647 and INS-647 transport rates. 
This relationship is more compatible with fluid-phase transport than a receptor-mediated process. 
A true receptor-mediated process would be expected to have a Km that is in the same range as the 
plasma levels of INS-647. Therefore, based on goodness of fit, the principle of parsimony, and 
the reasonability of parameter estimates we rejected the Michaelis-Menten model in favor of the 
fluid-phase transport model. The best-fit fluid-phase model parameter estimates are shown in 
Figure 4.1F. The decision to reject the Michaelis-Menten model was substantiated by results 
described in the following section. 
 To test whether the changing levels of glucose or insulin had effects on insulin efflux 
kinetics, we modeled temporal subsets of our data. Namely, we modeled data from t = 0 to either 
t = 5, 7, 10, 12.5, 15, 20, or 30 mins (Figure 4.3) to determine whether the mass transfer 
coefficient estimate varied at these time points. We found that the mass transfer coefficient 
estimate did not change when restricting analysis to earlier time points, although the variability 
in the estimate did increase (Figure 4.3). This suggests that the mass transfer coefficient is  
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Figure 4.1: Mathematical modeling predicts that insulin exits skeletal muscle capillaries by 
fluid-phase transport. A) Data from an INS-647 imaging experiment. B-D) Results from fitting 
experimental INS-647 imaging data to mathematical models describing diffusion, fluid-phase 
transport, or Michaelis-Menten transport kinetics. Plots are model simulations based on best-fit 
parameter estimates. e) Weighted sum of squared residuals for each of the different model 
simulations as compared to the experimental data for a group of n=6 mice. The number of 
variable parameters are indicated above the bar for each model. f) Best-fit fluid-phase transport 
model parameter estimates for a cohort of n=6 mice. Data are mean ± SEM. Param - parameters. 
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Figure 4.2: Michaelis-Menten model parameter estimates. A) Best-fit Michaelis-Menten 
model parameter estimates for a cohort of n=6 mice. Data are mean ± SEM. Km - substrate 
concentration at which the reaction rate is half of Vmax. Vmax – maximum reaction rate. 
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Figure 4.3: Temporal stability of the mass transfer coefficient. Best-fit mass transfer 
coefficient estimates from temporal subsets of INS-647 imaging experiments (n=6 mice). The x-
axis represents the final time point included in subsequent mathematical modeling.  
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relatively constant over the course of experiment. Because insulin and glucose change over the 
course of the experiment while the mass transfer coefficient remains stable, this implies that the  
mass transfer coefficient is independent of glucose and insulin levels. Moreover, these data 
provide a foundation for shortening the data acquisition time window in future experiments. 
 
Trans-endothelial insulin transport is non-saturable and does not require the insulin receptor 
 To test the model prediction that insulin efflux is not receptor-mediated, we treated mice 
with S961, a peptide insulin receptor antagonist that has nearly the same affinity for the insulin 
receptor as insulin (243). 10 minutes prior to the INS-647 bolus, mice were treated with 168 
nmol/kg of S961 (7-fold molar excess over insulin). Subsequently, in vivo imaging of INS-647 
was performed as described above. S961 effectively blocked both the insulin-induced lowering 
of blood glucose (Figure 4.4A) and insulin-stimulated muscle 2[14C]DG accumulation (Figure 
4.4B), suggesting that insulin receptors were successfully inhibited. However, we found that 
S961 had no effect on insulin transport kinetics (Figure 4.5A). Namely, S961 had no effect on 
either the mass transfer coefficient estimate (Figure 4.5B), the dissipation of the capillary / 
interstitial insulin gradient following INS-647 injection (model-independent parameter; Figure 
4.5C) nor the capillary and interstitial behavior of INS-647 (4.6A-D). These findings 
demonstrate that the insulin receptor does not mediate the transit of insulin across the capillary 
wall in skeletal muscle.  
 We then tested whether the movement of insulin across the endothelium was saturable. 
To do this, we treated mice with either 0.5U/kg INS-647, 1U/kg INS-647, 2U/kg INS-647, 
4U/kg INS-647, 4U/kg INS-647 and 4U/kg unlabeled insulin or 4U/kg INS-647 and 12U/kg of  
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Figure 4.4: Effects of S961 on insulin-stimulated glucose kinetics. A) Tail vein blood glucose 
levels following an INS-647 imaging experiment in mice treated either with a 4U/kg INS-647 
bolus alone (INS-647; n=4) or with an insulin receptor antagonist followed by the 4U/kg INS-
647 bolus (INS-647 + S961; n=6). B) Accumulation of 2[14C]deoxyglucose in various tissues 
during INS-647 imaging in mice treated with (INS-647 + S961; n=6) or without (INS-647; n=6) 
the insulin receptor antagonist. Groups were compared using unpaired Student’s t-test.   
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Figure 4.5: Trans-endothelial insulin efflux does not require the insulin receptor. A) 
Representative INS-647 images (maximum intensity projections) from mice pre-treated either 
with (4U/kg INS-647 + S961; 2nd from top) or without (INS-647 (4U/kg); top) an insulin 
receptor antagonist. B) Best-fit fluid-phase transport model estimates of the mass transfer 
coefficient in mice treated with (INS-647 + S961; n=5) and without (INS-647; n=6) the insulin 
receptor antagonist. C) The ratio of plasma to interstitial INS-647 as a function of time following 
injection. Interstitial INS-647 is defined as the average INS-647 intensity at 1-3µm from the 
capillary wall. Inset shows the exponential decay constant of the plasma to interstitial ratio, a 
model-independent descriptor of insulin efflux. Groups were compared using Student’s t-test. 
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Figure 4.6 Effects of S961 on model-independent insulin efflux kinetics. A) Plasma INS-647 
intensity as a function of time following 4U/kg INS-647 injection in mice treated with (INS-647 
+ S961; n=5) or without an insulin receptor antagonist (INS-647; n=6). B) Data from a 
normalized to plasma INS-647 intensity at t=0. C) Interstitial INS-647 intensity as a function of 
time following INS-647 injection. Interstitial INS-647 intensity is defined as the average INS-
647 intensity between 1-3mm from the capillary wall. D) Data from c normalized to interstitial 
INS-647 intensity at t=0min. 
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Figure 4.7: Insulin-647 imaging at different doses. Representative INS-647 images (max 
intensity projections) from mice treated with either 0.5U/kg INS-647 (n=7), 1U/kg INS-647 
(n=7), 2U/kg INS-647, 4U/kg INS-647 (n=6), 4U/kg INS-647 + 4U/kg unlabeled insulin (n=6), 
or 4U/kg INS-647 + 12U/kg unlabeled insulin (n=6). 
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Figure 4.8: Trans-endothelial insulin efflux is not saturable. A) The ratio of plasma to 
interstitial INS-647 as a function of time following injection in mice treated with either 0.5U/kg 
INS-647 (n=7), 1U/kg INS-647 (n=7), 2U/kg INS-647 (n=6), 4U/kg INS-647 (n=6), 4U/kg INS-
647 and 4U/kg unlabeled insulin (n=6), or 4U/kg INS-647 and 12U/kg unlabeled insulin (n=6). 
B) The exponential decay constant of the plasma / interstitial ratio plotted as a function of insulin 
dose. C) Best-fit fluid-phase transport model estimates of the mass transfer coefficient. For mice 
treated with 0.5U/kg or 1U/kg INS-647, the image signal-to-noise ratio was too low to allow for 
mathematical modeling. D) Capillary INS-647 intensity as a function of time following INS-647 
normalized to capillary INS-647 at t = 0 min. E) Interstitial INS-647 intensity as a function of 
time following INS-647 injection normalized to interstitial INS-647 at t = 0 min. Interstitial INS-
647 intensity is defined as the average INS-647 intensity between 1-3µm from the capillary wall. 
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unlabeled insulin (Figure 4.7). If insulin efflux were saturable, we would predict that 1) the rate 
at which plasma insulin equilibrates with the interstitial space would decrease with increasing 
doses of insulin and 2) unlabeled insulin would compete for the saturable transport machinery 
and reduce the apparent transport of INS-647. However, we found that the dissipation kinetics of  
the capillary/interstitial INS-647 gradient were the same regardless of the dose of insulin used 
(Figure 4.8, A and B). Furthermore, the mass transfer coefficient was not different for any of the 
doses that were amenable to mathematical modeling (Figure 4.8C; 2U/kg and above). Of note, 
low signal-to-noise ratio at doses below 2U/kg prevented stable, unique estimates of model 
parameters at these doses. The kinetics of INS-647 in the capillary varied depending on dose 
(Figure 4.8D), with lower doses of insulin being cleared more quickly than higher ones. These 
differences were also reflected in the interstitial INS-647 kinetics (Figure 4.8E). This finding is 
consistent with the notion that insulin appearance in the interstitial space is a linear function of 
the levels of insulin in the plasma (i.e. fluid-phase transport). Collectively, these results 
demonstrate that trans-endothelial insulin efflux is not saturable.  
 
Discussion 
One of insulin’s key functions is to stimulate muscle glucose uptake. Before insulin can 
stimulate muscle glucose uptake it must first cross the endothelial barrier separating the plasma 
from myocytes. Previous studies have shown that insulin-stimulated muscle glucose uptake 
depends on the ability of insulin to cross this endothelial barrier (136). Furthermore, experiments 
in insulin resistant subjects have shown that impaired insulin delivery is a feature of muscle 
insulin resistance (156, 212, 244) which is associated with Type II diabetes. Therefore, 
characterizing the mechanism of capillary endothelial insulin transport is critical to 
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understanding the progression of insulin resistance (245). With the use of our in vivo imaging 
technique, we advance the understanding of trans-endothelial insulin efflux by showing that 
insulin moves across the endothelium by fluid-phase transport.  Our findings extend those of 
Bergman and colleagues, who previously showed that the delivery of insulin to skeletal muscle is 
not saturable in dogs (157). Furthermore, we demonstrate that the insulin receptor is not required 
for the movement of insulin across the endothelium. This result is supported by experiments 
from Kahn and colleagues who showed that mice lacking insulin receptors on endothelial cells 
are fully insulin sensitive (158). 
Fluid-phase transport may be accomplished by either convective movement of insulin 
through inter-endothelial junctions, a non-specific vesicular process, or a combination of both. 
Of note, Bendayan et al. used immunoelectron microscopy to show that insulin can be localized 
inside endothelial vesicles (246), suggesting the importance of the latter mechanism. Caveolar 
vesicles, which can mediate the trans-endothelial movement of macromolecules, have also been 
implicated in the endothelial transport of insulin (154). Future experiments will be aimed at 
deconvolution of these mechanisms.  
One potential limitation of the current technique is measurement sensitivity. Namely, the 
lowest dose of INS-647 administered (0.5 U/kg) produces somewhat higher than physiological 
plasma insulin levels. Thus, we cannot rule out the existence of a low capacity, Michaelis-
Menten-like insulin transport mechanism which operates at lower insulin levels. Such a process 
would be non-insulin receptor-mediated as neither insulin receptor antagonism nor unlabeled 
insulin had any effect on insulin transport. As of yet, there is no evidence for the existence of 
such a process in vivo or its significance. However, it is possible that there is some vesicular 
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compartment (e.g. caveolae) that transports insulin at low concentrations via Michaelis-Menten 
kinetics. 
Many investigators have observed a delay between the rise in plasma insulin levels and 
the stimulation of glucose uptake in skeletal muscle (120). This delay has largely been attributed 
to the continuous endothelium of skeletal muscle capillaries, which limits the access of 
macromolecules to the interstitial space. Our findings regarding the mechanism of trans-
endothelial insulin efflux lend insight into the characterization of the endothelial barrier. Namely, 
the movement of insulin from the plasma to the interstitial space may be limited by the presence 
of the glycocalyx, the size of inter-endothelial junctions or pores, the transmission of convective 
forces to the capillary, the kinetics of vesicular trafficking, or the rate at which insulin can 
promote capillary recruitment. A better understanding of the variables controlling trans-
endothelial insulin transport will lead to improved therapeutic strategies aimed at reversing 
muscle insulin resistance. Such strategies might include small molecules that can enhance insulin 
delivery to skeletal muscle or, for diabetics, the synthesis of novel insulin analogs that can more 
readily access muscle. 
The mechanism of endothelial insulin transport has been controversial. Studies utilizing 
cultured monolayers of endothelial cells have shown that trans-endothelial insulin transport is a 
saturable, insulin-receptor mediated process (150, 152). In contrast, we convincingly 
demonstrate that insulin movement across the endothelium is non-saturable and does not require 
the insulin receptor in vivo. The contrasting results likely reflect the difference in behavior 
between endothelial cells in culture and capillaries in vivo. Endothelial monolayers are 100 times 
more permeable to proteins than are intact vessels (165) and lack the physiological milieu that 
profoundly influences endothelial function in live animals (164). Furthermore, cultured 
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endothelial cell experiments typically use macrovascular endothelial cells such as umbilical vein 
or aortic endothelial cells, whereas molecular exchange occurs in the microvasculature in vivo. 
The phenotypic contrast between microvascular and macrovascular endothelial cells (162) 
creates difficulties in interpretation. In fact, the mechanism by which insulin is taken up by 
endothelial cells depends on the type of endothelial cell used (155). 
  In vivo examinations of insulin delivery to the skeletal muscle interstitial fluid have 
similarly produced conflicting results (156–159, 239). Such studies have utilized interstitial fluid 
sampling methods such as microdialysis and lymph sampling or measured indices of total 
skeletal muscle insulin delivery. These techniques are limited because the number of capillaries 
feeding the space from which sampling is performed is unknown. Therefore, such techniques do 
not directly measure trans-endothelial molecular efflux but rather a combination of both 
microvascular perfusion and endothelial transport. That is to say, any change in muscle insulin 
availability could be due to a change in 1) the number of perfused capillaries, 2) insulin efflux 
across the endothelium, or 3) a combination of both. For instance, Konishi et al. recently 
reported that a mouse model lacking endothelial insulin receptors have delayed muscle insulin 
signaling following an insulin bolus (159). The implication is that insulin delivery to muscle is 
impaired. It is impossible to know whether such an effect is due to impaired insulin-stimulated 
perfusion or insulin efflux from capillaries. Given that insulin receptor antagonism has no effect 
on insulin efflux, and the compelling work from several laboratories that shows insulin 
stimulates skeletal muscle perfusion (89, 92, 247), it is likely that the delay in skeletal muscle 
insulin signaling in these mice is due to a reduction in insulin-stimulated capillary recruitment. 
However, it is impossible to directly deconvolve perfusion and efflux from this approach. With 
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intravital imaging, we measure insulin efflux at the level of individual capillaries, which allows 
us to directly measure trans-endothelial insulin efflux.  
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CHAPTER V 
 
IMPAIRED TRANS-ENDOTHELIAL INSULIN TRANSPORT IN SKELETAL MUSCLE 
OF OBESE MALE MICE IN VIVO 
 
Aims 
 Total insulin delivery to the interstitial space is reduced in insulin resistant humans and 
animal models. Whether this impairment in insulin delivery is due to reduced perfusion, trans-
endothelial insulin transport, or both is unknown. The aim of Chapter V is to utilize intravital 
insulin imaging to determine whether trans-endothelial insulin transport is reduced in a mouse 
model of obesity and insulin resistance.  
 
Experimental Approach 
Male and female 6-week old C57Bl/6J mice were fed a standard chow (5001 Laboratory 
Rodent Diet; Lab Diet) or HFD (60% calories from fat; Bioserv F3282) for 16 weeks. We chose 
this length of HFD because it induces skeletal muscle insulin resistance (248). For intravital 
microscopy experiments, mice were bred and housed at Vanderbilt University for the entirety of 
the experiment. One HFD-fed male mouse which underwent intravital microscopy was excluded 
due to a lack of weight gain and fat accumulation. For insulin tolerance tests and electron 
microscopy experiments, age-matched diet-induced obese (DIO) and lean control C57Bl/6J mice 
were purchased from Jackson Laboratory. 
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Results* 
HFD impairs trans-endothelial insulin transport in male mice 
We first tested the hypothesis that diet-induced obesity and skeletal muscle insulin 
resistance are associated with impaired trans-endothelial insulin transport. Lean and diet-induced 
obese (DIO) mouse models were generated by feeding male mice chow or HFD for 16 weeks. As 
expected, DIO mice weighed 52% more than their lean counterparts (Figure 5.1A) and had a 
2.5-fold increase in body fat percentage (Figure 5.1B).  
Using intravital insulin imaging, we observed that trans-endothelial insulin transport was 
impaired in DIO male mice (Figure 5.2). Namely, the rate at which plasma INS-647 equilibrated 
with the interstitial space was ~15% lower in DIO mice compared to lean mice (Figure 5.2, B 
and C, Figure 5.3). This indicates that trans-endothelial insulin transport is slower in DIO male 
mice. Following the INS-647 bolus, capillary INS-647 levels were consistently higher in DIO 
male mice (Figure 5.4A). The clearance rate of plasma INS-647, however, was not significantly 
different between groups (Figure 5.4, A and B). Consistent with higher levels of plasma INS-
647, DIO male mice also had higher absolute levels of interstitial INS-647 (Figure 5.4C). The 
rate of interstitial INS-647 appearance, however, was slightly, but non-significantly, lower in the 
DIO male mice (Figure 5.4D). Furthermore, the magnitude of the increased interstitial INS-647 
in DIO male mice (Figure 5.4C) was lower than that of the increase in plasma INS-647 (Figure 
5.4A). These findings indicate that, while DIO male mice had higher levels of plasma INS-647, a 
lower fraction of the plasma INS-647 was able to access the interstitial space. This demonstrates 
an impairment in trans-endothelial insulin transport.  
                                               
* These results are described in a manuscript which is in preparation for submission: Williams IM, 
McClatchey PM, Bonner JS, Valenzuela FA, Wasserman DH. Trans-endothelial insulin efflux is impaired 
in skeletal muscle of obese mice. 
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Figure 5.1: Effect of HFD on body mass and composition in male mice. A) Body mass and 
B) percent body fat in lean (n=12) and DIO (n=7) male mice undergoing intravital microscopy. 
DIO – diet-induced obese, HFD – high fat diet. Groups were compared using Student’s t-test. 
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Figure 5.2: Obese male mice have impaired trans-endothelial insulin efflux in skeletal 
muscle capillaries. A) Representative INS-647 images (maximum intensity projections) in lean 
(n=12) and DIO (n=7) male mice. B) The ratio of plasma to interstitial INS-647 as a function of 
time following INS-647 injection, normalized to the ratio at t = 0 min. C) Decay constant of the 
plasma / interstitial INS-647 ratio, a measure of trans-endothelial insulin efflux kinetics. INS-647 
– insulin-647, DIO – diet-induced obese. Groups were compared using Student’s t-test. 
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Figure 5.3: Trans-endothelial insulin efflux kinetics in lean and DIO male mice. The ratio of 
plasma to interstitial INS-647 intensity following INS-647 injection, a measure of trans-
endothelial insulin efflux. INS-647 – insulin-647. 
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Figure 5.4: Effects of HFD on plasma insulin clearance, interstitial appearance, and insulin 
delivery in male mice. A) Capillary plasma INS-647 intensity as a function of time following 
injection in lean (n=12) and DIO (n=7) male mice. Inset shows the decay constant of capillary 
INS-647. B) Data in A normalized to the capillary INS-647 intensity at t = 0 min. C) Interstitial 
INS-647 intensity as a function of time following injection. The interstitial space is defined as 
the region emanating 1-3µm from the capillary wall. D) Data in C normalized to the interstitial 
INS-647 intensity at t = 0 min. E) Total extravascular INS-647 in the field of view as a function 
of time following injection. F) Data in E normalized to the extravascular INS-647 intensity at t = 
0 min. Groups were compared either by Student’s t-test or by two-way repeated measures 
ANOVA. IU – intensity units, HFD – high fat diet. 
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Trans-endothelial insulin transport is one of three variables, including plasma insulin 
concentration and the capillary surface area for insulin exchange, that control muscle insulin  
delivery. We found that neither plasma-perfused surface area (Figure 5.5, A and B) nor 
capillary diameter (Figure 5.5, C and D) were affected by HFD. This suggests that the surface 
area for insulin exchange was the same in lean and DIO males. To determine whether the 
reduced trans-endothelial insulin transport in DIO males affected total insulin delivery, we 
measured INS-647 in the entire extravascular space. We found that, while the extravascular INS-
647 levels were consistently higher in DIO male mice, (Figure 5.4E), the rate of INS-647 
appearance in the extravascular space was reduced (Figure 5.4F). These findings indicate that 
the kinetics of insulin delivery to skeletal muscle are impaired in DIO male mice.  
 Following intravital microscopy experiments, we observed that DIO male mice had 
higher blood glucose levels (Figure 5.6A) and lower accumulation of the isotopic glucose tracer 
2[14C]DGP in the gastrocnemius (Figure 5.6B). These findings indicate that DIO male mice 
have whole-body and skeletal muscle insulin resistance. To confidently ensure that muscle 
insulin resistance could be detected using the same conditions as intravital microscopy 
experiments, we performed insulin tolerance tests with isotopic glucose tracers in a separate 
cohort of DIO male mice (Figure 5.7). This cohort of HFD-fed male mice also weighed more 
(Figure 5.8A) and had a higher percentage of body fat (Figure 5.8B) than their chow-fed 
counterparts. As expected, DIO male mice had a significantly impaired glucose-lowering 
response to insulin (Figure 5.7, A and B). Furthermore, the clearance of 2[14C]DG by the soleus, 
gastrocnemius, and vastus lateralis muscles was reduced in DIO male mice (Figure 5.7 C). 
These results confirm that DIO male mice display muscle insulin resistance. Therefore, muscle  
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Figure 5.5: HFD has no effect on plasma-perfused surface area or capillary diameter in 
male mice. A) Vascular cross-sectional surface area, as determined by the area of rhodamine 
dextran (vascular marker), as a function of time in lean (n=12) and DIO (n=7) male mice. INS-
647 was injected at t = 0 min. B) Average plasma-perfused surface area throughout the course of 
the intravital microscopy experiment. C) Capillary diameter as a function of time during 
intravital microscopy experiments. INS-647 was injected at t = 0 min. D) Average capillary 
diameter throughout the intravital microscopy experiment. Groups were compared using 
Student’s t-test. 
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Figure 5.6: HFD causes skeletal muscle insulin resistance in male mice. A) Terminal blood 
glucose following intravital microscopy experiments in lean (n=11) and DIO (n=7) male mice. 
B) Accumulation of the isotopic glucose tracer, 2[14C]2deoxyglucose-6-phosphate, in the 
gastrocnemius during intravital microscopy experiments. Groups were compared using Student’s 
t-test. 2DGP - 2[14C]2deoxyglucose-6-phosphate, dpm – disintegrations per minute. 
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Figure 5.7: DIO male mice display skeletal muscle insulin resistance. A) Glucose excursions 
in anesthetized lean (n=5) and DIO (n=7) male mice following a 4U/kg intravenous insulin 
bolus. B) Area under the glucose excursion curves in A. C) Clearance of 2[14C]2deoxyglucose 
during the insulin tolerance tests by the soleus, gastrocnemius, and vastus muscles. Groups were 
compared using Student’s t-test. 
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Figure 5.8: Effects of HFD on body mass and composition in male mice. A) Body mass and 
B) percent body fat in lean (n=5) and DIO (n=7) male mice undergoing insulin tolerance tests. 
Groups were compared using Student’s t-test. 
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insulin resistance is associated with impaired trans-endothelial insulin transport in DIO male 
mice. 
 
HFD causes ultrastructural defects in the skeletal muscle capillary endothelium of male mice 
In light of the finding that trans-endothelial insulin transport is delayed in DIO male 
mice, we hypothesized that this impairment would be associated with changes to the skeletal 
muscle capillary endothelium. To test this hypothesis, we assessed capillary endothelial 
ultrastructure with transmission electron microscopy (Figure 5.9). We observed that the density 
of vesicles in the endothelium was reduced by ~45% in DIO male mice (Figure 5.9, A-C). 
Neither the diameter of vesicles (Figure 5.9D), nor the localization of vesicles within the 
endothelium (Figure 5.9E), however, were altered in DIO male mice. Furthermore, the basement 
membrane thickness was not different between groups (Figure 5.9F). The reduction in 
endothelial vesicles observed in DIO males, which can serve as macromolecular transporters 
(146), may explain the impairment in trans-endothelial insulin transport.  
 
HFD does not alter trans-endothelial insulin efflux in females 
 We next tested whether the effects of HFD on trans-endothelial insulin transport were 
similar in female mice. Female mice fed HFD for 16 weeks weighed 30% more than their chow-
fed counterparts (Figure 5.10A). Interestingly, HFD-fed females did not have a significantly 
higher percentage of body fat than chow-fed mice (Figure 5.10B). We did not observe a 
difference in trans-endothelial insulin transport between chow and HFD-fed females (Figure 
5.11). Namely, there was no change in the dissipation of the plasma/interstitial INS-647 gradient 
(Figure 5.11, B and C, Figure 5.12). Similar to HFD-fed males, plasma INS-647 levels were  
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Figure 5.9: Skeletal muscle capillaries of DIO male mice contain fewer endothelial vesicles. 
A) Representative electron micrographs of the capillary endothelium in the gastrocnemius of 
lean and DIO male mice. B) Volume of vesicles relative to total endothelial volume in chow 
(n=5) and DIO (n=4) male mice. C) Frequency distribution of relative vesicular volume in all 
capillaries from chow (n=64) and DIO male mice (n=66). D) The average diameter of all 
endothelial vesicles in chow (n=227) and DIO (n=116) male mice. E) Frequency distribution of 
the localization of vesicles in the capillary endothelium. F) Average basement membrane 
thickness in capillaries from chow (n=31) and DIO male mice (n=31). In the box and whisker 
blots, the box extends from the 25th to the 75th percentiles and the whiskers indicate the range. 
Groups were compared using Student’s t-test. 
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Figure 5.10: Effects of high fat feeding on body mass and composition in female mice. A) 
Body mass and B) percent body fat in chow (n=6) and HFD-fed (n=8) female mice undergoing 
intravital microscopy. Groups were compared using Student’s t-test. 
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Figure 5.11: HFD does not alter trans-endothelial insulin efflux in females. A) 
Representative INS-647 images (maximum intensity projections) in chow (n=6) and HFD-fed 
(n=8) female mice. B) The ratio of plasma to interstitial INS-647 as a function of time following 
INS-647 injection, normalized to the ratio at t = 0 min. C) The gradient decay constant of the 
plasma to interstitial INS-647 ratio as a function of time. Groups were compared using Student’s 
t-test.   
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Figure 5.12: Trans-endothelial insulin efflux kinetics in chow and HFD-fed female mice. 
The ratio of plasma to interstitial INS-647 intensity as a function of time following INS-647 
injection, a measure of trans-endothelial insulin efflux. 
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higher in HFD-fed females following the INS-647 bolus (Figure 5.13A). However, the rate of 
INS-647 clearance from the plasma was not different between the two groups (Figure 5.13, A  
and B). HFD-females tended to have higher levels of interstitial INS-647 (Figure 5.13C) as 
expected from their higher levels of plasma INS-647. However, there was no difference in the 
rate of interstitial INS-647 appearance between chow and HFD-fed females (Figure 5.13D). 
With respect to microvascular hemodynamic indices, we did not observe any difference 
in either average plasma-perfused surface area (Figure 5.14, A and B) or capillary diameter 
(Figure 5.14, C and D). As expected from the lack of differences in capillary surface area 
(Figure 5.14B) and trans-endothelial insulin transport (Figure 5.11C), there was no change in 
total extravascular INS-647 delivery (Figure 5.13, E and F) in HFD-fed females. Following the 
intravital microscopy experiments, we did not observe any difference in terminal blood glucose 
(Figure 5.15A). HFD-fed females did have a 27% reduction in 2[14C]DGP accumulation in the 
gastrocnemius (Figure 5.15B), although this difference was not statistically significant. These 
findings suggest that, in contrast to males, 16 weeks of HFD does not alter trans-endothelial 
insulin transport and only causes mild skeletal muscle insulin resistance in females.  
 
 
Discussion 
 
In this study, we show for the first time that DIO male mice with skeletal muscle insulin 
resistance have an impairment in the movement of insulin across the skeletal muscle capillary 
endothelium in vivo. This delay in trans-endothelial insulin transport is associated with a loss of 
vesicles in the skeletal muscle capillary endothelium. Interestingly, female mice were protected 
from the effects of HFD on trans-endothelial insulin transport and skeletal muscle insulin 
resistance. These findings reveal a novel contributor to skeletal muscle insulin resistance in DIO 
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Figure 5.13: Effects of HFD on plasma insulin clearance, interstitial appearance, and total 
insulin delivery in female mice. A) Capillary INS-647 as a function of time following injection 
in female mice fed chow (n=6) or HFD (n=8). Inset shows the plasma INS-647 decay constant. 
B) Data in A normalized to the capillary INS-647 intensity at t = 0 min. C) Interstitial INS-647 
as a function of time following injection. The interstitial space is defined as the region emanating 
1-3µm from the capillary wall. D) Data in C normalized to the interstitial INS-647 intensity at t 
= 0 min. E) Total extravascular INS-647 in the field of view as a function of time following 
injection. F) Data in E normalized to the extravascular INS-647 at t = 0 min. Groups were 
compared either by Student’s t-test or two-way repeated measures ANOVA. 
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Figure 5.14: Effects of HFD on microvascular parameters in female mice. A) Vascular 
cross-sectional surface area, as determined by the area of rhodamine dextran (vascular marker), 
as a function of time in chow (n=6) and HFD-fed (n=7) female mice. INS-647 was injected at t = 
0 min. B) Average plasma-perfused surface area throughout the course of the intravital 
microscopy experiment. C) Capillary diameter as a function of time during intravital microscopy 
experiments. INS-647 was injected at t = 0 min. D) Average capillary diameter throughout the 
intravital microscopy experiment. Groups were compared using Student’s t-test.  
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Figure 5.15: Effects of HFD on glucose metabolism in female mice. A) Terminal blood 
glucose following intravital microscopy experiments in chow (n=6) and HFD-fed (n=7) female 
mice. B) Accumulation of the isotopic glucose tracer, 2[14C]2deoxyglucose-6-phosphate, in the 
gastrocnemius during intravital microscopy experiments. Groups were compared using Student’s 
t-test.  
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male mice. Namely, skeletal muscle insulin resistance may be due, in part, to an inability of 
insulin to cross the capillary endothelium and access myocytes. A critical and yet unresolved 
question is whether impaired trans-endothelial insulin transport contributes to skeletal muscle 
insulin resistance (245, 249). Most previous studies, but not all (213), have demonstrated that the 
delivery of insulin to skeletal muscle interstitial space is reduced in obese humans (244) and 
animal models (156, 212, 250). The delivery of insulin to skeletal muscle depends on both the 
capillary surface area for insulin exchange and the rate at which insulin moves across the 
capillary endothelium. Many studies have shown that insulin-stimulated skeletal muscle 
perfusion is reduced in obesity (89, 156, 173, 251). The contribution of trans-endothelial insulin 
transport to the reduced insulin delivery observed in obesity, however, has been unclear due to 
the lack of direct measurements in vivo. We utilized the intravital microscopy technique 
described in Chapter III to directly visualize and quantify the movement of insulin across the 
endothelium of individual skeletal muscle capillaries in vivo (252). This method has major 
advantages over in vitro studies of cultured endothelial cells. Namely, cultured endothelial cells 
are very different than capillaries in vivo with respect to microenvironment, protein expression, 
permeability, and the mechanism of insulin transport (164, 165, 252, 253). Utilizing direct 
measurements of trans-endothelial insulin transport in vivo, we demonstrate that the movement 
of insulin across the endothelium is impaired in the skeletal muscle of DIO male mice. 
 We observed a 15% reduction in trans-endothelial insulin transport in DIO male mice. 
The implication of this reduction in trans-endothelial insulin transport would presumably be a 
reduction in total delivery of insulin to skeletal muscle. Interestingly, we found that absolute 
extravascular levels of insulin were actually increased in DIO male mice. A limitation of this 
measurement is that it is made in a very small volume and may not reflect insulin delivery at the 
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whole muscle level. Regardless, this finding demonstrates, perhaps obviously, that in addition to 
surface area for insulin exchange and trans-endothelial insulin transport, plasma insulin 
concentration is an important determinant of muscle insulin delivery. In the current study, the 
higher plasma insulin levels in DIO male mice compensate for the reduced trans-endothelial 
insulin transport to maintain extravascular insulin delivery. Plasma insulin levels were most 
likely higher in DIO mice because the dose of INS-647 was normalized to total body mass and 
plasma volume does not scale with body mass in obese mice (254). Thus, the plasma insulin 
concentration was likely higher in DIO male mice because a greater amount of insulin was 
administered into a similar plasma volume. Nonetheless, the higher levels of plasma insulin 
alone would not be expected to affect trans-endothelial insulin transport because 1) insulin efflux 
is not saturable (252) and 2) HFD-female mice also have higher levels of plasma insulin but no 
change in trans-endothelial insulin transport. Furthermore, these experimental conditions 
recapitulate the hyperinsulinemia observed in obesity. We hypothesize that such 
hyperinsulinemia may be a compensatory mechanism to overcome defects in trans-endothelial 
insulin transport and maintain insulin levels at the myocyte.  Despite the higher levels of 
extravascular insulin in the DIO male mice, they still displayed skeletal muscle insulin 
resistance. This indicates cellular insulin resistance at the level of the myocyte. Thus, defects in 
trans-endothelial insulin transport compound with myocyte insulin resistance to severely impair 
insulin action in skeletal muscle during obesity. 
 The reduction of trans-endothelial insulin transport in DIO male mice is associated with a 
profound reduction in the density of endothelial vesicles. This is consistent with a previous 
finding from Bagi and colleagues who showed that the number of endothelial vesicles in 
coronary arterioles was reduced in humans with established Type 2 diabetes (255). Endothelial 
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vesicles can serve as macromolecular transporters (146) which may carry insulin (246). It is 
unclear whether these vesicles are distinct, transcytotic carriers or if they represent pores in the 
endothelium (147). We hypothesize that these capillary endothelial vesicles are likely 
components of pore networks for two reasons. First, trans-endothelial insulin efflux is not 
saturable in vivo (252). Assuming these vesicles do indeed carry insulin (246), the transport of 
insulin through endothelial pores is more compatible with the non-saturable nature of insulin 
transport. The presence of a non-saturable yet active, energy-requiring transcytotic transport 
mechanism seems unlikely. Furthermore, if individual vesicles were actively taking up 
macromolecules and being transcytosed across the endothelium, we would expect to see 
molecular accumulation in the capillary endothelium. However, unlike studies utilizing cultured 
endothelial cells (233), we have never observed the accumulation of any fluorescent molecule 
(dextrans, albumin, transferrin, insulin) in the endothelium of skeletal muscle capillaries. We do 
see uptake and accumulation of these molecules in the cells lining arterioles and venules, 
indicating that vesicular transcytosis may be a more relevant transport mechanism in larger blood 
vessels. Thus, we hypothesize that, in DIO male mice, the number of capillary endothelial pores 
available for insulin exchange is reduced, thereby impairing trans-endothelial insulin transport. 
 It should be noted that the magnitude in reduction of endothelial vesicles (45%) was 
much larger than the impairment in trans-endothelial insulin transport (15%). We have two 
hypotheses for this discrepancy. First, there may be an excess of endothelial pore surface area 
available for insulin exchange in healthy, lean mice. Thus, a more significant reduction in 
endothelial vesicular density may be required to severely limit trans-endothelial insulin transport. 
An alternative possibility is that paracellular permeability, as governed by the width of inter-
endothelial junctions, increases in DIO male mice to compensate for the reduction in 
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transcellular (i.e. vesicular pores) permeability. Indeed, there is considerable crosstalk between 
transcellular and paracellular transport pathways (256). Given the importance of fluid and 
macromolecular delivery, it would be expected that compensatory mechanisms exist to maintain 
these functions. Finally, we cannot exclude the possibility that the paracellular movement of 
insulin through inter-endothelial junctions is a greater determinant of trans-endothelial insulin 
transport than transcellular insulin movement. 
 Using our intravital microscopy technique, we also measured plasma-perfused surface 
area and capillary diameter, indices of microvascular structure and hemodynamics. We did not 
observe any difference between lean and DIO male mice in either of these parameters. 
Furthermore, the administration of insulin did not appear to have any effect on plasma-perfused 
surface area. This suggests that there was no effect of HFD on the capillary surface area 
available for insulin exchange. These findings are seemingly in contrast to previous studies 
utilizing contrast-enhanced ultrasound which concluded that 1) that insulin increases muscle 
microvascular perfusion (120, 156) and 2) insulin-stimulated muscle perfusion is reduced in 
obesity. The use of contrast-enhanced ultrasound to measure the distribution volume of ~1-3µm 
microbubbles gives an index of red blood cell distribution volume. This is different from our 
measurement of the distribution volume of a rhodamine-labeled plasma marker, 2MDa dextran. 
As insulin exists in plasma and not red blood cells, the measurement of plasma-perfused surface 
area is more relevant for assessing the surface area available for insulin exchange. Thus, it is 
possible that insulin and HFD have divergent effects on red blood cell and plasma distribution. 
Namely, while insulin increases and obesity decreases microbubble distribution volume (120), 
neither insulin nor obesity alter plasma-perfused surface area in skeletal muscle. Given that 
insulin and HFD alter microbubble velocity (120), it is likely that they also alter plasma velocity. 
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Regardless, changes in plasma velocity would not be predicted to alter trans-endothelial insulin 
transport as insulin is a relatively slowly equilibrating molecule (257). 
 In contrast to male mice, we found that female mice were protected from the deleterious 
effects of HFD on trans-endothelial insulin transport. The most likely explanation for this finding 
is that, while HFD-fed female mice were heavier than chow-fed mice, they did not have a 
significantly higher percentage of body fat. This observation is mostly consistent with a previous 
study which showed that 15 weeks of HFD causes weight gain but only a small increase in body 
fat percentage in female mice (258). Thus, HFD in the absence of obesity does not cause 
impaired capillary insulin transport in female mice. Consistent with the unaltered trans-
endothelial insulin transport, skeletal muscle insulin sensitivity, as measured by 2[14C]DGP 
accumulation, was only slightly and non-significantly reduced in HFD-fed females. This 
contrasts with male mice which develop severe skeletal muscle insulin resistance when fed a 
HFD. It is also conceivable that sex differences in microvascular function (259, 260) protect 
female mice from the endothelial dysfunction associated with HFD.  
In summary, we have shown for the first time that the movement of insulin across the 
endothelium in skeletal muscle capillaries is impaired in a mouse model of diet-induced obesity 
and insulin resistance. This impairment in trans-endothelial insulin transport is associated with a 
reduction in endothelial vesicles. These findings demonstrate that capillaries contribute to 
skeletal muscle insulin resistance. Treatments that increase trans-endothelial insulin transport 
may be useful in enhancing the delivery of insulin to skeletal muscle for the treatment of insulin 
resistance or in generating fast-acting insulin analogs for diabetics. 
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CHAPTER VI 
 
 
 
ACUTE NITRIC OXIDE SYNTHASE INHIBITION ACCELERATES TRANS-
ENDOTHELIAL INSULIN TRANSPORT IN VIVO 
 
 
 
Aims 
 Several studies have demonstrated that endothelial NO is positively correlated to skeletal 
muscle insulin action through its ability to increase microvascular perfusion. NO also regulates 
endothelial barrier permeability. This raises the possibility that NO may also regulate skeletal 
muscle insulin action through its effects on trans-endothelial insulin transport. The aim of 
Chapter VI is to investigate the effects of pharmacologically manipulating endothelial NO 
levels on trans-endothelial insulin transport in vivo. 
 
Experimental Approach 
To determine the effects of acutely modulating NO and blood pressure on trans-
endothelial insulin transport and glucose metabolism, mice were treated with either L-NAME 
(NOS inhibitor), SNP, (NO donor), phenylephrine, or hydralazine. Phenylephrine and 
hydralazine are direct smooth muscle acting drugs that raise and lower blood pressure, 
respectively (261, 262). For each individual drug treatment, the same protocol was used for 
intravital microscopy, blood pressure measurements, and insulin tolerance experiments. For the 
L-NAME experiment, mice were administered a 30 mg/kg i.v. bolus (50µL volume) of L-NAME 
or an equivalent volume of saline 15 minutes prior to the beginning of experiments (Figure 
6.1A). This timing and dose of L-NAME was chosen because it was previously shown to 
increase blood pressure (i.e. inhibit NOS) in rats (263). For SNP experiments, mice were treated 
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with a continuous infusion of either SNP (100µg/kg/min) or saline beginning 15 minutes before 
the experiment and continuing throughout the course of the study (Figure 6.6A). This dose was 
based on a previous study which showed that a 37µg/kg/min infusion lowered blood pressure 
within 15 minutes (264). We increased this dose to ensure that SNP would be effective in 
anesthetized mice. Phenylephrine and hydralazine were administered as primed, continuous 
infusions starting at 5 minutes prior to experiments and continuing throughout the study (Figure 
6.10A). Mice were given a 300µg/kg or 1mg/kg bolus followed by a 300µg/kg/min or 
1mg/kg/min continuous infusion of phenylephrine or hydralazine, respectively. These doses were 
chosen based on their ability to raise (phenylephrine) or lower (hydralazine) blood pressure (265, 
266). Control mice were treated with equivalent infusion rates and volumes of saline.  
 
 
Results* 
 
Acute L-NAME treatment accelerates trans-endothelial insulin transport  
We first tested the hypothesis that acutely reducing NO would impair insulin transport as 
suggested by studies in cultured bovine aortic endothelial cells (190). To reduce endothelial NO 
levels, we treated mice with L-NAME. L-NAME is an arginine-based inhibitor of all 3 isoforms 
of NOS and therefore reduces endothelial NO production (267). Mice received a 30 mg/kg i.v. 
bolus of L-NAME 15 minutes prior to intravital insulin imaging. As expected, treatment of mice 
with L-NAME increased blood pressure by ~30 mmHg throughout the course of the experiment 
(Figure 6.1, A and B). L-NAME treatment also reduced capillary diameter by ~0.4µm both 
prior to (Figure 6.1, C and D) and following the insulin bolus (Figure 6.1C). Finally, vascular 
NO signaling was dampened by L-NAME treatment as evidenced by lower levels of 
                                               
* These results are described in a manuscript which has been accepted for publication: Williams IM, 
McClatchey PM, Bracy DP, Valenzuela FA, Wasserman DH. Acute nitric oxide synthase inhibition 
accelerates trans-endothelial insulin efflux in vivo. Diabetes 2018. In press. 
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phosphorylated vasodilator-stimulated phosphoprotein (VASP) in the gastrocnemius (Figure 6.1, 
E-I). Taken together, these results suggest that vascular NO levels were effectively reduced by 
L-NAME treatment. 
After confirming that L-NAME reduced NO levels, we performed in vivo insulin imaging 
as described above. Interestingly, acute reduction of NO with L-NAME accelerated the kinetics 
of trans-endothelial insulin transport by ~30% (Figure 6.2). Namely, L-NAME increased the 
dissipation rate of the plasma/interstitial INS-647 gradient, indicating a more rapid movement of 
insulin across the endothelium (Figure 6.2, B and C, Figure 6.3A). This increase in trans-
endothelial insulin transport was not due changes in clearance of insulin from the plasma, which 
reflects whole body insulin clearance, (Figure 6.2D) but rather increased appearance of insulin 
in the muscle interstitial space (Figure 6.2E). Furthermore, there was no difference in plasma-
perfused surface area between saline and L-NAME-treated mice (Figure 6.3B). Therefore, L-
NAME, which increased capillary permeability to insulin without altering the surface area for 
insulin exchange, enhanced total extravascular insulin delivery (Figure 6.3, C and D). Thus, 
acute reduction of systemic NO by L-NAME accelerates the movement of insulin across the 
endothelium and increases total insulin delivery.  
 
Acute L-NAME treatment enhances the kinetics of insulin-induced glucose lowering 
Following the 4U/kg INS-647 bolus during intravital microscopy experiments, we 
observed that the blood glucose in L-NAME-treated mice was ~55mg/dl lower than in saline-
treated mice (Figure 6.4A), reflecting an increase in insulin sensitivity. Furthermore, L-NAME 
treatment resulted in a non-significant 35% increase in the accumulation of 2[14C]DGP, an 
isotopic glucose tracer, in the gastrocnemius (Figure 6.4B). These results suggest that acute  
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Figure 6.1: Acute L-NAME treatment increases blood pressure, reduces capillary diameter 
and decreases NO signaling. A) Mean arterial blood pressure measured through an indwelling 
carotid artery catheter in saline (n=4) and L-NAME-treated (n=4) mice. Mice were anesthetized 
with KXA and treated with either saline or 30mg/kg L-NAME at t= - 15 min. At t = 0 min, mice 
were administered a 4U/kg insulin bolus, as during the imaging experiments. B) Average MAP 
from t = - 10 to 15 min. C) Capillary diameter as a function of time during INS-647 imaging 
experiments. D) Average diameter of capillaries (rhodamine dextran-labeled vascular structures) 
at t = - 5 min. E) Representative immunoblots of phosphorylated VASP (S239) and GAPDH in 
gastrocnemius homogenates. F) Representative immunoblots of total VASP and GAPDH in 
gastrocnemius. G-I) Levels of (G) phosphorylated VASP (S239), (H) total VASP and (I) the 
ratio of pVASP/VASP as determined by densitometric analysis of immunoblots in saline (n=6) 
and L-NAME-treated (n=5) mice. Groups were compared using Student’s t-test. KXA – 
ketamine/xylazine/acepromazine cocktail, MAP – mean arterial pressure, L-NAME – L-NG-
Nitroarginine methyl ester, VASP – vasodilator-stimulated phosphoprotein, GAPDH – 
glyceraldehyde 3-phosphate dehydrogenase. 
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Figure 6.2: Acute inhibition of nitric oxide synthase by L-NAME enhances trans-
endothelial insulin efflux. A) Representative INS-647 images (max intensity projections) from 
mice treated with either saline (n=6) or L-NAME (30 mg/kg i.v.; n=6) 15 minutes prior to the 
4U/kg INS-647 bolus. B) The ratio of plasma to interstitial INS-647 as a function of time 
following injection normalized to the ratio at t = 0 min. C) The exponential decay constant of the 
plasma / interstitial INS-647 ratio, a measure of insulin efflux kinetics. D) Capillary INS-647 
intensity as a function of time following INS-647 injection. E) Interstitial INS-647 as a function 
of time following INS-647 injection. Interstitial INS-647 intensity is defined as the average INS-
647 intensity between 1-3µm from the capillary wall. Groups were compared using Student’s t-
test. INS-647 – insulin 647, IU – intensity units, L-NAME – L-NG-Nitroarginine methyl ester. 
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Figure 6.3: Acute L-NAME treatment increases capillary permeability to insulin and total 
extravascular insulin delivery. A) The ratio of plasma to interstitial INS-647 as a function of 
time following INS-647 injection in saline (n=6) and L-NAME-treated (n=6) mice. B) Vascular 
cross-sectional surface area over the course of the intravital microscopy experiment. INS-647 
was administered at t = 0 min. C) Average INS-647 intensity in the entire extravascular space of 
the field of view. D) Baseline-subtracted area under the extravascular INS-647 curve. Groups 
were compared using Student’s t-test. 
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Figure 6.4: Effects of acute L-NAME treatment on insulin-induced glucose lowering and 
2[14C]DGP accumulation during INS-647 imaging experiments. A) Tail-vein blood glucose 
levels following an INS-647 imaging experiment in mice treated with either saline (n=6) or L-
NAME (n=6). B) Accumulation of 2[14C]DGP in the gastrocnemius of mice treated with either 
saline (n=5) or L-NAME (n=5). Groups were compared using unpaired Student’s t-test. 
2[14C]2DGP – 2[14C]deoxyglucose-6-phosphate. 
  
 151 
 
Figure 6.5: Acute L-NAME treatment accelerates insulin-induced glucose lowering in 
conscious, unstressed mice. A) Arterial glucose excursions following a 25mU/kg insulin bolus 
(t = 0 min) in mice treated with saline (n=5) or L-NAME (n=4) 15 minutes prior to the insulin 
bolus. B) Glucose excursions from A displayed as a fraction of arterial glucose levels at t = 0 
min. C) Rate of fractional glucose disappearance from t = 0 to t = 6 min, an index of insulin 
sensitivity.  
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L-NAME treatment enhanced insulin-stimulated glucose metabolism. To more comprehensively 
assess the effects of L-NAME on insulin sensitivity, we performed frequently-sampled 
intravenous insulin tolerance tests (Figure 6.5). We chose to perform insulin tolerance tests as to 
mimic the experimental design of the intravital microscopy experiments, which also assessed the 
response to an insulin bolus. Following treatment with a 25mU/kg insulin bolus, L-NAME-
treated mice displayed a more rapid glucose lowering than saline-treated mice (Figure 6.5, A 
and B). Namely, the fractional fall in glucose per minute was increased by ~40% with L-NAME 
treatment (Figure 6.5C). These findings demonstrate that acute L-NAME treatment accelerates 
glucose lowering following an intravenous insulin bolus. 
 
Acute NO donor treatment does not affect trans-endothelial insulin transport kinetics 
In light of the finding that reducing endothelial NO with L-NAME enhanced trans-
endothelial insulin transport, we hypothesized that acutely raising NO would have the opposite 
effect. To test this hypothesis, we treated mice with a 100µg/kg/min continuous infusion of SNP, 
an NO donor. SNP treatment reduced blood pressure by 10mmHg during the treatment period 
prior to insulin stimulation (Figure 6.6, A and B). Interestingly, the hypotensive effect of SNP 
was abolished by insulin administration (Figure 6.6, A and B). The diameter of capillaries was 
unaffected by SNP treatment (Figure 6.6, C and D). Finally, the ratio of phosphorylated to total 
VASP, an index of vascular NO signaling, was increased by ~40%, although this difference was 
not statistically significant (Figure 6.6, E-I). These findings indicate that SNP treatment 
modestly elevated NO levels. 
Using intravital insulin imaging we observed that SNP treatment had no effect on trans-
endothelial insulin transport (Figure 6.7). Namely, SNP treatment did not alter the dissipation  
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rate of the plasma/interstitial INS-647 gradient (Figure 6.7, B and C, Figure 6.8A) nor the INS-
647 kinetics in the plasma and interstitial space (Figure 6.7, D and E). Furthermore, as SNP had 
no effect on plasma-perfused surface area (Figure 6.8B), it did not change total extravascular 
insulin delivery (Figure 6.8, C and D). Consistent with the lack of an SNP effect on trans-
endothelial insulin transport and insulin delivery, SNP treatment did not alter the blood glucose 
(Figure 6.9A) nor the accumulation of 2[14C]DGP in the gastrocnemius following the imaging 
experiment (Figure 6.9B). Taken together, these findings suggest that acutely increasing NO 
with SNP, in otherwise healthy mice, does not affect trans-endothelial insulin transport. 
 
NO-independent modulation of blood pressure does not affect trans-endothelial insulin 
transport kinetics 
As shown above, L-NAME treatment accelerates trans-endothelial insulin transport and 
increases blood pressure. To test whether the effects of L-NAME on trans-endothelial insulin 
transport kinetics were due solely to changes in blood pressure we treated mice with either 
phenylephrine or hydralazine. These drugs act directly on smooth muscle to raise and lower 
blood pressure, respectively (261, 262). Compared to saline-treated mice, phenylephrine raised 
blood pressure by ~15 mmHg whereas hydralazine lowered it by the same amount (Figure 6.10, 
A and B). Phenylephrine treatment reduced the initial capillary diameter by ~0.6µm (Figure 
6.10, C and D), although this effect was not sustained following the insulin bolus (Figure 
6.10C). Hydralazine had no effect on capillary diameter (Figure 6.10, C and D).  
Intravital imaging of insulin efflux revealed that neither phenylephrine nor hydralazine 
treatment affected the rate at which insulin transited the endothelium (Figure 6.11, B and C, 
Figure 6.12). Of note, phenylephrine did appear to enhance the clearance of INS-647 from the 
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Figure 6.6: Effects of SNP on blood pressure, capillary diameter, and nitric oxide signaling. 
A) Mean arterial blood pressure (MAP) measured through an indwelling carotid artery catheter 
in saline (n=4) and SNP-treated (n=4) mice. Of note, the saline control group is the same as used 
for determination of the blood pressure effects of L-NAME (Figure 1A).  Mice were 
anesthetized with KXA and treated with a continuous infusion SNP beginning at t = - 15 min and 
continuing throughout the experiment. At t = 0 min, mice were administered a 4U/kg bolus of 
insulin, as during the imaging experiments. B) Average MAP during SNP or saline treatment 
prior to (t = - 10 min to t = 0 min) or following (t = 0 min to t = 15 min) insulin treatment. C) 
Capillary diameter as a function of time during INS-647 imaging experiments. D) Average 
diameter of capillaries (rhodamine dextran-labeled vascular structures) at t = - 5 min. E) 
Representative immunoblots of phosphorylated VASP (S239) and GAPDH in gastrocnemius. F) 
Representative immunoblots of total VASP and GAPDH in gastrocnemius. G-I) Levels of (G) 
phosphorylated VASP (S239), (H) total VASP and (I) the ratio of pVASP/VASP as determined 
by densitometric analysis of immunoblots in saline (n=6) and SNP-treatmed mice (n=6). Groups 
were compared using Student’s t-test. SNP – sodium nitroprusside. 
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Figure 6.7: Nitric oxide donor treatment has no effect on trans-endothelial insulin efflux 
kinetics. A) Representative INS-647 images (max intensity projections) from mice treated with 
either saline (n=8) or 100µg/kg/min SNP (n=7). Continuous infusions of saline or SNP were 
begun 15 min prior to the INS-647 bolus and continued throughout the experiment. B) The ratio 
of plasma to interstitial INS-647 as a function of time following injection normalized to the ratio 
at t = 0 min. C) The exponential decay constant of the plasma / interstitial INS-647 ratio, a 
measure of insulin efflux kinetics. D) Capillary INS-647 intensity as a function of time following 
INS-647 injection. E) Interstitial INS-647 as a function of time following INS-647 injection. 
Interstitial INS-647 intensity is defined as the average INS-647 intensity between 1-3µm from 
the capillary wall. Groups were compared using Student’s t-test. INS-647 – insulin 647, SNP – 
sodium nitroprusside.  
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Figure 6.8: No effect of SNP treatment on gastrocnemius insulin delivery. A) The ratio of 
plasma to interstitial INS-647 as a function of time following INS-647 injection in saline (n=8) 
or SNP-treated mice (n=7). B) Vascular cross-sectional surface area over the course of the 
intravital microscopy experiment. INS-647 was administered at t = 0 min. C) Average INS-647 
intensity in the entire extravascular space of the field of view. D) Baseline-subtracted area under 
the extravascular INS-647 curve. Groups were compared using Student’s t-test. 
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Figure 6.9: No effect of SNP treatment on insulin-induced glucose lowering and 2[14C]DGP 
accumulation during INS-647 imaging experiments. A) Tail-vein blood glucose levels 
following an INS-647 imaging experiment in mice treated with either saline (n=8) or SNP (n=7). 
B) Accumulation of 2[14C]DGP in the gastrocnemius. Groups were compared using unpaired 
Student’s t-test. 
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Figure 6.10: Effects of phenylephrine and hydralazine on blood pressure and capillary 
diameter. A) Mean arterial blood pressure (MAP) measured through an indwelling carotid artery 
catheter in saline (n=4), phenylephrine (n=4), or hydralazine-treated (n=3) mice.  Mice were 
anesthetized with KXA and treated with a continuous infusion of either saline, phenylephrine, or 
hydralazine beginning at t = - 5 min and continuing throughout the experiment. At t = 0, mice 
were administered a 4U/kg insulin bolus, as during the imaging experiments. B) Average MAP 
from t = - 5 to 15 min. C) Capillary diameter as a function of time during INS-647 imaging 
experiments in mice treated with saline (n=6), phenylephrine (n=7), or hydralazine (n=6). D) 
Average diameter of capillaries at t = - 5 min. Groups were compared with a one-way ANOVA 
followed by Dunnett’s test for multiple comparisons to a control group (saline). 
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Figure 6.11: Neither a direct smooth muscle-acting vasoconstrictor nor dilator alter trans-
endothelial insulin efflux. 
A) Representative INS-647 images (max intensity projections) from mice treated with either 
saline (n=6), phenylephrine (n=7), or hydralazine (n=6). Primed, continuous infusions of saline, 
phenylephrine (300µg/kg bolus, 300µg/kg/min continuous infusion), or hydralazine (1mg/kg 
bolus, 1mg/kg/min continuous infusion) were begun 5 min prior to the INS-647 bolus. B) The 
ratio of plasma to interstitial INS-647 as a function of time following injection normalized to the 
ratio at t = 0 min. C) The exponential decay constant of the plasma/interstitial INS-647 ratio, a 
measure of insulin efflux kinetics. Groups were compared using one-way ANOVA followed by 
Dunnett’s test for multiple comparisons to a control group (saline). 
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Figure 6.12: Effects of phenylephrine and hydralazine on the plasma/interstitial INS-647 
ratio. The ratio of plasma to interstitial INS-647 as a function of time following INS-647 
injection in mice treated with saline (n=6), phenylephrine (n=7), or hydralazine (n=6).   
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plasma but this was also associated with a reduced appearance of INS-647 in the interstitial 
space in skeletal muscle (Figure 6.13, A-D). This suggests that, while phenylephrine may 
enhance the whole-body clearance of insulin from the plasma by other organs, (Figure 6.13B), it 
does not change trans-endothelial insulin transport in skeletal muscle capillaries (Figure 6.11C).  
Phenylephrine treatment had no effect on plasma-perfused surface area (Figure 6.13E) and 
therefore, combined with its effect to dampen interstitial INS-647 appearance (Figure 6.13C), 
reduced total extravascular insulin delivery (Figure 6.13, F and G). Thus, it appears that while 
phenylephrine does not affect either trans-endothelial insulin transport or the surface area for 
insulin exchange, it diverts insulin away from muscle by increasing its clearance by other organs. 
In total, these findings indicate that increasing or decreasing blood pressure by ~15mmHg does 
not affect trans-endothelial insulin transport. 
With respect to glucose metabolism, phenylephrine treatment resulted in a non-
significant ~50mg/dl increase in glucose following intravital insulin imaging (Figure 6.14A). 
Furthermore, phenylephrine reduced the accumulation of 2[14C]DGP in the gastrocnemius 
indicating that it induced skeletal muscle insulin resistance (Figure 6.14B). Hydralazine had no 
effect on either blood glucose or gastrocnemius 2[14C]DGP accumulation (Figure 6.14B). Taken 
together, these results suggest that phenylephrine induces skeletal muscle insulin resistance 
through a mechanism that does not involve alterations to trans-endothelial insulin transport 
kinetics.  
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Figure 6.13: Effects of phenylephrine and hydralazine on plasma insulin clearance, 
interstitial appearance, and insulin delivery. A) Capillary INS-647 intensity as a function of 
time following INS-647 injection in mice treated with saline (n=6), phenylephrine (n=7), or 
hydralazine (n=6). B) Data in A normalized to capillary INS-647 at t = 0 min. C) Interstitial INS-
647 as a function of time following INS-647 injection. Interstitial INS-647 intensity is defined as 
the average INS-647 intensity between 1-3µm from the capillary wall. D) Data in C normalized 
to interstitial INS-647 at t = 0 min. E) Vascular cross-sectional surface area over the course of 
the intravital microscopy experiment. F) Average INS-647 intensity in the entire extravascular 
space of the field of view. G) Baseline-subtracted area under the extravascular INS-647 curve. 
Groups were compared with a one-way ANOVA followed by Dunnett’s test for multiple 
comparisons to a control group (saline). 
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Figure 6.14: Effects of phenylephrine and hydralazine on insulin-induced glucose lowering 
and 2[14C]DGP accumulation during INS-647 imaging experiments. A) Tail-vein blood 
glucose levels following an INS-647 imaging experiment in mice treated with either saline (n=5), 
phenylephrine (n=7), or hydralazine (n=6). B) Accumulation of 2[14C]DGP in the gastrocnemius 
of mice treated with either saline (n=6), phenylephrine (n=7), or hydralazine (n=6). Groups were 
compared using one-way ANOVA followed by Dunnett’s test for multiple comparisons to a 
control group (saline).  
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Discussion 
 
In this study, we utilized intravital imaging of fluorescent insulin to show that acute 
reduction of endothelial NO with L-NAME accelerates the rate at which insulin moves across the 
endothelium in skeletal muscle capillaries. This increase in trans-endothelial insulin transport 
kinetics was also associated with increased insulin delivery and accelerated whole-body insulin 
action. Interestingly, treatment with SNP, an NO donor, did not alter trans-endothelial insulin 
transport kinetics. Furthermore, a direct-acting vasoconstrictor, phenylephrine, had no effect on 
trans-endothelial insulin transport kinetics, indicating that the effects of L-NAME on trans-
endothelial insulin transport kinetics are not due solely to blood pressure changes. These findings 
demonstrate that acute pharmacological NO reduction induces changes to the skeletal muscle 
microvasculature which increase insulin efflux and delivery.  
 Several previous studies have investigated the effects of NO on microvascular 
permeability. With respect to insulin, Wang et al. demonstrated that inhibition of NO with L-
NAME reduced the uptake of FITC-labeled insulin into cultured bovine aortic endothelial cells 
(190). This finding suggested that NO is a positive regulator of trans-endothelial insulin transport 
in vitro, which is seemingly at odds with the present study which shows that L-NAME enhances 
trans-endothelial insulin transport in vivo. It is conceivable that L-NAME may block the non-
specific vesicular uptake of insulin into endothelial cells and thereby promote more efficient 
paracellular movement of insulin through inter-endothelial junctions. Additionally, the 
hemodynamic effects of L-NAME on the microvasculature, which are present in vivo but not in 
vitro, may contribute to the contrasting results. Another important consideration is that the 
mechanism of trans-endothelial insulin transport is different in vivo than in cell culture and 
depends on the type of endothelial cell used (155). With our intravital microscopy technique, we 
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can directly visualize and quantitate the movement of insulin across the endothelium in skeletal 
muscle capillaries in vivo.  
 Other groups have assessed the effects of modulating NO on microvascular permeability 
in vivo to macromolecules besides insulin. While the precise effects of NO on capillary 
permeability are still debated, it is clear that they are dependent on context (185, 268). Under 
basal conditions, NO reduction by NOS inhibition increases capillary permeability in a number 
of different species and vascular beds including skeletal muscle (183, 184, 269). On the other 
hand, hyperproduction of NO during pathological inflammatory states also increases capillary 
permeability (185). Thus, it appears that the relationship between endothelial NO production and 
microvascular permeability is U-shaped, with low and high levels of NO being associated with 
increased capillary permeability. This is consistent with the present study where we show that, 
during a non-inflammatory state, reduction of NO with L-NAME increases the permeability of 
skeletal muscle capillaries to insulin. Interestingly, increasing NO availability in otherwise 
healthy mice with SNP had no effect on capillary permeability to insulin. It is possible that high 
levels of NO only increase microvascular permeability during inflammatory conditions in which 
oxidant production is also elevated.  
 Mechanistically, we found that the effect of L-NAME on trans-endothelial insulin 
transport was not due to changes in blood pressure alone, as phenylephrine also raised blood 
pressure but did not alter trans-endothelial insulin transport. These findings suggest that L-
NAME increases trans-endothelial insulin transport either through direct effects on the capillary 
endothelium or by altering the trans-capillary balance of Starling forces. The findings described 
in Chapter IV demonstrated that insulin moves across the capillary endothelium in skeletal 
muscle either by a convective paracellular route or by non-saturable vesicular transcytosis (252). 
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Malik and colleagues used electron microscopy to show that treatment of mice with L-NAME 
opens inter-endothelial junctions (183). This increased distance between endothelial cells would 
allow for enhanced paracellular extravasation of insulin across the endothelium, consistent with 
our previous findings. Furthermore, in the present study we show that L-NAME reduces 
capillary diameter, indicating that L-NAME treatment most likely alters capillary 
hemodynamics. These hemodynamic effects may alter the balance of Starling forces across the 
endothelium and, subsequently, the convective movement of insulin into the interstitial space. 
Finally, it is also conceivable that reduction of endothelial NO production affects either the 
abundance of endothelial vesicles or the kinetics of their trafficking.  
 Consistent with the increase in trans-endothelial insulin transport and insulin delivery, we 
found that acute inhibition of NOS with L-NAME increased the effect of insulin on whole-body 
glucose kinetics.  This corroborates the findings of Vincent et al. who showed that, following 15 
minutes of a continuous insulin and L-NAME infusion in rats, L-NAME treatment increased 
femoral artery blood flow without changing arteriovenous glucose difference across the hindlimb 
(95). This indicates that, at this early time point, insulin-stimulated muscle glucose uptake is 
enhanced by L-NAME treatment. Interestingly, these investigators also showed that by 30 
minutes, the hindlimb arteriovenous glucose difference was reduced whereas femoral artery 
blood flow remained elevated in the L-NAME group, indicating a small reduction in insulin-
stimulated muscle glucose uptake. Taken together, these findings suggest that L-NAME initially 
increases skeletal muscle insulin action whereas more prolonged administration results in 
skeletal muscle insulin resistance.  
Previous studies in humans and rodents have generally found a negative relationship 
between NOS inhibition and muscle insulin sensitivity during insulin clamps (119, 186, 187). In 
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the present study, we show that L-NAME treatment accelerates insulin-stimulated glucose 
lowering during an insulin tolerance test. Differences in study design may explain these 
seemingly contradictory findings. Insulin clamps, as used previously, (119, 186, 187) are usually 
designed to assess steady-state insulin action whereas the glucose response to an insulin bolus is 
an indicator of the kinetics of insulin action. Thus, it is possible that L-NAME treatment 
enhances the kinetics of insulin action while also reducing maximal steady-state insulin-
stimulated glucose disposal. These differing effects can be reconciled considering that L-NAME 
both increases the movement of insulin across the endothelium while also reducing skeletal 
muscle perfusion (95, 119). We hypothesize that the effect of L-NAME to increase capillary 
permeability to insulin accelerates the kinetics of insulin action. On the other hand, the L-
NAME-induced reduction in muscle perfusion is most likely responsible for limiting maximal 
steady-state insulin action. It is interesting to speculate that these opposing effects of L-NAME 
may be protective, serving to buffer the muscle from changes in macromolecular delivery. 
Namely, when NO bioavailability and muscle perfusion are reduced, capillaries become more 
permeable thereby compensating for the reduced perfusion and maintaining macromolecular 
delivery.  
Another key distinction between the present study and previous investigations (119, 186, 
188, 189)  is the timing and duration of NOS inhibition. Previous insulin clamp studies have 
typically infused NOS inhibitors after establishing steady-state hyperinsulinemia (119, 186). This 
is different from our experimental design, where we treated mice with L-NAME prior to insulin 
stimulation. Furthermore, studies utilizing genetic deletion of NOS (188, 189) assess the effects 
of chronic NO reduction. In the current study, we were interested in determining the acute role of 
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NO in the delivery of an insulin bolus to skeletal muscle. We chose to study nonsteady-state 
insulin action as it is more physiologically relevant than a prolonged steady-state insulin clamp.  
 In light of the finding that L-NAME increased trans-endothelial insulin transport, we 
speculated that treating mice with SNP, an NO donor, would have the opposite effect. However, 
we found that there was no effect of NO on either trans-endothelial insulin transport or 
accumulation of 2[14C]DGP in the gastrocnemius. This finding is largely consistent with 
previous studies, which showed that SNP infusion either does not alter insulin-stimulated 
glucose disposal (115) or slightly reduces it (264). One limitation of our study is that, despite 
infusing a high dose of SNP which was previously shown to have major cardiovascular and 
metabolic effects (264), blood pressure was only lowered by ~10mmHg and the 40% increase in 
VASP activation (i.e. NO signaling) was not statistically significant. The blood pressure 
response to SNP may have been attenuated because mice are already hypotensive when 
anesthetized. Furthermore, because insulin stimulates NO production from endothelial cells 
(108), it is possible that NO signaling is already near-maximal in the saline-treated control mice. 
In this situation, SNP may have little additional effect on VASP activation. As such, we 
hypothesize that, under conditions where endothelial NO is sufficient, adding more NO gives no 
further benefit to trans-endothelial insulin transport or muscle insulin sensitivity.  
 As noted above, we also demonstrated that while phenylephrine and hydralazine raise 
and lower blood pressure, respectively, neither drug altered trans-endothelial insulin transport. 
These findings suggest that the L-NAME-induced increase in trans-endothelial insulin transport 
is not due to elevated blood pressure alone. One caveat, however, is that L-NAME treatment 
raised blood pressure by 30mmHg whereas phenylephrine only raised it by 15mmHg. Thus, it is 
possible that a more pronounced increase in blood pressure might affect trans-endothelial insulin 
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transport. In contrast to L-NAME, however, phenylephrine induced muscle insulin resistance 
during intravital microscopy experiments through a mechanism independent of trans-endothelial 
insulin transport. Previous studies of phenylephrine and muscle insulin sensitivity are limited, 
with one study in humans showing that phenylephrine has no effect on whole-body insulin 
sensitivity (270). However, other adrenergic receptor agonists have been shown to cause 
peripheral insulin resistance (271).  In the current study, we showed that, although the 
relationship between plasma and interstitial insulin was not different with phenylephrine 
treatment, there was a lower total delivery of insulin to the interstitial space. It is possible that 
phenylephrine induced muscle insulin resistance either by diverting insulin to other organs or by 
limiting the microvascular delivery of glucose to muscle. 
 In summary, we demonstrate that reduction of endothelial NO enhances trans-endothelial 
insulin transport in vivo by a mechanism that is independent of blood pressure alone. Thus, acute 
reduction of NO levels has contrasting effects on microvascular perfusion and the capillary 
exchange of insulin, the net effect of which is to increase insulin delivery to skeletal muscle. 
These findings highlight the importance of considering the targeted blood vessel type (i.e. artery 
vs. capillary), kinetics of NO modulation, and desired microvascular exchange properties when 
designing NO-based therapies for metabolic disease. 
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Chapter VII 
 
ANGIOTENSIN-(1-7), A VASOACTIVE PEPTIDE HORMONE, IMPROVES 
INSULIN SENSITIVITY IN DIET-INDUCED OBESE MICE 
 
 
Aims 
 Our laboratory and others have found that chronic treatment of obese mouse models with 
vasodilators improves muscle insulin sensitivity. Ang-(1-7) is a vasodilatory peptide of the renin-
angiotensin system that acutely increases insulin sensitivity and improves glucose homeostasis in 
rodent models of diet-induced insulin resistance. Whether chronic treatment of obese mice with 
Ang-(1-7) can reverse muscle insulin resistance is unknown. The aims of Chapter VII are to 1) 
determine whether Ang-(1-7) can restore skeletal muscle insulin sensitivity in a mouse model of 
obesity and insulin resistance and 2) investigate potential mechanisms by which chronic 
vasodilator therapy improves insulin sensitivity. 
 
Experimental Approach 
Male 6 week-old C57BL/6J mice (Jackson Laboratory) were fed a standard chow (5001 
Laboratory Rodent Diet) or 60% HFD (Bioserv F3282) ad libitum for 11 weeks. After 8 weeks 
of diet, subcutaneous osmotic mini-pumps (Alzet Model 2004) were implanted to deliver Ang-
(1-7) [400 ng/kg/min; Bachem] or saline vehicle for 3 weeks. This dosing regimen of Ang-(1-7) 
was chosen as it has been shown to improve endothelial function in HFD mice independent of 
changes in body weight (272). 
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Results* 
 
Effect of Ang-(1-7) on cardiovascular indices 
Plasma Ang-(1-7) was reduced in HFD versus chow-fed mice (Table 7.1; p=0.045 diet 
effect). Chronic Ang-(1-7) infusion restored HFD-induced reductions in the peptide to 
approximately 70% of levels seen in chow-fed mice. There were significant diet (p=0.015) and 
interaction (p=0.004) effects for plasma Ang II, which were driven entirely by increased Ang II 
levels in chow-fed mice following Ang-(1-7) treatment. HFD mice had increased systolic 
(p=0.001), diastolic (p=0.039) and mean (p=0.001) blood pressure, with no difference in HR 
(p=0.129). There was no effect of Ang-(1-7) on blood pressure or HR in chow-fed or HFD mice 
(Table 7.1).  
 
Effect of Ang-(1-7) on metabolic indices: 
Body weight and adiposity were higher in HFD mice (p=0.001 diet effect; Table 7.2). 
Ang-(1-7) did not alter body weight in HFD or chow-fed mice; however, there was a small 
reduction in adiposity (p=0.040 drug effect). HFD mice had higher basal arterial glucose and 
insulin (p=0.018 and p=0.001 diet effect, respectively), with no difference in NEFA. Ang-(1-7) 
tended to lower basal insulin (p=0.055 drug effect), but did not alter fasting glycemia or NEFA. 
During steady-state hyperinsulinemia, glucose was clamped at ~140 mg•dl-1 glucose in both 
HFD and chow-fed mice (Figure 7.1, A and B). HFD mice maintained higher insulin levels 
during the clamp (p=0.002 diet effect; Table 7.2), compared with chow-fed mice. Ang-(1-7) did 
not alter clamp glucose and insulin levels, but significantly enhanced insulin-mediated 
suppression of NEFA (p=0.001 drug effect; Table 7.2).  
                                               
* These results have been published in: Williams IM, Otero YF, Bracy DP, Wasserman DH, Biaggioni I, 
Arnold AC. Chronic Angiotensin-(1-7) improves insulin sensitivity in high-fat fed mice independent of 
blood pressure. Hypertension 2016 May;67(5):983-91. PMID:26975707. 
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Table 7.1.  Hormonal and Cardiovascular Effects of Chronic Ang-(1-7) Administration  
Parameter, unit 
Chow 
Vehicle 
Chow 
Ang-(1-7) 
HFD 
Vehicle 
HFD 
Ang-(1-7) 
PDiet PDrug PInt 
n 9 10 6 7    
Ang-(1-7), ng/ml 2.94±1.29 1.72±0.90 0.45±0.15 1.97±1.31 0.045 0.267 0.191 
Ang II, ng/ml 0.16±0.06 0.51±0.14 0.18±0.02 0.09±0.03 0.015 0.074 0.004 
SBP, mm Hg 123±5 128±3 143±4 143±3 0.001 0.574 0.566 
DBP, mm Hg 97±5 98±4 109±3 104±3 0.039 0.658 0.515 
MBP, mm Hg 110±5 113±3 126±3 123±2 0.001 0.949 0.454 
Heart Rate, bpm 647±41 701±24 618±21 648±19 0.129 0.119 0.652 
Data are mean±SEM and were analyzed by two-way ANOVA for diet effect (PDiet), drug 
effect (PDrug), and their interaction (PInt). HFD, high fat diet; Ang, angiotensin; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure. 
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Table 7.2.  Metabolic Effects of Chronic Ang-(1-7) Administration  
Parameter, unit 
Chow 
Vehicle 
Chow 
Ang-(1-7) 
HFD 
Vehicle 
HFD 
Ang-(1-7) 
PDiet PDrug PInt 
n 9 10 6 7    
Body Mass, g 29±1 28±1 39±2 37±1 0.001 0.321 0.981 
Adiposity, % 6.7±0.7 6.5±0.2 35.6±2.6 30.1±1.4 0.001 0.040 0.056 
Glucose, mg/dl        
   Basal 132±7 131±7 152±13 153±7 0.018 0.969 0.923 
   Clamp 141±3 142±4 133±3 137±3 0.078 0.555 0.603 
Insulin, pmol/l        
   Basal 226±40 136±19 648±100 533±47 0.001 0.055 0.843 
   Clamp 585±59 569±58 1518±430 1245±290 0.002 0.549 0.480 
NEFA, mmol/l        
   Basal 0.81±0.12 0.62±0.13 0.57±0.10 0.37±0.08 0.055 0.129 0.947 
   Clamp 0.25±0.06 0.05±0.03 0.25±0.05 0.11±0.06 0.677 0.001 0.472 
Data are mean±SEM and were analyzed by two-way ANOVA for diet effect (PDiet), drug effect 
(PDrug), and their interaction (PInt). Metabolic hormones were measured in arterial blood at 
baseline (basal), and during steady state of hyperinsulinemic-euglycemic clamps (clamp). HFD, 
high fat diet; Ang, angiotensin; NEFA, non-esterified fatty acids. 
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Ang-(1-7) reverses HFD-induced skeletal muscle (skeletal muscle) insulin resistance: 
The glucose infusion rate required to maintain euglycemia during steady state 
hyperinsulinemia, a measure of whole-body insulin sensitivity, was similar following Ang-(1-7) 
versus saline treatment in chow-fed mice (Figure 7.1, C and E; p=0.143). As expected, HFD 
mice had lower whole-body insulin sensitivity compared with chow fed-mice (p=0.001). Ang-(1-
7) doubled the glucose infusion rate required to maintain euglycemia in HFD mice (Figure 7.1, 
D and F; p=0.017). This enhanced whole body insulin sensitivity was due to increased insulin-
stimulated peripheral glucose disposal (Rd; Figure 7.2A; p=0.049). There was no effect of Ang-
(1-7) on insulin-mediated suppression of endogenous glucose production (EndoRa; Figure 7.2B; 
p=0.476). Consistent with effects on peripheral glucose disposal, Ang-(1-7) augmented insulin-
stimulated glucose uptake (Rg) in soleus, gastrocnemius, and vastus muscles in HFD mice, with 
no effect in epididymal adipose or cardiac tissue (Figure 7.2, C and D). Ang-(1-7) did not alter 
Rd, EndoRa or Rg in chow-fed mice (Figure 7.3). 
 
Ang-(1-7) does not improve measures of perfusion in HFD mice:  
To determine if the Ang-(1-7)-mediated improvement in insulin sensitivity was due to 
improved vascular glucose delivery, we measured indices of skeletal muscle perfusion in HFD 
mice. Levels of a capillary density marker (CD31) were not different in gastrocnemius muscle 
following Ang-(1-7) treatment (Figure 7.4, A and B). Hind limb perfusion, measured by 
deposition of colored microspheres at the end of the insulin clamp, was not different between 
treatment groups (Figure 7.4C). Finally, Ang-(1-7) did not alter cardiac function (Table 7.3).  
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Figure 7.1: Ang-(1-7) improves whole-body insulin sensitivity in high-fat diet (HFD)-fed 
mice. A, B: Arterial glucose levels were maintained at ~140 mg/dl during insulin clamps by 
variable venous infusion of 50% glucose. C, D: The glucose infusion rate (GIR) needed to 
maintain euglycemia, a measure of whole-body insulin sensitivity, over the 120 min period of the 
insulin clamp. E: There was no effect of Ang-(1-7) on mean steady-state GIR (measured from 
t=80-120 min of the insulin clamp) in chow fed mice. F: Ang-(1-7) significantly increased the 
mean steady-state GIR in HFD mice. 
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Figure 7.2: Ang-(1-7) improves insulin sensitivity in high-fat diet (HFD) mice by increasing 
insulin-stimulated skeletal muscle glucose uptake. 
A: Ang-(1-7) increased peripheral glucose disposal (Rd) in HFD mice as determined by 
steadystate plasma levels of 3[3H]glucose. B: Ang-(1-7) had no effect on the insulin-stimulated 
rate of endogenous glucose production (EndoRa). C, D: Ang-(1-7) increased the glucose 
metabolic index(Rg) in gastrocnemius, vastus, and soleus skeletal muscles from HFD mice as 
determined by 2[14C]deoxyglucose accumulation, with no effect in epididymal fat or heart.  
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Figure 7.3: Chronic Ang-(1-7) infusion does not alter glucose turnover or tissue-specific 
glucose uptake in chow-fed mice. A and B: There were no differences in the basal and insulin-
stimulated clamp rates of (A) endogenous glucose production (EndoRa) or (B) peripheral glucose 
disposal (Rd) following Ang-(1-7) versus vehicle in chow fed mice. C: The glucose metabolic 
index (Rg) in various insulin-sensitive tissues was also not different between groups. 
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Figure 7.4: Ang-(1-7) infusion does not change capillary density or insulin-stimulated 
muscle perfusion in high fat diet-fed (HFD) mice. A: Representative 175X magnification 
micrographs of gastrocnemius sections from clamped mice stained immunohistochemically for 
CD31 to visualize blood vessels. B: The number of CD31+ structures per field of view, an index 
of capillary density, was not altered by Ang-(1-7) treatment in chow or HFD mice. C: Colored 
microspheres (15µm-diameter) were administered into the carotid artery at the end of 
hyperinsulinemic-euglycemic clamps, with their deposition measured in soleus, gastrocnemius, 
and vastus skeletal muscles, to obtain an index of hind limb perfusion. There was no difference 
in hind limb perfusion following vehicle versus Ang-(1-7) treatment in HFD mice. 
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Table 7.3: Effect of Ang-(1-7) on Cardiac Function in High-Fat Fed Mice  
Parameter (unit) Vehicle Ang-(1-7) P Value 
n 6 7  
Cardiac output (ml/min) 23.2 ± 1.9 24.1 ± 1.6 0.714 
Stroke volume (µl)  35.6 ± 2.9 34.3 ± 2.4 0.732 
Ejection fraction (%) 78.1 ± 1.3 80.4 ± 0.5 0.146 
Fractional shortening (%) 45.8 ± 1.2 47.8 ± 0.5 0.143 
Left ventricular mass (mg) 102.8 ± 9.3 89.8 ± 3.9 0.226 
LVIDd (mm) 3.36 ± 0.13 3.27 ± 0.09 0.592 
LIVDs (mm) 1.82 ± 0.09 1.71 ±0.06 0.332 
LVPWd (mm) 1.02 ± 0.09 0.92 ± 0.04 0.325 
LVPWs (mm) 1.39 ± 0.10 1.34 ± 0.03 0.645 
IVSd (mm) 1.03 ± 0.02 1.02 ± 0.02 0.627 
IVSs (mm) 1.32 ± 0.04 1.27 ± 0.03 0.347 
Data are mean ± SEM. Parameters of cardiac function were calculated from M-mode echocardiographic 
tracings. Ang, angiotensin; LVIDd, left ventricular internal dimension, diastolic; LVIDs, left ventricular 
internal dimension, systolic; LVPWd, left ventricular posterior wall, diastolic; LVPWs, left ventricular 
posterior wall, systolic; IVSd, interventricular septum, diastolic; IVSs, interventricular septum, systolic. 
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Ang-(1-7) enhances sarcolemmal Glut4 translocation in HFD mice:  
A critical step in insulin-stimulated muscle glucose uptake is translocation of Glut4 from 
intracellular vesicles to the sarcolemma.  To determine if Ang-(1-7) improves skeletal muscle 
insulin sensitivity by increasing sarcolemmal Glut4 levels, we measured Glut4 abundance within 
the region demarcated by the sarcolemmal marker Cav3 in gastrocnemius muscle (Figure 7.5A). 
Ang-(1-7) increased mean Glut4 fluorescence at the muscle plasma membrane in HFD mice 
(Figure 7.5B; p=0.011). This increased Glut4 trafficking was associated with reduced total 
AS160 protein, a negative regulator of Glut4 translocation (Figure 7.5C; p=0.034), with no 
effect on phosphorylated AS160 (p=0.999). Ang-(1-7) did not alter phosphorylated or total Akt 
in HFD mice (Figure 7.6).  
 
 
Discussion 
 
The main finding of this study is that chronic systemic Ang-(1-7) administration reverses 
HFD-induced whole-body insulin resistance by enhancing insulin-stimulated muscle glucose 
uptake. These insulin-sensitizing effects of Ang-(1-7) on skeletal muscle were associated with 
increased sarcolemmal Glut4 levels and down-regulation of AS160, a negative regulator of Glut4 
translocation. Importantly, these effects occurred independent of changes in body weight, blood 
pressure, and measures of systemic and regional perfusion. Taken together, these findings 
provide evidence for blood pressure-independent effects of Ang-(1-7) on insulin action, and 
further support targeting this peptide to treat insulin resistance in cardiometabolic disease.  
 Numerous previous studies using intraperitoneal glucose and insulin tolerance tests have 
demonstrated that activation of the Ang-(1-7)/mas axis improves whole-body glucose intestinal 
glucose absorption, glucose-stimulated insulin secretion, insulin sensitivity, glucose  
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Figure 7.5: Ang-(1-7) increases sarcolemmal Glut4 in high-fat diet (HFD) mice by reducing 
levels of AS160, a negative regulator of Glut4 trafficking.  
A: Representative 500x magnification micrographs of gastrocnemius sections from HFD mice 
treated with vehicle versus Ang-(1-7). Sections were stained for Cav3 (green) and Glut4 (white) 
and images were obtained by confocal microscopy. B: Ang-(1-7) increased sarcolemmal Glut4, 
measured as the mean Glut4 fluorescence intensity in the region demarcated by Cav3 staining. 
C: Immunoblot of gastrocnemius extracts from clamped HFD vehicle and Ang-(1-7)-treated 
mice. Ang-(1-7) decreased total AS160 protein levels, with no effect on phosphorylated AS160.  
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Figure 7.6: Chronic Ang-(1-7) treatment does not alter skeletal muscle Akt 
phosphorylation or protein levels. Immunoblot of gastrocnemius extracts from high-fat diet fed 
(HFD) mice treated with antibodies against total Akt, phosphorylated Akt [pAkt(S473)], and the 
loading control GAPDH. There was no effect of chronic Ang-(1-7) infusion on Akt or 
phosphorylated Akt protein levels in HFD mice. 
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homeostasis (207–209, 273). These tests involve a number of variables including effectiveness, 
and counter-regulatory responses. Here, we specifically measured the contribution of insulin 
sensitivity to Ang-(1-7)-induced improvements in glucose tolerance using insulin clamps. 
Moreover, by combining the insulin clamp with isotopic glucose tracers, as in the present study, 
we are able to assess tissue-specific insulin action. Using this gold standard method, we provide 
evidence that restoration of physiological Ang-(1-7) levels improves whole-body insulin 
sensitivity in a well-established animal model of cardiometabolic syndrome that exhibits mild 
hyperglycemia, hyperinsulinemia, insulin resistance, and modest hypertension (274). We did not 
observe an effect of chronic Ang-(1-7) in chow-fed mice, in contrast to reports showing acute 
intravenous Ang-(1-7) enhances insulin sensitivity in lean anesthetized rats (123, 275). This may 
reflect differences in species and methodology, as well as compensatory mechanisms to 
prolonged Ang-(1-7) elevation including mas receptor internalization (276).  
Interestingly, Ang-(1-7) did not alter the mild fasting hyperglycemia induced by HFD 
feeding in this study. The first response, however, to increased insulin action is compensation by 
the endocrine pancreas. This is evidenced by an initial reduction in insulin, without changes in 
blood glucose or hemoglobin A1c levels (277). In our study, Ang-(1-7) treated-mice had 
approximately 20% lower fasting insulin levels than vehicle-treated mice. Similarly, short-term 
Ang-(1-7) treatment (2 to 4 weeks) lowers plasma insulin levels in fructose fed rats, but does not 
lower fasting glycemia (207, 209). Longer-term Ang-(1-7) treatment (8-24 weeks) lowers both 
fasting insulinemia and glycemia in animal models of cardiometabolic syndrome (209, 273). 
Thus, an improvement in insulin sensitivity precedes and contributes to normalization of 
glycemia. In our study, it is likely glycemia would have been lowered with more prolonged Ang-
(1-7) treatment. 
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The reason for maintained hyperglycemia following short-term Ang-(1-7) treatment is 
unclear. It is conceivable that an increase in basal glucose transport and/or delivery would 
increase muscle glucose uptake and normalize fasting glycemia. In this study, sarcolemmal Glut4 
levels and skeletal muscle perfusion were both measured under the insulin-stimulated conditions. 
It is not likely that the lack of effect of Ang-(1-7) on skeletal muscle perfusion in our study 
would contribute to the preserved basal hyperglycemia, given that an increase in glucose delivery 
in the absence of hyperinsulinemia has no impact on glucose uptake (278). Importantly, an 
improvement in insulin sensitivity alone has beneficial effects on cardiometabolic health. For 
example, insulin sensitivity is a stronger predictor of type 2 diabetes development compared with 
fasting glucose or HbA1c (279, 280). Furthermore, insulin sensitivity is a stronger risk factor for 
cardiovascular disease than hyperglycemia (281).  
Over-activation of the renin-angiotensin system, and in particular Ang II, is associated 
with development of skeletal muscle and hepatic insulin resistance (282, 283). We found that 
chronic Ang-(1-7) infusion improves insulin-stimulated muscle glucose uptake in HFD mice. 
This corroborates in vitro studies showing that Ang-(1-7) potentiates insulin-stimulated muscle 
glucose uptake in normal rodents and reverses Ang II-induced muscle insulin resistance (284, 
285). Ang-(1-7) did not alter basal or insulin-stimulated hepatic glucose output in HFD mice, 
which was normal in HFD compared with chow-fed mice. The lack of hepatic insulin resistance 
in HFD mice is consistent with previous reports from our group (196, 286). This is likely due to 
the high physiologic insulin dose infused during clamps, which could mask more subtle effects 
of Ang-(1-7) on hepatic insulin sensitivity. Ang-(1-7) reduced adiposity and improved insulin-
stimulated suppression of lipolysis in our study, consistent with reports showing improved 
adipose insulin action (207, 273). Although there was no effect of Ang-(1-7) on adipose glucose 
 185 
uptake during insulin clamps, one cannot rule out an indirect contribution of reduced adiposity to 
improved insulin sensitivity.  
 It is unclear to what extent the vascular effects of Ang-(1-7) contribute to its metabolic 
effects. Ang-(1-7) promotes endothelial-dependent vasodilation in macro- and micro-vessels 
(206). The improved glucose tolerance in fructose-fed rats with Ang-(1-7) was associated with 
blood pressure-lowering (207, 208), which could indicate vasodilation and manifest as improved 
glucose delivery and insulin sensitivity. Ang-(1-7) did not alter blood pressure or cardiac 
function, however, in HFD mice. The lack of a depressor effect in our model is consistent with 
accumulating evidence showing that the anti-hypertensive effect of Ang-(1-7) is not apparent in 
all research models.  There are several potential reasons for varying blood pressure effects with 
Ang-(1-7) including species differences, diet, and dose, duration, and route of treatment. The 
discrepancy between the two previous studies and our results most likely reflects differences in 
animal models. Fructose-fed rats do not gain weight during the first 8 weeks of feeding and, for 
the most part, develop isolated systolic hypertension (287). In contrast, high fat diet-fed mice 
have about 5 times more adiposity than their lean counterparts, and develop both systolic and 
diastolic hypertension. The hypertension in these two models may therefore be driven by 
different mechanisms with varying sensitivity to Ang-(1-7).  
 Ang-(1-7) could also influence regional perfusion to improve insulin sensitivity. Indeed, 
acute Ang-(1-7) increases muscle microvascular perfusion in normal rats (123). We were unable 
to detect differences in insulin-stimulated muscle perfusion following Ang-(1-7) in HFD mice. 
There are several possible explanations: (1) previous studies used acute intravenous Ang-(1-7) 
and were performed under anesthesia (123), which alone has hemodynamic effects; (2) the 
ability of acute Ang-(1-7) to promote peripheral vasodilation could be lost following prolonged 
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exposure; (3) while microsphere deposition is the gold standard for assessing microvascular 
perfusion in conscious animals, it may not give the resolution necessary to detect small changes; 
(4) the mild hyperglycemia in HFD mice may contribute to endothelial dysfunction, thus 
preventing the vasodilatory actions of Ang-(1-7); and (5) Ang-(1-7) may improve other aspects 
of endothelial function that enhance skeletal muscle insulin action such as trans-endothelial 
insulin transport from capillaries to the myocyte surface.  
 Given that we did not observe changes in perfusion, we examined direct effects of Ang-
(1-7) on skeletal muscle. A critical component of skeletal muscle insulin action is partitioning of 
Glut4 to the sarcolemma to enhance glucose transport (288). Chronic Ang-(1-7) potentiated 
insulin-stimulated Glut4 translocation in HFD mice, thereby increasing glucose transport into 
myocytes. This is consistent with previous reports demonstrating effects of Ang-(1-7) on Glut4. 
Namely, ACE2 deletion in mice reduces skeletal muscle Glut4 expression, an effect reversed by 
Ang-(1-7) infusion (284). Furthermore, ACE inhibition, which increases Ang-(1-7) levels, 
improves insulin sensitivity by enhancing Glut4 translocation (289). Insulin stimulates Glut4 
translocation via activation of the PI3K/Akt pathway. Ultimately, Akt phosphorylates and 
inactivates AS160 to allow Glut4-containing vesicles to fuse with the sarcolemma (290). In 
normal and fructose-fed rats, Ang-(1-7) stimulates Akt phosphorylation in insulin-sensitive 
tissues (207, 291, 292). In addition, Ang-(1-7) increases AS160 phosphorylation in normal and 
diabetic rats (291, 293). In our study, Ang-(1-7) reduced AS160 protein levels, which 
functionally promotes increased Glut4 at the myocyte plasma membrane (294), independent of 
changes in classical Akt signaling. The precise mechanism suppressing AS160 levels is unclear, 
but may involve transcriptional regulation.  
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 There are some potential limitations to these studies. We did not examine receptor and 
related intracellular signaling mechanisms involved in Ang-(1-7) metabolic effects. The 
literature suggests that most, if not all, of Ang-(1-7) actions in vivo are mediated by mas 
receptors (295). Indeed, the ability of Ang-(1-7) to augment insulin-mediated glucose disposal is 
mas-dependent in anesthetized rats (123). There is evidence, however, that AT2 receptors 
participate in complex vascular effects of Ang-(1-7). Furthermore, due to limitations in blood 
volume sampling in mice, we were unable to measure all components of the circulating renin 
angiotensin system. The few studies examining Ang-(1-7) effects on renin angiotensin system 
components showed no effect on renin activity in lean rats (296), and reduced aldosterone in 
fructose-fed rats. We observed significant plasma Ang II elevations following Ang-(1-7) infusion 
in chow-fed mice, with no effect in HFD mice. A similar elevation was observed in lean rats and 
thought to reflect a homeostatic feedback response. Finally, it should be noted that the HFD has 
lower sodium content compared with the control diet. Despite lower sodium, HFD mice 
exhibited a cardiometabolic syndrome-like phenotype and did not have increased renin 
angiotensin system components. Furthermore, all HFD mice were fed the same diet, indicating 
the improved insulin sensitivity with Ang-(1-7) was sodium-independent.  
In summary, these studies show that chronic Ang-(1-7) reverses diet-induced muscle 
insulin resistance by enhancing insulin-stimulated Glut4 translocation. Importantly, these effects 
occurred even when giving a dose of Ang-(1-7) that does not lower blood pressure. These 
findings provide evidence for divergence between Ang-(1-7) effects on blood pressure and 
glucose metabolism, and support the growing notion that the renin angiotensin system influences 
whole body physiology beyond control of blood pressure (297).  
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CHAPTER VIII 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary 
The findings presented in this Dissertation greatly improve our understanding of the 
microvascular control of muscle insulin action. The major advance described in this work is the 
development of an intravital microscopy technique to directly visualize and measure the rate of 
insulin movement across the endothelium of muscle capillaries. These are the first direct 
measurements of trans-endothelial insulin transport in vivo. Using this technique, I discovered 
that trans-endothelial transport is accomplished by a fluid-phase transport mechanism that is not 
saturable and does not require the insulin receptor (Figure 8.1A). This is different than what has 
been observed in cell culture and highlights the importance of studying endothelial transport 
function in vivo. Furthermore, I directly show for the first time that trans-endothelial insulin 
transport is reduced in a mouse model of obesity and insulin resistance (Figure 8.1B). These 
novel findings reveal that the capillary endothelium is a contributor to muscle insulin resistance. 
I also found that reducing endothelial NO bioavailability paradoxically increases the movement 
of insulin across the endothelium and enhances the kinetics of insulin action. Finally, I 
demonstrate that chronic treatment with Ang-1-7, a vasodilatory peptide that improves 
endothelial function, can restore insulin sensitivity in a mouse model of diet-induced insulin 
resistance. Collectively, these findings demonstrate that muscle insulin action is inextricably 
linked to microvascular function.   
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Figure 8.1: Working model of trans-endothelial insulin transport. A) Model of trans-endothelial 
insulin transport in lean mice. Insulin crosses the endothelium by a fluid-phase transport mechanism 
which is non-saturable and does not require the insulin receptor. Fluid-phase transport may involve 
both paracellular (inter-endothelial junctions) and transcellular (endothelial channels) mechanisms. B) 
In DIO mice, the number of endothelial vesicles is reduced and the transport of insulin is impaired. 
However, because DIO mice have higher capillary levels of insulin, they are able to overcome the 
impaired trans-endothelial insulin transport and maintain insulin levels in the interstitial space. DIO – 
diet-induced obese. 
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Implications and Hypotheses 
The mechanism of trans-endothelial insulin transport 
As described in Chapter IV, I found that the movement of INS-647 across the 
endothelium is not saturable nor can it be blocked by an insulin receptor antagonist. These 
findings suggest that insulin is transported passively across the endothelium in vivo. Potential 
passive transport mechanisms include a) diffusion of insulin down a concentration gradient b) 
convection, or the movement of insulin through bulk fluid filtration across the capillary wall, and 
c) a combination of both. In analyzing insulin imaging data, we observed that the rate of insulin 
appearance in the interstitial space depended solely on the concentration of insulin in the plasma 
rather than on the trans-endothelial concentration gradient. This suggests that insulin is being 
transported by convection rather than diffusion. Indeed, using mathematical modeling we 
demonstrated that a convection model was a better fit for the insulin transport data than a 
diffusion model. Thus, we initially hypothesized that insulin was most likely being moved across 
the endothelium by paracellular fluid flux through inter-endothelial junctions. An astute reviewer 
noted that insulin could also be moving through the endothelium by a non-specific, non-saturable 
vesicular process such as micropinocytosis. In fact, previous investigators had observed insulin 
inside endothelial vesicles suggesting that insulin can be transported transcellularly (246). This 
process cannot be distinguished from convection mathematically as both are linear functions of 
plasma insulin concentrations. Therefore, we concluded that insulin moves across the 
endothelium by fluid-phase transport, a term which encompasses both convection and 
micropinocytosis.  
I am skeptical of the hypothesis that insulin moves across the endothelium by 
micropinocytosis for two reasons. Micropinocytosis, and subsequent transcytosis, would involve 
 191 
an accumulation of insulin in vesicles in the endothelium. I have never observed endothelial 
insulin accumulation in capillaries. However, I have seen significant accumulation of INS-647 in 
the endothelium lining larger venules (Figure 8.2). Thus, if insulin were accumulating in the 
capillary endothelium, I would be able to see it. Second, dextran is a marker of pinocytosis. If the 
muscle capillary endothelium were capable of significant pinocytosis, one would expect to see 
dextran accumulation in the capillary endothelium. Again, I have never observed capillary 
endothelial accumulation of dextrans ranging in molecular weight from 3kDa to 2MDa. The 
2MDa dextran does accumulate in the venular endothelium (Figure 8.2), suggesting that larger 
microvessels have a higher pinocytotic capacity than capillaries. Thus, endocytosis and vesicular 
accumulation of plasma molecules appear to be characteristics of venular, but not capillary, 
endothelium in muscle. This suggests that insulin moves across the endothelium by moving 
through transcellular and/or paracellular endothelial (Figure 8.1A). 
The hypothesis that insulin moves paracellularly across the endothelium through inter-
endothelial junctions is inconsistent with previous observations of insulin localized within 
endothelial vesicles (246). An explanation which unifies these findings is that endothelial 
vesicles are not discrete vesicles but rather parts of pores in the endothelium. That is to say, 
endothelial vesicles observed by two-dimensional electron microscopy may actually be part of 
3D vesicle networks that effectively form channels through the endothelium (Figure 8.1A). In 
fact, there is evidence that endothelial vesicles can transiently fuse to form trans-endothelial 
channels which support macromolecular transport (298, 299).  
A limitation of our intravital microscopy technique is that we must administer high doses 
of fluorescent insulin due to the sensitivity of fluorescence microscopy and low circulating 
insulin concentrations. Klip and colleagues, studying cultured endothelial cells, raised the  
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Figure 8.2: Insulin and dextran accumulate in the endothelium of post-capillary venules. 
Intravital microscopy images of insulin-647 (left panels) and rhodamine-labeled 2MDa dextran 
(right panels) in venules (top panels) and capillaries (bottom panels). Both insulin and dextran 
can be seen accumulating in the endothelium of venules but not capillaries. Arrows indicate 
regions of insulin accumulation in the endothelium.  
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intriguing possibility that insulin can be transported by two distinct pathways: 1) an insulin-
receptor mediated transcytotic process that occurs at physiological insulin concentrations and 2) 
a non-saturable, micropinocytotic pathway that operates at pharmacological insulin 
concentrations (233). As discussed above, the lack of capillary endothelial insulin or dextran 
accumulation in vivo calls this transcytosis-based hypothesis into question. Furthermore, it is 
possible that the cultured endothelial cells used in by Klip and colleagues may be more 
representative of venules, in which case insulin accumulation would be expected. While the 
capillary endothelium does not accumulate insulin, it is possible that insulin binding to its 
receptor on the luminal endothelial surface may have important effects on vascular function and 
insulin action.  
In summary, based on intravital imaging of trans-endothelial insulin transport and the 
considerations above, we hypothesize that insulin moves convectively through inter-endothelial 
junctions and trans-endothelial channels (Figure 8.1A).  
 
Trans-endothelial insulin transport and insulin action  
 Previous studies have suggested that the trans-endothelial transport of insulin is rate-
limiting for insulin action in muscle (72, 73, 138). I have also observed a strong temporal 
correlation between the appearance of insulin in the interstitial space and whole-body insulin 
action. Namely, an intravenous bolus injection of insulin fully equilibrates with the muscle 
interstitial space in roughly 5 minutes, approximately the same period of time in which insulin-
stimulated glucose lowering is maximal. Thus, our direct measurements of trans-endothelial 
insulin transport lend further support to the idea that the capillary endothelium governs the rate 
of muscle insulin action. 
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 A major function of the endothelium, as it relates to insulin action, is to control insulin's 
access to muscle. Capillary permeability to insulin controls both the kinetics and absolute levels 
of muscle insulin exposure. The manner in which changes to trans-endothelial insulin transport 
affect muscle insulin exposure depends on insulin clearance by other organs. For instance, if 
trans-endothelial insulin transport in muscle is reduced, then first-pass insulin extraction by the 
muscle will also be reduced. However, if insulin clearance by other organs such as liver and 
kidney are also decreased, then plasma insulin will remain elevated. The muscle will be able to 
extract this insulin on subsequent passes. In this case, the kinetics, but not absolute levels, of 
insulin delivery would be delayed. On the other hand, if there is an isolated impairment in 
muscle insulin extraction, the liver and kidney may remove the excess insulin not extracted by 
muscle. In this case, the absolute delivery of insulin to the muscle would be reduced. These 
scenarios highlight the importance of plasma insulin concentration to muscle insulin delivery. 
Namely, because insulin appearance in the interstitial space is a linear function of plasma insulin 
and trans-endothelial insulin transport, high plasma levels of insulin can overcome defects in 
trans-endothelial insulin transport. This is what we observed in obese, insulin resistant mice 
where a 40% increase in plasma insulin levels overcame a 15% reduction in trans-endothelial 
insulin transport to maintain insulin delivery (Chapter V). As such, the kinetics, but not absolute 
levels, of insulin delivery were impaired in these mice. 
  
Trans-endothelial insulin transport and insulin resistance 
The primary reason for which the present work was undertaken was to determine whether 
impaired trans-endothelial insulin transport contributes to skeletal muscle insulin resistance. 
Indeed, I observed a 15% reduction in trans-endothelial insulin transport in male mice made 
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obese and insulin resistant by 16 weeks of high fat feeding. Thus, in the setting of obesity and 
insulin resistance, the capillary endothelium limits the access of insulin to skeletal muscle. 
However, this reduction in capillary permeability to insulin did not reduce the absolute levels of 
insulin in the interstitial space. As described above, insulin in the interstitial space was actually 
increased in obese mice due to a 40% increase in plasma insulin levels following the intravenous 
insulin bolus. These findings indicate that the kinetics, but not absolute levels, of insulin delivery 
are impaired in obese, insulin resistant mice. A delay in trans-endothelial insulin transport would 
be predicted to cause a delay in muscle insulin action. Indeed, obese, insulin resistant humans 
require more time and insulin to dispose of an oral glucose load (300). Olefsky and colleagues 
utilized insulin clamps to show that this delay in whole-body insulin action was due in part to a 
delay in the onset kinetics of insulin-stimulated peripheral glucose disposal (300). Thus, the 
delay in peripheral insulin action observed in obesity may be caused by reduced capillary 
permeability to insulin in skeletal muscle. Delayed insulin action, especially in the context of 
physiological feeding, may increase the amount of time that obese individuals spend in 
hyperglycemia. These repeated, transient bouts of postprandial hyperglycemia may contribute to 
obesity-associated co-morbidities.   
As trans-endothelial insulin transport was only measured at one time point during the 
development of diet-induced insulin resistance, it is unclear whether this process is a cause or 
consequence of muscle insulin resistance. It is possible that impaired trans-endothelial insulin 
transport occurs prior to the development of overt myocellular insulin resistance. In fact, Kim et 
al. observed aortic endothelial dysfunction after just 1 week of a high fat diet, prior to the 
development of muscle insulin resistance (182). Subsequently, hypersecretion of insulin from b-
cells may be a response to overcome impaired trans-endothelial insulin transport and preserve 
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muscle insulin action. Alternatively, impaired trans-endothelial insulin transport may be a 
consequence of whole body insulin resistance. Insulin resistance at the whole body level results 
in a host of abnormalities including increased free fatty acids, glucose, inflammatory mediators, 
reactive oxygen species and extracellular matrix accumulation. The prolonged exposure of the 
capillary endothelium to this milieu may drive endothelial dysfunction and reduce trans-
endothelial insulin transport. In support of this hypothesis, Lindner and colleagues found that 
microvascular hemodynamic function only declined after the development of obesity and 
glucose intolerance in monkeys (172). Thus, it is possible that a model of more severe insulin 
resistance may display a greater impairment in trans-endothelial insulin transport. 
The delayed trans-endothelial insulin transport observed in obese male mice was 
associated with a 50% reduction in endothelial vesicles. As discussed above, these vesicles may 
represent channels or pores in the endothelium. If the availability of endothelial channels is 
reduced in obese mice, this may provide a structural basis for the reduction in trans-endothelial 
insulin transport. Interestingly, the reduction in endothelial vesicles (50%) was much larger than 
the impairment in trans-endothelial insulin transport (15%). This may reflect 1) that there is an 
excess of trans-endothelial channels available for insulin exchange and only a severe reduction 
of these channels would impact trans-endothelial insulin transport or 2) paracellular insulin 
transport through inter-endothelial junctions increases to compensate for reduced transcellular 
transport.  
Collectively, my findings indicate that the endothelium delays insulin’s access to skeletal 
muscle in a mouse model of obesity and insulin resistance. The structural determinants of this 
impairment, as well its chronological appearance during the development of insulin resistance, 
remain to be determined.  
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Nitric oxide and trans-endothelial insulin transport 
 After observing delayed trans-endothelial insulin transport in obese male mice, we 
considered potential molecular determinants of this defect. A likely candidate was NO. NO 
exerts a plethora of beneficial effects on endothelial function, is correlated positively with 
muscle insulin sensitivity, and has been shown to be reduced in the setting of obesity and insulin 
resistance. Thus, we hypothesized that a reduction in endothelial NO bioavailability caused the 
impaired trans-endothelial insulin transport observed in obese male mice. To explore this 
hypothesis, we initially tested whether pharmacologically reducing NO in lean, insulin sensitive 
mice would impair trans-endothelial insulin transport. To our surprise, we found the opposite to 
be true. Namely, reducing endothelial NO with a NOS inhibitor (L-NAME) actually increased 
the rate at which insulin was transported across the endothelium. Consistent with increased 
capillary permeability to insulin, L-NAME also enhanced the glucose-lowering effect of insulin. 
As discussed in detail in the Discussion of Chapter VI, these findings corroborate previously 
reported effects of NO reduction on vascular permeability and elucidate a novel role for NO in 
the control of insulin action kinetics. To the best of my knowledge, this is the first report of a 
pharmacological intervention which enhances the delivery of insulin to the muscle.  
Given that L-NAME increases trans-endothelial insulin transport, it may be a useful tool 
to better understand the molecular, cellular, and structural determinants of this process. At 
present, the precise mechanism by which L-NAME increases capillary permeability to insulin is 
unclear. Based on previous work from the Granger and Malik laboratories, we hypothesize that 
L-NAME may increase trans-endothelial insulin transport by 3 non-mutually exclusive 
mechanisms. First, L-NAME may cause a widening of inter-endothelial junctions. This would 
result in reduced resistance to paracellular insulin flux across the endothelium. Indeed, electron 
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microscopic analysis of skeletal muscle capillaries revealed an opening of inter-endothelial 
junctions after L-NAME treatment (183). Second, given that L-NAME treatment increases blood 
pressure and reduces capillary diameter, it most likely has hemodynamic effects in the 
microvasculature. These hemodynamic effects may alter the balance of fluid pressures across the 
capillary wall and, subsequently, trans-capillary fluid flux. Thus, L-NAME may enhance the 
transport of insulin by increasing convective fluid flux. Finally, it is possible that L-NAME 
increases the density or stability of trans-endothelial channels which support insulin transport. 
Further dissection of the mechanism by which L-NAME increases trans-endothelial insulin 
transport would 1) afford a better understanding of the mechanism of insulin transport and 2) 
guide attempts to specifically reverse engineer the permeability-enhancing effects of L-NAME.  
A conundrum raised by the findings described in Chapter VI is the connection between 
obesity, insulin resistance, NO bioavailability and trans-endothelial insulin transport. Many 
investigators have found that obesity and insulin resistance are associated with reduced NO 
bioavailability (181). Given these previous observations and our finding that pharmacological 
reduction of NO increases capillary permeability, one might predict that obese, insulin resistant 
mice would have increased trans-endothelial insulin transport. However, we found the opposite 
to be true. Before discussing potential explanations of this conundrum, it is important to note that 
there have been no direct measurements of muscle capillary NO production. This is the process 
of interest for trans-endothelial insulin transport. Most previous studies have utilized indirect 
measures of NO bioavailability in larger vessels. Thus, the effect of obesity and insulin 
resistance on NO levels in skeletal muscle capillaries is unclear.  
If we assume that muscle capillary NO bioavailability is indeed reduced in DIO mice, 
there are two potential explanations for the counterintuitive observations that 1) reducing NO 
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increases trans-endothelial insulin transport 2) DIO mice have reduced endothelial NO and 3) 
DIO mice have impaired trans-endothelial import. First, it is possible that concurrent cellular 
events in the endothelium overcome the reduction in NO bioavailability to reduce permeability 
of capillaries to insulin. For instance, obesity and insulin resistance are associated with increased 
endothelial generation of superoxide, a free radical (301). Superoxide can react with NO to form 
peroxynitrite. Not only does this reaction inactivate NO and reduce its bioavailability, but 
peroxynitrite itself can form lipid and protein adducts which impart adverse effects on vascular 
function (302). Thus, it is possible that increased peroxynitrite generation in the endothelium of 
DIO mice counteracts the effects of reduced NO bioavailability and diminishes trans-endothelial 
insulin transport. A second possibility is that a reduction in NO bioavailability is a homeostatic 
feedback mechanism to maintain trans-endothelial insulin transport at a more physiological level. 
That is to say, the impairment in trans-endothelial insulin transport observed in obese mice may 
be even greater were it not for reduced endothelial NO generation.  
In summary, inhibition of NOS increases trans-endothelial insulin transport and 
accelerates whole body insulin action. The precise mechanism by which L-NAME increases the 
flux of insulin across the endothelium remains to be determined. Furthermore, the relationship 
between obesity, endothelial NO, oxidative stress, and trans-endothelial insulin transport 
warrants further investigation. 
 
Vasodilators and muscle insulin sensitivity 
 Previous work from our laboratory showed that chronic, but not acute, treatment of obese 
mice with vasodilators restores insulin sensitivity (195, 196). These findings suggested that 1) 
augmenting perfusion alone does not rescue muscle insulin action and 2) chronic vasodilator 
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treatment induces structural changes to the muscle, including increased capillarization and 
reduced ECM accumulation, which improve muscle insulin sensitivity. In Chapter VII, we 
treated obese mice with Ang-(1-7), a vasodilatory peptide hormone of the renin-angiotensin 
system which has been shown to improve endothelial function. Thus, we hypothesized that 
chronic Ang-(1-7) treatment would improve muscle insulin sensitivity by augmenting the access 
of glucose and insulin to skeletal muscle. While Ang-(1-7) treatment did restore muscle insulin 
action, it did so by enhancing Glut4 translocation rather than by improving muscle perfusion. 
Thus, chronic Ang-(1-7) treatment improves muscle insulin sensitivity by augmenting glucose 
transport. At present, it is unclear whether this effect of Ang-(1-7) is mediated by myocytes or 
the vasculature. It is possible that Ang-(1-7) treatment may improve insulin signaling and Glut4 
translocation by stimulation of the mas receptor, which is expressed in skeletal muscle. 
Alternatively, it is possible that chronic vasodilation increases delivery of oxygen to muscle 
which may enhance muscle fat oxidation. In support of this hypothesis, we observed that Ang-(1-
7) treatment caused a slight reduction in adiposity in obese mice. An elevated capacity to oxidize 
lipids may reduce accumulation of toxic lipid species which can impair insulin signaling. 
Whether the insulin-sensitizing effects of vasodilators are due to direct myocellular or vascular 
effects warrants further investigation. 
 
Future Directions 
Intravital microscopy and trans-endothelial insulin transport 
 Controversies regarding biological mechanisms are often resolved through improvements 
in methodology. The development of intravital microscopy to study trans-endothelial insulin 
transport has fundamentally changed our understanding of this process. Using this technique, we 
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have challenged the longstanding receptor-mediated transcytosis model of trans-endothelial 
insulin transport and discovered that, in vivo, insulin moves across the muscle capillary 
endothelium by convection. While intravital microscopy has afforded us the first direct 
measurements of trans-endothelial insulin transport, there is certainly room for improvement. 
One limitation of intravital fluorescence microscopy is sensitivity. In its current iteration, in vivo 
insulin imaging requires the use of high doses of fluorescent insulin due to low circulating 
insulin concentrations and fluorescence detection limits. While we have considerable evidence 
that insulin is transported across the endothelium by fluid-phase transport, it would be ideal to 
definitively demonstrate this at physiological insulin concentrations. The lowest dose we have 
imaged is 0.5U/kg. This dose would be predicted to give plasma insulin levels which start at 
16nM immediately following injection and fall to 4nM after 5 minutes. Under physiological 
conditions, circulating insulin concentrations range from 1nM to 50pM. In order to move into the 
physiological range of plasma insulin concentrations, the sensitivity of fluorescent insulin 
detection needs to increase by ~20 fold. This may be achieved through a combination of 
modifications including using brighter dyes, objectives with higher light-collecting capacity, 
higher laser power and longer pixel dwell times, more sensitive non-descanned detectors, and 
computational techniques such as adaptive optics. It should be noted that increases in sensitivity 
may come at the expense of other parameters including imaging speed, field of view, and 
phototoxicity.   
Another aspect of imaging on which we can improve is our understanding of the cellular 
and structural landscape of the tissue being imaged. Currently, we measure insulin 
concentrations in the intravascular and the extravascular space as indicated by the presence or 
absence of a rhodamine-labeled 2MDa dextran vascular marker, respectively. We assume that 
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the region emanating 1 – 3 µm from the capillary wall is the interstitial space. This assumption is 
based on electron microscopic analysis of muscle sections and the smooth exponential decay of 
insulin concentrations in this space. Ideally, we should validate this assumption in a more 
rigorous manner. For instance, we could determine the co-localization of interstitial INS-647 
with a fluorescent, non-metabolizable extracellular marker such as inulin. Additionally, our two-
compartment model of insulin movement is an oversimplification of the complex structure of 
muscle tissue.  It would be useful to visualize the location of the ECM, myofibers, endothelial 
cells, lymphatic vessels, and pericytes in order to define muscle compartments with more 
granularity. These elements of muscle can be detected using a combination of second harmonic 
microscopy to image collagen fibers and cell type-specific expression of genetically-encoded 
fluorescent proteins. More sophisticated imaging of tissue structures may allow us to make 
detailed measurements of insulin movement through complex muscle compartments. 
As with most high-resolution intravital microscopy experiments, one concern is the 
relevance of the small region being imaged to the behavior of the tissue as a whole. To illustrate 
this point, we image a 0.02 mm3 volume of tissue which represents just ~0.04% of the entire 
lateral gastrocnemius. Drawing conclusions about tissue-level function from microscale 
measurements will require a better understanding of the intra-individual variability of trans-
endothelial insulin transport. There are several layers of variability which are important to 
consider. First, it would be very useful to know the variability of individual capillary 
permeabilities. This can be accomplished by modifying my automated image analysis script to 
analyze trans-endothelial insulin transport on a per-capillary basis. Such data may reveal 
subpopulations of capillaries with varying permeabilities to insulin. Furthermore, systematic 
measurements of trans-endothelial insulin transport at well-defined points within the exposed 
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tissue would allow us to determine whether certain regions of the tissue are more preferable for 
comparison. It is also possible that capillaries of superficial myofibers, similar to the ones we 
image, have different characteristics than those located deeper in the tissue. We could use two-
photon microscopy to make this determination. Finally, microvascular properties vary depending 
on the type of muscle (i.e. glycolytic vs. oxidative) being studied. In the work described above, 
we have exclusively imaged the superficial lateral gastrocnemius which is composed mostly of 
Type II glycolytic fibers. It would be interesting to determine whether the mechanism and 
regulation of trans-endothelial insulin transport is similar in Type I oxidative fibers. In summary, 
a better understanding the variability of trans-endothelial insulin transport on multiple scales 
would allow us to 1) determine the degree to which our current measurements represent all of 
skeletal muscle and 2) design experiments and comparisons with maximal statistical power.  
All biological processes are both 1) emergent properties of events occurring at a lower 
scale as well as 2) individual components of higher-order processes. An ideal strategy to advance 
our understanding of trans-endothelial insulin transport would be to connect our intravital 
microscopy measurements with processes at both smaller and larger spatial scales. For instance, 
the use of electron microscopy to measure vesicular density and inter-endothelial junction 
distance would allow us to relate endothelial ultrastructure to capillary transport function. 
Furthermore, the development of techniques to measure whole muscle insulin clearance would 
allow us to determine whether changes to trans-endothelial insulin transport scale to the entire 
muscle.  Using this approach, we would be able to discover important molecular regulators of 
insulin access by identifying key variables that have effects over multiple scales. 
A limitation of most intravital microscopy techniques is the requirement of anesthesia to 
stabilize animals for imaging. To a varying degree, all anesthetics cause changes to both 
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cardiovascular function and metabolism. These changes could presumably alter the rate or 
regulation of trans-endothelial insulin transport. It should be noted, however, that our 
measurement of the trans-endothelial insulin gradient in anesthetized mice is similar to that of 
conscious humans as measured by microdialysis (137). Regardless, it would be ideal to study 
trans-endothelial insulin transport in the absence of anesthesia. Investigators in neuroscience 
have engineered miniature confocal microscopes that can be affixed to windows implanted in the 
skulls of mice (303). This allows for long-term subcellular resolution fluorescence microscopy in 
the brain of freely moving mice. Adapting this concept to the muscle, while logistically 
challenging, may offer an opportunity to study insulin transport in conscious, freely moving 
animals. Furthermore, the implantation of window chambers onto muscle would allow for 
repeated measurements of trans-endothelial insulin transport in the same mouse. Such 
experiments would give us the ability to correlate changes in trans-endothelial insulin efflux with 
disease progression. 
Another way to improve our investigation of trans-endothelial insulin transport would be 
to administer insulin in a more physiological manner. Currently, we give intravenous bolus 
injections of insulin into the peripheral circulation which is different than the physiological 
secretion of insulin by b cells into the portal circulation. Infusing insulin into the portal vein, 
while technically challenging in mice, may reveal additional regulatory mechanisms of trans-
endothelial insulin transport. An even more elegant approach would be to genetically ligate a 
fluorescent protein to endogenous insulin. In this case, one could measure trans-endothelial 
insulin transport in response to endogenously secreted insulin following physiological stimuli. 
However, fluorescent proteins are large and their conjugation to insulin may affect trans-
endothelial insulin transport and insulin action. This technical hurdle may eventually be solved 
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by the development of smaller genetically-encodable fluorescent tags or other in vivo 
endogenous labeling strategies. 
There are limitations to drawing conclusions about human obesity and insulin resistance 
from experiments in mouse models. As such, the holy grail would be ideal to directly measure 
trans-endothelial insulin transport in human skeletal muscle. There are a few different strategies 
which may afford this measurement. Schnitzer and colleagues have utilized two-photon 
microscopy combined with microendoscopy to measure sarcomere contractile dynamics in 
human skeletal muscle (304). It is feasible that his approach could be adapted to measure trans-
endothelial insulin efflux. Alternatively, it is conceivable that future insulin probes may allow for 
non-invasive discrimination between plasma and interstitial insulin. That is to say, if an insulin 
probe were to behave differently in various compartments, these differences may be detected by 
an imaging modality such as magnetic resonance imaging. Such technical advances would allow 
us to determine the contribution of trans-endothelial insulin transport to muscle insulin resistance 
in humans.  
 
The mechanism of trans-endothelial insulin transport 
Intravital insulin imaging revealed that insulin is transported across the endothelium by a 
fluid-phase transport mechanism that is not saturable and does not require the insulin receptor. 
Moreover, a mathematical model predicted that insulin moved across the endothelium by 
convection rather than diffusion. This model prediction should be tested experimentally in future 
studies.  If insulin is indeed moving convectively across the endothelium, manipulating trans-
capillary fluid flux should have predictable effects on trans-endothelial insulin transport. Fluid 
efflux is governed by the balance of hydrostatic and oncotic pressure gradients (Starling forces) 
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across the capillary wall. In resting skeletal muscle, the balance of Starling forces promote net 
fluid efflux from the capillaries to the interstitial space (305). In preliminary studies, I 
administered a continuous infusion of unlabeled 70 kDa dextran in an attempt to increase plasma 
oncotic pressure. The predicted effect of increasing plasma oncotic pressure would be to either 
inhibit or reverse trans-endothelial fluid efflux. Dextran treatment slightly reduced hematocrit, 
indicating fluid re-absorption from the extravascular to intravascular space (data not shown). 
However, there was no effect of dextran treatment on trans-endothelial insulin efflux (data not 
shown). It is unclear whether dextran actually altered trans-capillary fluid flux in muscle. Future 
investigations into the convective nature of trans-endothelial insulin transport should utilize 
protocols which verifiably alter fluid filtration in the region of tissue being imaged. 
Subsequently, the effects of both increasing and decreasing fluid efflux on trans-endothelial 
insulin transport should be determined. 
Another question regarding the mechanism of trans-endothelial insulin transport is if 
insulin moves paracellularly (around the endothelial cells) or transcellularly (through the 
endothelial cells). A paracellular process would involve insulin moving through inter-endothelial 
junctions. Transcellular mechanisms might include pinocytotic transcytosis or movement 
through endothelial pores. Several experimental strategies can be employed to distinguish 
between these different routes. First, one could stain muscle sections with gold-conjugated 
insulin antibodies to visualize the distribution of insulin at the ultrastructural level. Subsequently, 
the distribution of insulin located in inter-endothelial junctions (paracellular) and vesicles 
(transcellular) could be quantified. If insulin were found in vesicles, intravital microscopy could 
be used to determine the functional significance of transcytosis to trans-capillary insulin 
transport. As vesicular transcytosis requires the GTPase dynamin, one could use a dynamin 
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inhibitor such as Dyngo-4a to determine whether transcytosis is required for trans-endothelial 
insulin transport. Alternatively, amiloride, a purported fluid-phase endocytosis inhibitor, can be 
used to determine whether micropinocytosis is involved in trans-endothelial insulin transport. In 
addition to using these drugs in intravital insulin imaging experiments, it would be prudent to use 
electron microscopy to assess their effects on both endothelial ultrastructure and insulin 
localization. If insulin is found in vesicles but cannot be blocked by transcytosis or pinocytosis 
inhibitors, this would suggest that endothelial vesicles seen in 2D are actually components of 3D 
trans-endothelial channels. To confirm this hypothesis, one could utilize a volumetric electron 
microscopy technique such as focused ion beam – scanning electron microscopy or serial block-
face scanning electron microscopy. On the other hand, if insulin is found exclusively in inter-
endothelial junctions, then various pharmacological and genetic approaches could be used to 
widen these junctions. Subsequently, the effect of manipulating junction distance on trans-
endothelial insulin transport could be assessed with intravital microscopy.  
Another interesting observation that warrants further investigation is that insulin 
accumulates in the endothelium of larger microvessels such as venules (Figure 8.2). The 
function and nature of this venular insulin accumulation is unclear. The experiments which I 
have performed (Chapter IV) and proposed above could be repeated in arterioles and venules to 
determine the mechanism of endothelial insulin accumulation in these vessels. Given that 
venules are more permeable to insulin than capillaries, it is possible that venular insulin transport 
is an important aspect of insulin delivery and insulin action. One potential indicator of the 
importance of venules insulin action would be proximity to the insulin receptor and PI3K/Akt 
signaling machinery. Put another way, if the myocellular insulin receptor and signaling 
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machinery is highly clustered in regions close to venules, this may suggest that venules are an 
important source of insulin for the muscle.  
 
Trans-endothelial insulin transport, nitric oxide and insulin resistance 
 We observed a 15% reduction in trans-endothelial insulin transport in mice fed an HFD 
for 16 weeks. As discussed above, it is unclear whether this impairment in trans-endothelial 
insulin transport is a cause or consequence of insulin resistance. Time course experiments where 
both muscle insulin sensitivity and trans-endothelial insulin transport are measured following 
various durations of HFD would allow us to make this determination. Furthermore, it would be 
interesting to examine other models of insulin resistance to determine whether impaired trans-
endothelial insulin transport is a ubiquitous feature of insulin resistance. For instance, one could 
study models of acute insulin resistance such as lipid or cytokine-infused mice. Finally, utilizing 
mouse models with more severe insulin resistance and/or overt diabetes would inform us if 
microvascular defects worsen with disease progression. 
 While the effect of diet-induced obesity to delay trans-endothelial insulin transport is 
relatively low (~15%), enhancing muscle insulin delivery may still be a useful treatment strategy 
in overcoming insulin resistance. For instance, it would be interesting to determine whether L-
NAME, which we have shown to increase trans-endothelial insulin transport, would improve 
trans-endothelial insulin transport and insulin action in DIO mice. Other molecules that 
transiently increase permeability, such as VEGF or histamine, would also be useful in testing this 
hypothesis. Ultimately, utilizing findings regarding the precise mechanism of trans-endothelial 
insulin transport in lean mice will provide the best opportunity for engineering strategies to 
enhance insulin delivery in DIO mice. For instance, we have observed that DIO male mice have 
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a 50% reduction in the density of endothelial vesicles. If experiments in lean mice indicate that 
these vesicles are important for trans-endothelial insulin transport, then targeted strategies could 
be developed to restore vesicular density in DIO mice. Alternatively, if inter-endothelial 
junctions are deemed to be more relevant to trans-endothelial insulin transport, then one could 
experimentally widen these junctions to normalize insulin delivery. 
 Finally, the connection between capillary NO bioavailability, trans-endothelial insulin 
transport, and diet-induced insulin resistance warrants further investigation. An important first 
step would be to determine whether muscle capillaries produce NO and if this process is 
impaired in DIO mice. To make these measurements, one could image fluorescent nitric oxide 
reporters with intravital microscopy. Furthermore, experimentally manipulating endothelial NO 
levels in DIO mice will allow us to determine whether NO bioavailability contributes to impaired 
trans-endothelial insulin transport. In Chapter VI, we observed that reducing NO bioavailability 
with L-NAME increased trans-endothelial insulin transport. It will be interesting to determine 
whether NOS inhibition has the same effect in DIO mice. Another potential area of exploration is 
the enhanced superoxide-mediated NO inactivation and peroxynitrite formation observed in 
obesity and insulin resistance. To determine whether this process alters trans-endothelial insulin 
efflux, one could treat lean mice with a peroxynitrite donor or pharmacologically reduce 
peroxynitrite formation in DIO mice. 
 
Concluding Remarks 
 The findings presented in this Dissertation describe novel mechanisms by which the 
capillary endothelium regulates insulin action and insulin resistance. The major advance 
described herein is the development of an intravital microscopy technique to directly measure 
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trans-endothelial insulin transport. This is the first report of such measurements in vivo. Using 
this technique, we have discovered the mechanism of trans-endothelial insulin transport and 
found that impaired movement of insulin across the endothelium contributes to muscle insulin 
resistance. These findings support the notion that the capillary endothelium is a key regulator of 
muscle insulin action. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 211 
REFERENCES 
 
1.  Fryar, C. D., Carroll, M. D., and Ogden, C. L. (2016) Prevalence of Overweight, Obesity, 
and Extreme Obesity Among Adults Aged 20 and Over: United States, 1960–1962 
Through 2013–2014. [online] 
https://www.cdc.gov/nchs/data/hestat/obesity_adult_13_14/obesity_adult_13_14.pdf 
(Accessed May 19, 2018) 
2.  Hales, C. M., Fryar, C. D., Carroll, M. D., Freedman, D. S., and Ogden, C. L. (2018) 
Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and 
Age, 2007-2008 to 2015-2016. JAMA. 319, 1723 
3.  Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. 
C., Biryukov, S., Abbafati, C., Abera, S. F., Abraham, J. P., Abu-Rmeileh, N. M. E., 
Achoki, T., AlBuhairan, F. S., Alemu, Z. A., Alfonso, R., Ali, M. K., Ali, R., Guzman, N. 
A., Ammar, W., Anwari, P., Banerjee, A., Barquera, S., Basu, S., Bennett, D. A., Bhutta, 
Z., Blore, J., Cabral, N., Nonato, I. C., Chang, J.-C., Chowdhury, R., Courville, K. J., 
Criqui, M. H., Cundiff, D. K., Dabhadkar, K. C., Dandona, L., Davis, A., Dayama, A., 
Dharmaratne, S. D., Ding, E. L., Durrani, A. M., Esteghamati, A., Farzadfar, F., Fay, D. F. 
J., Feigin, V. L., Flaxman, A., Forouzanfar, M. H., Goto, A., Green, M. A., Gupta, R., 
Hafezi-Nejad, N., Hankey, G. J., Harewood, H. C., Havmoeller, R., Hay, S., Hernandez, 
L., Husseini, A., Idrisov, B. T., Ikeda, N., Islami, F., Jahangir, E., Jassal, S. K., Jee, S. H., 
Jeffreys, M., Jonas, J. B., Kabagambe, E. K., Khalifa, S. E. A. H., Kengne, A. P., Khader, 
Y. S., Khang, Y.-H., Kim, D., Kimokoti, R. W., Kinge, J. M., Kokubo, Y., Kosen, S., 
Kwan, G., Lai, T., Leinsalu, M., Li, Y., Liang, X., Liu, S., Logroscino, G., Lotufo, P. A., 
Lu, Y., Ma, J., Mainoo, N. K., Mensah, G. A., Merriman, T. R., Mokdad, A. H., 
Moschandreas, J., Naghavi, M., Naheed, A., Nand, D., Narayan, K. M. V., Nelson, E. L., 
Neuhouser, M. L., Nisar, M. I., Ohkubo, T., Oti, S. O., Pedroza, A., Prabhakaran, D., Roy, 
N., Sampson, U., Seo, H., Sepanlou, S. G., Shibuya, K., Shiri, R., Shiue, I., Singh, G. M., 
Singh, J. A., Skirbekk, V., Stapelberg, N. J. C., Sturua, L., Sykes, B. L., Tobias, M., Tran, 
B. X., Trasande, L., Toyoshima, H., van de Vijver, S., Vasankari, T. J., Veerman, J. L., 
Velasquez-Melendez, G., Vlassov, V. V., Vollset, S. E., Vos, T., Wang, C., Wang, S. X., 
Weiderpass, E., Werdecker, A., Wright, J. L., Yang, Y. C., Yatsuya, H., Yoon, J., Yoon, 
S.-J., Zhao, Y., Zhou, M., Zhu, S., Lopez, A. D., Murray, C. J. L., Gakidou, E., Wang, X., 
Weiderpass, E., Werdecker, A., Wright, J. L., Yang, Y. C., Yatsuya, H., Yoon, J., Yoon, 
S.-J., Zhao, Y., Zhou, M., Zhu, S., Lopez, A. D., Murray, C. J. L., and Gakidou, E. (2014) 
Global, regional, and national prevalence of overweight and obesity in children and adults 
during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. 
Lancet. 384, 766–781 
4.  Beccuti, G., and Pannain, S. (2011) Sleep and obesity. Curr. Opin. Clin. Nutr. Metab. 
Care. 14, 402–12 
5.  Trasande, L., Blustein, J., Liu, M., Corwin, E., Cox, L. M., and Blaser, M. J. (2013) Infant 
antibiotic exposures and early-life body mass. Int. J. Obes. (Lond). 37, 16–23 
6.  Correll, C. U., Lencz, T., and Malhotra, A. K. (2011) Antipsychotic drugs and obesity. 
Trends Mol. Med. 17, 97–107 
7.  Bose, M., Oliván, B., and Laferrère, B. (2009) Stress and obesity: the role of the 
hypothalamic-pituitary-adrenal axis in metabolic disease. Curr. Opin. Endocrinol. 
Diabetes. Obes. 16, 340–6 
 212 
8.  Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., and Anis, A. H. 
(2009) The incidence of co-morbidities related to obesity and overweight: A systematic 
review and meta-analysis. BMC Public Health. 9, 88 
9.  Karter, A. J., Mayer-Davis, E. J., Selby, J. V, D’Agostino, R. B., Haffner, S. M., 
Sholinsky, P., Bergman, R., Saad, M. F., and Hamman, R. F. (1996) Insulin sensitivity 
and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and 
women. The Insulin Resistance and Atherosclerosis Study. Diabetes. 45, 1547–55 
10.  Preis, S. R., Massaro, J. M., Robins, S. J., Hoffmann, U., Vasan, R. S., Irlbeck, T., Meigs, 
J. B., Sutherland, P., D’Agostino, R. B., O’Donnell, C. J., Fox, C. S., and Fox, C. S. 
(2010) Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the 
Framingham heart study. Obesity (Silver Spring). 18, 2191–8 
11.  Abate, N., Garg, A., Peshock, R. M., Stray-Gundersen, J., and Grundy, S. M. (1995) 
Relationships of generalized and regional adiposity to insulin sensitivity in men. J. Clin. 
Invest. 96, 88–98 
12.  Wildman, R. P., Muntner, P., Reynolds, K., McGinn, A. P., Rajpathak, S., Wylie-Rosett, 
J., and Sowers, M. R. (2008) The Obese Without Cardiometabolic Risk Factor Clustering 
and the Normal Weight With Cardiometabolic Risk Factor Clustering. Arch. Intern. Med. 
168, 1617 
13.  Centers for Disease Control and Prevention (2017) National Diabetes Statistics Report, 
2017., [online] https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-
statistics-report.pdf (Accessed May 21, 2018) 
14.  POSNER, B. I., KELLY, P. A., SHIU, R. P. C., and FRIESEN, H. G. (1974) Studies of 
Insulin, Growth Hormone and Prolactin Binding: Tissue Distribution, Species Variation 
and Characterization. Endocrinology. 95, 521–531 
15.  Czech, M. P., Tencerova, M., Pedersen, D. J., and Aouadi, M. (2013) Insulin signalling 
mechanisms for triacylglycerol storage. Diabetologia. 56, 949–64 
16.  Leavens, K. F., and Birnbaum, M. J. (2011) Insulin signaling to hepatic lipid metabolism 
in health and disease. Crit. Rev. Biochem. Mol. Biol. 46, 200–215 
17.  Biolo, G., and Wolfe, R. R. (1993) Insulin action on protein metabolism. Baillieres. Clin. 
Endocrinol. Metab. 7, 989–1005 
18.  Begg, D. P., and Woods, S. C. (2012) The Central Insulin System and Energy Balance. in 
Handbook of experimental pharmacology, pp. 111–129, 10.1007/978-3-642-24716-3_5 
19.  Zhao, W. Q., and Alkon, D. L. (2001) Role of insulin and insulin receptor in learning and 
memory. Mol. Cell. Endocrinol. 177, 125–34 
20.  Sliwowska, J. H., Fergani, C., Gawałek, M., Skowronska, B., Fichna, P., and Lehman, M. 
N. (2014) Insulin: its role in the central control of reproduction. Physiol. Behav. 133, 197–
206 
21.  Daly, P. A., and Landsberg, L. Hypertension in Obesity and NIDDM Role of Insulin and 
Sympathetic Nervous System. [online] 
http://care.diabetesjournals.org/content/14/3/240.full-text.pdf (Accessed May 20, 2018) 
22.  Boutens, L., and Stienstra, R. (2016) Adipose tissue macrophages: going off track during 
obesity. Diabetologia. 59, 879–894 
23.  Draznin, B. (2010) Mitogenic action of insulin: friend, foe or ‘frenemy’? Diabetologia. 
53, 229–233 
24.  DeFronzo, R. A., Cooke, C. R., Andres, R., Faloona, G. R., and Davis, P. J. (1975) The 
effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. 
 213 
J. Clin. Invest. 55, 845–55 
25.  LUNDBAEK, K. (1948) Metabolic abnormalities in starvation diabetes. Yale J. Biol. Med. 
20, 533–44 
26.  Dunaif, A. (1997) Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and 
Implications for Pathogenesis 1. Endocr. Rev. 18, 774–800 
27.  Van Cromphaut, S. J., Vanhorebeek, I., and Van den Berghe, G. (2008) Glucose 
metabolism and insulin resistance in sepsis. Curr. Pharm. Des. 14, 1887–99 
28.  Tritos, N. A., and Mantzoros, C. S. (1998) Syndromes of Severe Insulin Resistance. J. 
Clin. Endocrinol. Metab. 83, 3025–3030 
29.  Golay, A., Chen, Y. D., and Reaven, G. M. (1986) Effect of differences in glucose 
tolerance on insulin’s ability to regulate carbohydrate and free fatty acid metabolism in 
obese individuals. J. Clin. Endocrinol. Metab. 62, 1081–8 
30.  Weyer, C., Tataranni, P. A., Bogardus, C., and Pratley, R. E. (2001) Insulin Resistance 
and Insulin Secretory Dysfunction Are Independent Predictors of Worsening of Glucose 
Tolerance During Each Stage of Type 2 Diabetes Development. Diabetes Care. 24, 89–94 
31.  Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., and Kivimäki, M. (2012) 
Prediabetes: a high-risk state for diabetes development. Lancet (London, England). 379, 
2279–90 
32.  Bergman, R. N. Lilly Lecture 1989 Toward Physiological Understanding of Glucose 
Tolerance Minimal-Model Approach. [online] 
http://diabetes.diabetesjournals.org/content/38/12/1512.full-text.pdf (Accessed May 21, 
2018) 
33.  Weyer, C., Bogardus, C., Mott, D. M., and Pratley, R. E. (1999) The natural history of 
insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes 
mellitus. J. Clin. Invest. 104, 787–94 
34.  Shanik, M. H., Xu, Y., Skrha, J., Dankner, R., Zick, Y., and Roth, J. (2008) Insulin 
resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 
31 Suppl 2, S262-8 
35.  Forbes, J. M., and Cooper, M. E. (2013) Mechanisms of Diabetic Complications. Physiol. 
Rev. 93, 137–188 
36.  Reaven, G. M. (1993) Role of Insulin Resistance in Human Disease (Syndrome X): An 
Expanded Definition. Annu. Rev. Med. 44, 121–131 
37.  Reaven, G. M. (1988) Banting lecture 1988. Role of insulin resistance in human disease. 
Diabetes. 37, 1595–607 
38.  Yip, J., Facchini, F. S., and Reaven, G. M. (1998) Resistance to Insulin-Mediated Glucose 
Disposal as a Predictor of Cardiovascular Disease. J. Clin. Endocrinol. Metab. 83, 2773–
2776 
39.  Howard, G., O’Leary, D. H., Zaccaro, D., Haffner, S., Rewers, M., Hamman, R., Selby, J. 
V., Saad, M. F., Savage, P., and Bergman, R. (1996) Insulin Sensitivity and 
Atherosclerosis. Circulation. 93, 1809–1817 
40.  Esposito, K., Chiodini, P., Colao, A., Lenzi, A., and Giugliano, D. (2012) Metabolic 
syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 35, 
2402–11 
41.  Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., 
Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., Holtzman, D. M., and 
Nathan, D. M. (2018) Brain insulin resistance in type 2 diabetes and Alzheimer disease: 
 214 
concepts and conundrums. Nat. Rev. Neurol. 14, 168–181 
42.  American Diabetes Association, A. D. (2013) Economic costs of diabetes in the U.S. in 
2012. Diabetes Care. 36, 1033–46 
43.  Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de 
Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., Isasi, C. R., Jiménez, M. C., Jordan, 
L. C., Judd, S. E., Lackland, D., Lichtman, J. H., Lisabeth, L., Liu, S., Longenecker, C. T., 
Mackey, R. H., Matsushita, K., Mozaffarian, D., Mussolino, M. E., Nasir, K., Neumar, R. 
W., Palaniappan, L., Pandey, D. K., Thiagarajan, R. R., Reeves, M. J., Ritchey, M., 
Rodriguez, C. J., Roth, G. A., Rosamond, W. D., Sasson, C., Towfighi, A., Tsao, C. W., 
Turner, M. B., Virani, S. S., Voeks, J. H., Willey, J. Z., Wilkins, J. T., Wu, J. H., Alger, H. 
M., Wong, S. S., Muntner, P., and American Heart Association Statistics Committee and 
Stroke Statistics Subcommittee, O. behalf of the A. H. A. S. C. and S. S. (2017) Heart 
Disease and Stroke Statistics-2017 Update: A Report From the American Heart 
Association. Circulation. 135, e146–e603 
44.  Kelley, D., Mitrakou, A., Marsh, H., Schwenk, F., Benn, J., Sonnenberg, G., Arcangeli, 
M., Aoki, T., Sorensen, J., and Berger, M. (1988) Skeletal muscle glycolysis, oxidation, 
and storage of an oral glucose load. J. Clin. Invest. 81, 1563–1571 
45.  DeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., and Felber, J. P. (1981) 
The effect of insulin on the disposal of intravenous glucose. Results from indirect 
calorimetry and hepatic and femoral venous catheterization. Diabetes. 30, 1000–7 
46.  Jensen, J., Rustad, P. I., Kolnes, A. J., and Lai, Y.-C. (2011) The role of skeletal muscle 
glycogen breakdown for regulation of insulin sensitivity by exercise. Front. Physiol. 2, 
112 
47.  Rabinowitz, D., and Zierler, K. L. (1962) FOREARM METABOLISM IN OBESITY 
AND ITS RESPONSE TO INTRA- ARTERIAL INSULIN. CHARACTERIZATION OF 
INSULIN RE- SISTANCE AND EVIDENCE FOR ADAPTIVE HYPERINSULINISM *. 
J. Clin. Invest. [online] 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC291152/pdf/jcinvest00321-0095.pdf 
(Accessed January 19, 2018) 
48.  DeFronzo, R. A., and Tripathy, D. (2009) Skeletal muscle insulin resistance is the primary 
defect in type 2 diabetes. Diabetes Care. 32 Suppl 2, S157-63 
49.  Gulli, G., Ferrannini, E., Stern, M., Haffner, S., and DeFronzo, R. A. (1992) The 
metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two 
Mexican-American NIDDM parents. Diabetes. 41, 1575–86 
50.  Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., 
and Groop, L. (1989) Early Metabolic Defects in Persons at Increased Risk for Non-
Insulin-Dependent Diabetes Mellitus. N. Engl. J. Med. 321, 337–343 
51.  Goodpaster, B. H., Kelley, D. E., Wing, R. R., Meier, A., and Thaete, F. L. (1999) Effects 
of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes. 48, 
839–47 
52.  Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M., Walker, 
E. A., Nathan, D. M., and Diabetes Prevention Program Research Group (2002) Reduction 
in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. 
Med. 346, 393–403 
53.  DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) 
Trial Investigators, Gerstein, H. C., Yusuf, S., Bosch, J., Pogue, J., Sheridan, P., Dinccag, 
 215 
N., Hanefeld, M., Hoogwerf, B., Laakso, M., Mohan, V., Shaw, J., Zinman, B., and 
Holman, R. R. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with 
impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. 
Lancet. 368, 1096–1105 
54.  Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., and Vigneri, R. (2009) Insulin receptor 
isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology 
and disease. Endocr. Rev. 30, 586–623 
55.  Haeusler, R. A., McGraw, T. E., and Accili, D. (2017) Biochemical and cellular properties 
of insulin receptor signalling. Nat. Rev. Mol. Cell Biol. 19, 31–44 
56.  Thong, F. S. L., Dugani, C. B., and Klip, A. (2005) Turning Signals On and Off: GLUT4 
Traffic in the Insulin-Signaling Highway. Physiology. 20, 271–284 
57.  Mandarino, L. J., Printz, R. L., Cusi, K. A., Kinchington, P., O’Doherty, R. M., Osawa, 
H., Sewell, C., Consoli, A., Granner, D. K., and DeFronzo, R. A. (1995) Regulation of 
hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle. Am. 
J. Physiol. Metab. 269, E701–E708 
58.  Zierath, J. R., Houseknecht, K. L., Gnudi, L., and Kahn, B. B. (1997) High-fat feeding 
impairs insulin-stimulated GLUT4 recruitment via an early insulin-signaling defect. 
Diabetes. 46, 215–23 
59.  Cline, G. W., Petersen, K. F., Krssak, M., Shen, J., Hundal, R. S., Trajanoski, Z., Inzucchi, 
S., Dresner, A., Rothman, D. L., and Shulman, G. I. (1999) Impaired Glucose Transport as 
a Cause of Decreased Insulin-Stimulated Muscle Glycogen Synthesis in Type 2 Diabetes. 
N. Engl. J. Med. 341, 240–246 
60.  Bonadonna, R. C., Del Prato, S., Bonora, E., Saccomani, M. P., Gulli, G., Natali, A., 
Frascerra, S., Pecori, N., Ferrannini, E., Bier, D., Cobelli, C., and DeFronzo, R. A. (1996) 
Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of 
NIDDM. Diabetes. 45, 915–25 
61.  Kelley, D. E., Mintun, M. A., Watkins, S. C., Simoneau, J. A., Jadali, F., Fredrickson, A., 
Beattie, J., and Thériault, R. (1996) The effect of non-insulin-dependent diabetes mellitus 
and obesity on glucose transport and phosphorylation in skeletal muscle. J. Clin. Invest. 
97, 2705–2713 
62.  Kelley, D. E., Mokan, M., and Mandarino, L. J. (1992) Intracellular defects in glucose 
metabolism in obese patients with NIDDM. Diabetes. 41, 698–706 
63.  Thorburn, A. W., Gumbiner, B., Bulacan, F., Wallace, P., and Henry, R. R. (1990) 
Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-
dependent (type II) diabetes independent of impaired glucose uptake. J. Clin. Invest. 85, 
522–9 
64.  Shulman, G. I., Rothman, D. L., Jue, T., Stein, P., DeFronzo, R. A., and Shulman, R. G. 
(1990) Quantitation of Muscle Glycogen Synthesis in Normal Subjects and Subjects with 
Non-Insulin-Dependent Diabetes by 13 C Nuclear Magnetic Resonance Spectroscopy. N. 
Engl. J. Med. 322, 223–228 
65.  Petersen, K. F., Dufour, S., Savage, D. B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G. 
W., Befroy, D., Zemany, L., Kahn, B. B., Papademetris, X., Rothman, D. L., and 
Shulman, G. I. (2007) The role of skeletal muscle insulin resistance in the pathogenesis of 
the metabolic syndrome. Proc. Natl. Acad. Sci. 104, 12587–12594 
66.  Boucher, J., Kleinridders, A., and Kahn, C. R. (2014) Insulin Receptor Signaling in 
Normal and Insulin-Resistant States. Cold Spring Harb. Perspect. Biol. 6, a009191–
 216 
a009191 
67.  Samuel, V. T., and Shulman, G. I. (2012) Mechanisms for Insulin Resistance: Common 
Threads and Missing Links. Cell. 148, 852–871 
68.  Wu, H., and Ballantyne, C. M. (2017) Skeletal muscle inflammation and insulin resistance 
in obesity. J. Clin. Invest. 127, 43–54 
69.  Muoio, D. M. M., and Neufer, P. D. D. (2012) Lipid-induced mitochondrial stress and 
insulin action in muscle. Cell Metab. 15, 595–605 
70.  Williams, A. S., Kang, L., and Wasserman, D. H. (2015) The extracellular matrix and 
insulin resistance. Trends Endocrinol. Metab. 26, 357–366 
71.  Wasserman, D. H., Kang, L., Ayala, J. E., Fueger, P. T., and Lee-Young, R. S. (2011) The 
physiological regulation of glucose flux into muscle in vivo. J. Exp. Biol. 214, 254–62 
72.  Yang, Y. J., Hope, I. D., Ader, M., and Bergman, R. N. (1989) Insulin transport across 
capillaries is rate limiting for insulin action in dogs. J. Clin. Invest. 84, 1620–8 
73.  Chiu, J. D., Richey, J. M., Harrison, L. N., Zuniga, E., Kolka, C. M., Kirkman, E., 
Ellmerer, M., and Bergman, R. N. (2008) Direct administration of insulin into skeletal 
muscle reveals that the transport of insulin across the capillary endothelium limits the time 
course of insulin to activate glucose disposal. Diabetes. 57, 828–35 
74.  Rorsman, P., and Braun, M. (2013) Regulation of Insulin Secretion in Human Pancreatic 
Islets. Annu. Rev. Physiol. 75, 155–179 
75.  Shapiro, E. T., Tillil, H., Miller, M. A., Frank, B. H., Galloway, J. A., Rubenstein, A. H., 
and Polonsky, K. S. (1987) Insulin secretion and clearance. Comparison after oral and 
intravenous glucose. Diabetes. 36, 1365–71 
76.  Bishop, J. S., Steele, R., Altszuler, N., Dunn, A., Bjerknes, C., and de Bodo, R. C. (1965) 
Effects of insulin on liver glycogen synthesis and breakdown in the dog. Am. J. Physiol. 
Content. 208, 307–316 
77.  Moore, M. C., Coate, K. C., Winnick, J. J., An, Z., and Cherrington, A. D. (2012) 
Regulation of hepatic glucose uptake and storage in vivo. Adv. Nutr. 3, 286–94 
78.  Ader, M., Stefanovski, D., Kim, S. P., Richey, J. M., Ionut, V., Catalano, K. J., Hucking, 
K., Ellmerer, M., Van Citters, G., Hsu, I. R., Chiu, J. D., Woolcott, O. O., Harrison, L. N., 
Zheng, D., Lottati, M., Kolka, C. M., Mooradian, V., Dittmann, J., Yae, S., Liu, H., 
Castro, A. V. B., Kabir, M., and Bergman, R. N. (2014) Hepatic insulin clearance is the 
primary determinant of insulin sensitivity in the normal dog. Obesity (Silver Spring). 22, 
1238–45 
79.  Kim, S. P., Ellmerer, M., Kirkman, E. L., and Bergman, R. N. (2007) β-Cell “rest” 
accompanies reduced first-pass hepatic insulin extraction in the insulin-resistant, fat-fed 
canine model. Am. J. Physiol. Metab. 292, E1581–E1589 
80.  Mittelman, S. D., Van Citters, G. W., Kim, S. P., Davis, D. A., Dea, M. K., Hamilton-
Wessler, M., and Bergman, R. N. (2000) Longitudinal compensation for fat-induced 
insulin resistance includes reduced insulin clearance and enhanced beta-cell response. 
Diabetes. 49, 2116–25 
81.  Erdmann, J., Kallabis, B., Oppel, U., Sypchenko, O., Wagenpfeil, S., and Schusdziarra, V. 
(2008) Development of hyperinsulinemia and insulin resistance during the early stage of 
weight gain. Am. J. Physiol. Metab. 294, E568–E575 
82.  Ferrannini, E., Bjorkman, O., Reichard, G. A., Pilo, A., Olsson, M., Wahren, J., and 
DeFronzo, R. A. (1985) The disposal of an oral glucose load in healthy subjects. A 
quantitative study. Diabetes. 34, 580–8 
 217 
83.  Stubbs, W., Kelly, D., Morgan, I., and Alberti, K. G. M. M. (1982) Insulin Clearance by 
Perfused Rat Lung. Horm. Metab. Res. 14, 8–9 
84.  Kelbaek, H., Munck, O., Christensen, N. J., and Godtfredsen, J. (1989) Central 
haemodynamic changes after a meal. Br. Heart J. 61, 506–9 
85.  Duckworth, W. C., Bennett, R. G., and Hamel, F. G. (1998) Insulin degradation: progress 
and potential. Endocr. Rev. 19, 608–24 
86.  Rabkin, R., Ryan, M. P., and Duckworth, W. C. (1984) The renal metabolism of insulin. 
Diabetologia. 27, 351–7 
87.  Liang, C., Doherty, J. U., Faillace, R., Maekawa, K., Arnold, S., Gavras, H., Hood, W. B., 
and Jr. (1982) Insulin infusion in conscious dogs. Effects on systemic and coronary 
hemodynamics, regional blood flows, and plasma catecholamines. J. Clin. Invest. 69, 
1321–36 
88.  Baron, A. D. (1994) Hemodynamic actions of insulin. Am. J. Physiol. 267, E187-202 
89.  Laakso, M., Edelman, S. V, Brechtel, G., and Baron, A. D. (1990) Decreased effect of 
insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for 
insulin resistance. J. Clin. Invest. 85, 1844–52 
90.  Baron, A. D., and Brechtel, G. (1993) Insulin differentially regulates systemic and skeletal 
muscle vascular resistance. Am. J. Physiol. 265, E61-7 
91.  Yki-Järvinen, H., and Utriainen, T. (1998) Insulin-induced vasodilatation: physiology or 
pharmacology? Diabetologia. 41, 369–79 
92.  Rattigan, S., Clark, M. G., and Barrett, E. J. (1997) Hemodynamic actions of insulin in rat 
skeletal muscle: evidence for capillary recruitment. Diabetes. 46, 1381–8 
93.  Coggins, M., Lindner, J., Rattigan, S., Jahn, L., Fasy, E., Kaul, S., and Barrett, E. (2001) 
Physiologic hyperinsulinemia enhances human skeletal muscle perfusion by capillary 
recruitment. Diabetes. 50, 2682–90 
94.  Barrett, E. J., and Rattigan, S. (2012) Muscle perfusion: its measurement and role in 
metabolic regulation. Diabetes. 61, 2661–8 
95.  Vincent, M. A., Clerk, L. H., Lindner, J. R., Klibanov, A. L., Clark, M. G., Rattigan, S., 
and Barrett, E. J. (2004) Microvascular recruitment is an early insulin effect that regulates 
skeletal muscle glucose uptake in vivo. Diabetes. 53, 1418–23 
96.  Vincent, M. A., Clerk, L. H., Lindner, J. R., Price, W. J., Jahn, L. A., Leong-Poi, H., and 
Barrett, E. J. (2006) Mixed meal and light exercise each recruit muscle capillaries in 
healthy humans. Am. J. Physiol. Metab. 290, E1191–E1197 
97.  Newman, J. M. B., Ross, R. M., Richards, S. M., Clark, M. G., and Rattigan, S. (2007) 
Insulin and contraction increase nutritive blood flow in rat muscle in vivo determined by 
microdialysis of L-[14C]glucose. J. Physiol. 585, 217–29 
98.  Poole, D. C., Brown, M. D., and Hudlicka, O. (2008) Counterpoint: There is not capillary 
recruitment in active skeletal muscle during exercise. J. Appl. Physiol. 104, 891–893 
99.  Clark, M. G., Rattigan, S., Barrett, E. J., and Vincent, M. A. (2008) Point:Counterpoint: 
There is/is not capillary recruitment in active skeletal muscle during exercise. J. Appl. 
Physiol. 104, 889–891 
100.  Westerbacka, J., Wilkinson, I., Cockcroft, J., Utriainen, T., Vehkavaara, S., and Yki-
Järvinen, H. (1999) Diminished wave reflection in the aorta. A novel physiological action 
of insulin on large blood vessels. Hypertens. (Dallas, Tex.  1979). 33, 1118–22 
101.  Renaudin, C., Michoud, E., Rapin, J. R., Lagarde, M., and Wiernsperger, N. (1998) 
Hyperglycaemia modifies the reaction of microvessels to insulin in rat skeletal muscle. 
 218 
Diabetologia. 41, 26–33 
102.  Chen, Y. L., and Messina, E. J. (1996) Dilation of isolated skeletal muscle arterioles by 
insulin is endothelium dependent and nitric oxide mediated. Am. J. Physiol. 270, H2120-4 
103.  McKay, M. K., and Hester, R. L. (1996) Role of nitric oxide, adenosine, and ATP-
sensitive potassium channels in insulin-induced vasodilation. Hypertens. (Dallas, Tex.  
1979). 28, 202–8 
104.  Eringa, E. C., Stehouwer, C. D. A., Merlijn, T., Westerhof, N., and Sipkema, P. (2002) 
Physiological concentrations of insulin induce endothelin-mediated vasoconstriction 
during inhibition of NOS or PI3-kinase in skeletal muscle arterioles. Cardiovasc. Res. 56, 
464–71 
105.  Grover, A., Padginton, C., Wilson, M. F., Sung, B. H., Izzo, J. L., and Dandona, P. (1995) 
Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study. 
Hypertens. (Dallas, Tex.  1979). 25, 779–84 
106.  Feldman, R. D., and Bierbrier, G. S. (1993) Insulin-mediated vasodilation: impairment 
with increased blood pressure and body mass. Lancet (London, England). 342, 707–9 
107.  Steinberg, H. O., Brechtel, G., Johnson, A., Fineberg, N., and Baron, A. D. (1994) Insulin-
mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin 
to increase nitric oxide release. J. Clin. Invest. 94, 1172–9 
108.  Zeng, G., and Quon, M. J. (1996) Insulin-stimulated production of nitric oxide is inhibited 
by wortmannin. Direct measurement in vascular endothelial cells. J. Clin. Invest. 98, 894–
8 
109.  Muniyappa, R., Montagnani, M., Koh, K. K., and Quon, M. J. (2007) Cardiovascular 
Actions of Insulin. Endocr. Rev. 28, 463–491 
110.  Denninger, J. W., and Marletta, M. A. (1999) Guanylate cyclase and the ⋅NO/cGMP 
signaling pathway. Biochim. Biophys. Acta - Bioenerg. 1411, 334–350 
111.  Cardillo, C., Nambi, S. S., Kilcoyne, C. M., Choucair, W. K., Katz, A., Quon, M. J., and 
Panza, J. A. (1999) Insulin stimulates both endothelin and nitric oxide activity in the 
human forearm. Circulation. 100, 820–5 
112.  Halseth, A. E., Bracy, D. P., and Wasserman, D. H. (1998) Limitations to exercise- and 
maximal insulin-stimulated muscle glucose uptake. J. Appl. Physiol. 85, 2305–2313 
113.  Pitkanen, O. P., Laine, H., Kemppainen, J., Eronen, E., Alanen, A., Raitakari, M., Kirvela, 
O., Ruotsalainen, U., Knuuti, J., Koivisto, V. A., and Nuutila, P. (1999) Sodium 
nitroprusside increases human skeletal muscle blood flow, but does not change flow 
distribution or glucose uptake. J. Physiol. 521 Pt 3, 729–37 
114.  Nuutila, P., Raitakari, M., Laine, H., Kirvelä, O., Takala, T., Utriainen, T., Mäkimattila, 
S., Pitkänen, O. P., Ruotsalainen, U., Iida, H., Knuuti, J., and Yki-Järvinen, H. (1996) 
Role of blood flow in regulating insulin-stimulated glucose uptake in humans. Studies 
using bradykinin, [15O]water, and [18F]fluoro-deoxy-glucose and positron emission 
tomography. J. Clin. Invest. 97, 1741–1747 
115.  Natali, A., Quiñones Galvan, A., Pecori, N., Sanna, G., Toschi, E., and Ferrannini, E. 
(1998) Vasodilation with sodium nitroprusside does not improve insulin action in essential 
hypertension. Hypertens. (Dallas, Tex.  1979). 31, 632–6 
116.  Natali, A., Bonadonna, R., Santoro, D., Galvan, A. Q., Baldi, S., Frascerra, S., Palombo, 
C., Ghione, S., and Ferrannini, E. (1994) Insulin resistance and vasodilation in essential 
hypertension. Studies with adenosine. J. Clin. Invest. 94, 1570–6 
117.  Jamerson, K. A., Nesbitt, S. D., Amerena, J. V, Grant, E., and Julius, S. (1996) 
 219 
Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects. 
Hypertens. (Dallas, Tex.  1979). 27, 854–8 
118.  Baron, A. D., Steinberg, H., Brechtel, G., and Johnson, A. (1994) Skeletal muscle blood 
flow independently modulates insulin-mediated glucose uptake. Am. J. Physiol. 266, 
E248-53 
119.  Baron, A. D., Steinberg, H. O., Chaker, H., Leaming, R., Johnson, A., and Brechtel, G. 
(1995) Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity 
and responsiveness in lean humans. J. Clin. Invest. 96, 786–92 
120.  Barrett, E. J., Wang, H., Upchurch, C. T., and Liu, Z. (2011) Insulin regulates its own 
delivery to skeletal muscle by feed-forward actions on the vasculature. Am. J. Physiol. 
Endocrinol. Metab. 301, E252-63 
121.  Ellmerer, M., Kim, S. P., Hamilton-Wessler, M., Hucking, K., Kirkman, E., and Bergman, 
R. N. (2004) Physiological Hyperinsulinemia in Dogs Augments Access of 
Macromolecules to Insulin-Sensitive Tissues. Diabetes. 53, 2741–2747 
122.  Weinhandl, H., Pachler, C., Mader, J. K., Ikeoka, D., Mautner, A., Falk, A., Suppan, M., 
Pieber, T. R., and Ellmerer, M. (2007) Physiological hyperinsulinemia has no detectable 
effect on access of macromolecules to insulin-sensitive tissues in healthy humans. 
Diabetes. 56, 2213–7 
123.  Fu, Z., Zhao, L., Aylor, K. W., Carey, R. M., Barrett, E. J., and Liu, Z. (2014) 
Angiotensin-(1-7) recruits muscle microvasculature and enhances insulin’s metabolic 
action via mas receptor. Hypertension. 63, 1219–27 
124.  Lillioja, S., Young, A. A., Culter, C. L., Ivy, J. L., Abbott, W. G., Zawadzki, J. K., Yki-
Järvinen, H., Christin, L., Secomb, T. W., and Bogardus, C. (1987) Skeletal muscle 
capillary density and fiber type are possible determinants of in vivo insulin resistance in 
man. J. Clin. Invest. 80, 415–24 
125.  Prior, S. J., Goldberg, A. P., Ortmeyer, H. K., Chin, E. R., Chen, D., Blumenthal, J. B., 
and Ryan, A. S. (2015) Increased Skeletal Muscle Capillarization Independently Enhances 
Insulin Sensitivity in Older Adults After Exercise Training and Detraining. Diabetes. 64, 
3386–3395 
126.  Bonner, J. S., Lantier, L., Hasenour, C. M., James, F. D., Bracy, D. P., and Wasserman, D. 
H. (2013) Muscle-specific vascular endothelial growth factor deletion induces muscle 
capillary rarefaction creating muscle insulin resistance. Diabetes. 62, 572–80 
127.  Pries, A. R., and Secomb, T. W. (2014) Making microvascular networks work: 
angiogenesis, remodeling, and pruning. Physiology (Bethesda). 29, 446–55 
128.  Michel, C. C., and Curry, F. E. (1999) Microvascular permeability. Physiol. Rev. 79, 703–
61 
129.  Mann, G. E., Yudilevich, D. L., and Sobrevia, L. (2003) Regulation of Amino Acid and 
Glucose Transporters in Endothelial and Smooth Muscle Cells. Physiol. Rev. 83, 183–252 
130.  Regittnig, W., Ellmerer, M., Fauler, G., Sendlhofer, G., Trajanoski, Z., Leis, H.-J., 
Schaupp, L., Wach, P., and Pieber, T. R. (2003) Assessment of transcapillary glucose 
exchange in human skeletal muscle and adipose tissue. Am. J. Physiol. Endocrinol. Metab. 
285, E241-51 
131.  Maggs, D. G., Jacob, R., Rife, F., Lange, R., Leone, P., During, M. J., Tamborlane, W. V, 
and Sherwin, R. S. (1995) Interstitial fluid concentrations of glycerol, glucose, and amino 
acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in 
skeletal muscle. J. Clin. Invest. 96, 370–377 
 220 
132.  FUCHI, T., ROSDAHL, H., HICKNER, R. C., UNGERSTEDT, U., and HENRIKSSON, 
J. (1994) Microdialysis of rat skeletal muscle and adipose tissue: dynamics of the 
interstitial glucose pool. Acta Physiol. Scand. 151, 249–260 
133.  Aukland, K., and Reed, R. K. (1993) Interstitial-lymphatic mechanisms in the control of 
extracellular fluid volume. Physiol. Rev. 73, 1–78 
134.  Sherwin, R. S., Kramer, K. J., Tobin, J. D., Insel, P. A., Liljenquist, J. E., Berman, M., and 
Andres, R. (1974) A model of the kinetics of insulin in man. J. Clin. Invest. 53, 1481–92 
135.  Rasio, E. A., Mack, E., Egdahl, R. H., and Herrera, M. G. Passage of Insulin and Inulin 
Across Vascular Membranes in the Dog The biological activity of a hormone depends on 
its reaching the cell membrane of the target tissue in effective concentration. Small 
molecules diffuse easily across vascular endothelium, and their concentrations in. [online] 
http://diabetes.diabetesjournals.org/content/17/11/668.full-text.pdf (Accessed May 23, 
2018) 
136.  Yang, Y. J., Hope, I. D., Ader, M., and Bergman, R. N. (1994) Importance of 
transcapillary insulin transport to dynamics of insulin action after intravenous glucose. 
Am. J. Physiol. 266, E17-25 
137.  Sjostrand, M., Holmang, A., Lonnroth, P., Sjöstrand, M., Holmäng, A., and Lönnroth, P. 
(1999) Measurement of interstitial insulin in human muscle. Am. J. Physiol. 276, E151-4 
138.  Miles, P. D., Levisetti, M., Reichart, D., Khoursheed, M., Moossa, A. R., and Olefsky, J. 
M. (1995) Kinetics of insulin action in vivo. Identification of rate-limiting steps. Diabetes. 
44, 947–53 
139.  Wagenmakers, A. J. M., Strauss, J. A., Shepherd, S. O., Keske, M. A., and Cocks, M. 
(2016) Increased muscle blood supply and transendothelial nutrient and insulin transport 
induced by food intake and exercise: effect of obesity and ageing. J. Physiol. 594, 2207–
22 
140.  Sarin, H. (2010) Physiologic upper limits of pore size of different blood capillary types 
and another perspective on the dual pore theory of microvascular permeability. J. 
Angiogenes. Res. 2, 14 
141.  Bruns, R. R., and Palade, G. E. (1968) Studies on blood capillaries. I. General 
organization of blood capillaries in muscle. J. Cell Biol. 37, 244–76 
142.  Simionescu, N. (1983) Cellular aspects of transcapillary exchange. Physiol. Rev. 63, 
1536–79 
143.  Clough, G., and Michel, C. C. (1981) The role of vesicles in the transport of ferritin 
through frog endothelium. J. Physiol. 315, 127–42 
144.  Simionescu, M., and Simionescu, N. (1991) Endothelial transport of macromolecules: 
transcytosis and endocytosis. A look from cell biology. Cell Biol. Rev. 25, 1–78 
145.  Gustavsson, J., PARPAL, S., KARLSSON, M., RAMSING, C., Thorn, H., Borg, M., 
Lindroth, M., PETERSON, K. H., Magnusson, K.-E. E., Strâlfors, P., and STRaLFORS, 
P. (1999) Localization of the insulin receptor in caveolae of adipocyte plasma membrane. 
FASEB J. 13, 1961–71 
146.  Predescu, S. A., Predescu, D. N., and Malik, A. B. (2007) Molecular determinants of 
endothelial transcytosis and their role in endothelial permeability. Am. J. Physiol. Lung 
Cell. Mol. Physiol. 293, L823-42 
147.  Rippe, B., Rosengren, B.-I., Carlsson, O., and Venturoli, D. (2002) Transendothelial 
Transport: The Vesicle Controversy. J. Vasc. Res. 39, 375–390 
148.  Wagner, R. C., and Casley-Smith, J. R. (1981) Endothelial vesicles. Microvasc. Res. 21, 
 221 
267–298 
149.  BAR, R. S., HOAK, J. C., and PEACOCK, M. L. (1978) INSULIN RECEPTORS IN 
HUMAN ENDOTHELIAL CELLS: IDENTIFICATION AND CHARACTERIZATION 
1. J. Clin. Endocrinol. Metab. 47, 699–702 
150.  King, G. L., and Johnson, S. M. (1985) Receptor-mediated transport of insulin across 
endothelial cells. Science. 227, 1583–6 
151.  Bar, R. S., Boes, M., and Sandra, A. (1988) Vascular transport of insulin to rat cardiac 
muscle. Central role of the capillary endothelium. J. Clin. Invest. 81, 1225–33 
152.  Wang, H., Liu, Z., Li, G., and Barrett, E. J. (2006) The vascular endothelial cell mediates 
insulin transport into skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 291, E323-32 
153.  Schnitzer, J. E., Oh, P., Pinney, E., and Allard, J. (1994) Filipin-sensitive caveolae-
mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and 
capillary permeability of select macromolecules. J. Cell Biol. 127, 1217–32 
154.  Wang, H., Wang, A. X., and Barrett, E. J. (2011) Caveolin-1 is required for vascular 
endothelial insulin uptake. Am. J. Physiol. Endocrinol. Metab. 300, E134-44 
155.  Azizi, P. M., Zyla, R. E., Guan, S., Wang, C., Liu, J., Bolz, S.-S., Heit, B., Klip, A., and 
Lee, W. L. (2014) Clathrin-dependent entry and vesicle-mediated exocytosis define 
insulin transcytosis across microvascular endothelial cells. Mol. Biol. Cell. 26, 740–50 
156.  Kubota, T., Kubota, N., Kumagai, H., Yamaguchi, S., Kozono, H., Takahashi, T., Inoue, 
M., Itoh, S., Takamoto, I., Sasako, T., Kumagai, K., Kawai, T., Hashimoto, S., Kobayashi, 
T., Sato, M., Tokuyama, K., Nishimura, S., Tsunoda, M., Ide, T., Murakami, K., 
Yamazaki, T., Ezaki, O., Kawamura, K., Masuda, H., Moroi, M., Sugi, K., Oike, Y., 
Shimokawa, H., Yanagihara, N., Tsutsui, M., Terauchi, Y., Tobe, K., Nagai, R., Kamata, 
K., Inoue, K., Kodama, T., Ueki, K., and Kadowaki, T. (2011) Impaired insulin signaling 
in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell 
Metab. 13, 294–307 
157.  Steil, G. M., Ader, M., Moore, D. M., Rebrin, K., and Bergman, R. N. (1996) 
Transendothelial insulin transport is not saturable in vivo. No evidence for a receptor-
mediated process. J. Clin. Invest. 97, 1497–503 
158.  Vicent, D., Ilany, J., Kondo, T., Naruse, K., Fisher, S. J., Kisanuki, Y. Y., Bursell, S., 
Yanagisawa, M., King, G. L., and Kahn, C. R. (2003) The role of endothelial insulin 
signaling in the regulation of vascular tone and insulin resistance. J. Clin. Invest. 111, 
1373–80 
159.  Konishi, M., Sakaguchi, M., Lockhart, S. M., Cai, W., Li, M. E., Homan, E. P., Rask-
Madsen, C., and Kahn, C. R. (2017) Endothelial insulin receptors differentially control 
insulin signaling kinetics in peripheral tissues and brain of mice. Proc. Natl. Acad. Sci. 
114, E8478–E8487 
160.  Jansson, P.-A. A. E., Fowelin, J. P., von Schenck, H. P., Smith, U. P., Lönnroth, P. N., and 
Lonnroth, P. N. (1993) Measurement by Microdialysis of the Insulin Concentration in 
Subcutaneous Interstitial Fluid: Importance of the Endothelial Barrier for Insulin. 
Diabetes. 42, 1469–73 
161.  Zawieja, S. D., Wang, W., Wu, X., Nepiyushchikh, Z. V., Zawieja, D. C., and 
Muthuchamy, M. (2012) Impairments in the intrinsic contractility of mesenteric collecting 
lymphatics in a rat model of metabolic syndrome. Am. J. Physiol. Circ. Physiol. 302, 
H643–H653 
162.  Aird, W. C. (2007) Phenotypic heterogeneity of the endothelium: I. Structure, function, 
 222 
and mechanisms. Circ. Res. 100, 158–73 
163.  Aird, W. C. (2007) Phenotypic Heterogeneity of the Endothelium: II. Representative 
Vascular Beds. Circ. Res. 100, 174–190 
164.  Durr, E., Yu, J., Krasinska, K. M., Carver, L. A., Yates, J. R., Testa, J. E., Oh, P., and 
Schnitzer, J. E. (2004) Direct proteomic mapping of the lung microvascular endothelial 
cell surface in vivo and in cell culture. Nat. Biotechnol. 22, 985–92 
165.  Albelda, S. M., Sampson, P. M., Haselton, F. R., McNiff, J. M., Mueller, S. N., Williams, 
S. K., Fishman, A. P., and Levine, E. M. (1988) Permeability characteristics of cultured 
endothelial cell monolayers. J. Appl. Physiol. 64, 308–22 
166.  Muñoz, P., Rosemblatt, M., Testar, X., Palacín, M., Thoidis, G., Pilch, P. F., and Zorzano, 
A. (1995) The T-tubule is a cell-surface target for insulin-regulated recycling of 
membrane proteins in skeletal muscle. Biochem. J. 312 ( Pt 2), 393–400 
167.  Lauritzen, H. P. M. M. (2006) Imaging of Insulin Signaling in Skeletal Muscle of Living 
Mice Shows Major Role of T-Tubules. Diabetes. 55, 1300–1306 
168.  Steinberg, H. O., Chaker, H., Leaming, R., Johnson, A., Brechtel, G., and Baron, A. D. 
(1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications 
for the syndrome of insulin resistance. J. Clin. Invest. 97, 2601–10 
169.  Vollenweider, P., Randin, D., Tappy, L., Jéquier, E., Nicod, P., and Scherrer, U. (1994) 
Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal 
muscle in obese humans. J. Clin. Invest. 93, 2365–2371 
170.  Barton, M., Baretella, O., and Meyer, M. R. (2012) Obesity and risk of vascular disease: 
importance of endothelium-dependent vasoconstriction. Br. J. Pharmacol. 165, 591–602 
171.  Van Guilder, G. P., Stauffer, B. L., Greiner, J. J., and DeSouza, C. A. (2008) Impaired 
endothelium-dependent vasodilation in overweight and obese adult humans is not limited 
to muscarinic receptor agonists. Am. J. Physiol. Circ. Physiol. 294, H1685–H1692 
172.  Chadderdon, S. M. S. S. M., Belcik, J. T., Bader, L., Peters, D. M., Kievit, P., Alkayed, N. 
J., Kaul, S., Grove, K. L., Lindner, J. R. J., Laakso, M., Edelman, S., Brechtel, G., Baron, 
A., Coggins, M., Lindner, J. R. J., Rattigan, S., Dawson, D., Vincent, M., Barrett, E., 
Vincent, M., Barrett, E., Lindner, J. R. J., Clark, M., Rattigan, S., Vincent, M., Clerk, L., 
Lindner, J. R. J., Vincent, M., Clerk, L., Lindner, J. R. J., Vollus, G., Bradley, E., Roberts, 
M., Chadderdon, S. M. S. S. M., Belcik, J. T., Smith, E., Clerk, L., Vincent, M., Barrett, 
E., Lankford, M., Lindner, J. R. J., Clerk, L., Vincent, M., Jahn, L., Liu, Z., Lindner, J. R. 
J., Barrett, E., Kim, F., Pham, M., Maloney, E., Shim, C., Kim, S., Chadderdon, S. M. S. 
S. M., Chawengsub, Y., Gauthier, K., Campbell, W., Larsen, B., Miura, H., Hatoum, O., 
Mustafa, S., Sharma, V., McNeill, J., Ozkor, M., Quyyumi, A., Bellien, J., Iacob, M., 
Gutierrez, L., Knights, K., Rowland, A., Miners, J., Bremer, A., Stanhope, K., Graham, J., 
Chadderdon, S. M. S. S. M., Belcik, J. T., Bader, L., Tigno, X., Gerzanich, G., Hansen, B., 
Hansen, B., Bodkin, N., Kahn, S., Bellien, J., Remy-Jouet, I., Iacob, M., Fleming, I., 
Natarajan, R., Nadler, J., Spector, A., Norris, A., Clark, S., Fuchs, L., Miura, H., Wachtel, 
R., Liu, Y., Pfister, S., Falck, J., Campbell, W., Pritchard, K., Wong, P., Stemerman, M., 
Stapleton, P., Goodwill, A., James, M., Frisbee, J., Yu, Z., Huse, L., Adler, P., Chen, M., 
Yang, Z., Smith, K., Carter, J., Nadler, J., Natarajan, R., Gu, J., Rossi, J., Nunemaker, C., 
Chen, M., Pei, H., Bauersachs, J., Popp, R., Hecker, M., Sauer, E., Fleming, I., Busse, R., 
Kim, J., Montagnani, M., Koh, K., Quon, M., Amati, F., Dubé, J., Coen, P., Stefanovic-
Racic, M., Toledo, F., Goodpaster, B., Shen, S., Reaven, G., Farquhar, J., Iyer, A., Kauter, 
K., and Alam, M. (2016) Temporal Changes in Skeletal Muscle Capillary Responses and 
 223 
Endothelial-Derived Vasodilators in Obesity Related Insulin Resistance. Diabetes. 65, 
db151574 
173.  Clerk, L. H., Vincent, M. A., Jahn, L. A., Liu, Z., Lindner, J. R., and Barrett, E. J. (2006) 
Obesity Blunts Insulin-Mediated Microvascular Recruitment in Human Forearm Muscle. 
Diabetes. 55, 1436–1442 
174.  Clark, M. G. (2008) Impaired microvascular perfusion: a consequence of vascular 
dysfunction and a potential cause of insulin resistance in muscle. Am. J. Physiol. Metab. 
295, E732–E750 
175.  Frisbee, J. C., Wu, F., Goodwill, A. G., Butcher, J. T., and Beard, D. A. (2011) Spatial 
heterogeneity in skeletal muscle microvascular blood flow distribution is increased in the 
metabolic syndrome. Am. J. Physiol. Regul. Integr. Comp. Physiol. 301, R975-86 
176.  Gavin, T. P., Stallings, H. W., Zwetsloot, K. A., Westerkamp, L. M., Ryan, N. A., Moore, 
R. A., Pofahl, W. E., and Hickner, R. C. (2005) Lower capillary density but no difference 
in VEGF expression in obese vs. lean young skeletal muscle in humans. J. Appl. Physiol. 
98, 315–21 
177.  Williams, I. M., Otero, Y. F., Bracy, D. P., Wasserman, D. H., Biaggioni, I., and Arnold, 
A. C. (2016) Chronic Angiotensin-(1-7) Improves Insulin Sensitivity in High-Fat Fed 
Mice Independent of Blood Pressure. Hypertension. 67, 983–91 
178.  Reddy, K. G., Nair, R. N., Sheehan, H. M., and Hodgson, J. M. (1994) Evidence that 
selective endothelial dysfunction may occur in the absence of angiographic or ultrasound 
atherosclerosis in patients with risk factors for atherosclerosis. J. Am. Coll. Cardiol. 23, 
833–43 
179.  Deanfield, J. E., Halcox, J. P., and Rabelink, T. J. (2007) Endothelial function and 
dysfunction: testing and clinical relevance. Circulation. 115, 1285–95 
180.  Muniyappa, R., and Sowers, J. R. (2013) Role of insulin resistance in endothelial 
dysfunction. Rev. Endocr. Metab. Disord. 14, 5–12 
181.  Sansbury, B. E., and Hill, B. G. (2014) Regulation of obesity and insulin resistance by 
nitric oxide. Free Radic. Biol. Med. 73, 383–99 
182.  Kim, F., Pham, M., Maloney, E., Rizzo, N. O., Morton, G. J., Wisse, B. E., Kirk, E. A., 
Chait, A., and Schwartz, M. W. (2008) Vascular inflammation, insulin resistance, and 
reduced nitric oxide production precede the onset of peripheral insulin resistance. 
Arterioscler. Thromb. Vasc. Biol. 28, 1982–8 
183.  Predescu, D., Predescu, S., Shimizu, J., Miyawaki-Shimizu, K., and Malik, A. B. (2005) 
Constitutive eNOS-derived nitric oxide is a determinant of endothelial junctional integrity. 
Am. J. Physiol. Cell. Mol. Physiol. 289, L371–L381 
184.  Kurose, I., Kubes, P., Wolf, R., Anderson, D. C., Paulson, J., Miyasaka, M., and Granger, 
D. N. (1993) Inhibition of nitric oxide production. Mechanisms of vascular albumin 
leakage. Circ. Res. 73, 164–71 
185.  Yuan, S. Y. (2006) New insights into eNOS signaling in microvascular permeability. Am. 
J. Physiol. Circ. Physiol. 291, H1029–H1031 
186.  Roy, D., Perreault, M., and Marette, A. (1998) Insulin stimulation of glucose uptake in 
skeletal muscles and adipose tissues in vivo is NO dependent. Am. J. Physiol. Metab. 274, 
E692–E699 
187.  Vincent, M. A., Barrett, E. J., Lindner, J. R., Clark, M. G., and Rattigan, S. (2003) 
Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in 
response to insulin. Am. J. Physiol. Endocrinol. Metab. 285, E123-9 
 224 
188.  Shankar, R. R., Wu, Y., Shen, H. Q., Zhu, J. S., and Baron, A. D. (2000) Mice with gene 
disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. 
Diabetes. 49, 684–7 
189.  Duplain, H., Burcelin, R., Sartori, C., Cook, S., Egli, M., Lepori, M., Vollenweider, P., 
Pedrazzini, T., Nicod, P., Thorens, B., and Scherrer, U. (2001) Insulin Resistance, 
Hyperlipidemia, and Hypertension in Mice Lacking Endothelial Nitric Oxide 
SynthaseNote Added in Proof. Circulation. 104, 342–345 
190.  Wang, H., Wang, A. X., Aylor, K., and Barrett, E. J. (2013) Nitric oxide directly promotes 
vascular endothelial insulin transport. Diabetes. 62, 4030–42 
191.  Gudbjörnsdóttir, S., Sjöstrand, M., Strindberg, L., and Lönnroth, P. (2005) Decreased 
muscle capillary permeability surface area in type 2 diabetic subjects. J. Clin. Endocrinol. 
Metab. 90, 1078–82 
192.  Halseth, A. E., Bracy, D. P., and Wasserman, D. H. (2000) Limitations to basal and 
insulin-stimulated skeletal muscle glucose uptake in the high-fat-fed rat. Am. J. Physiol. 
Metab. 279, E1064–E1071 
193.  Kolka, C. M., Richey, J. M., Castro, A. V. B. de, Broussard, J. L., Ionut, V., and Bergman, 
R. N. (2015) Lipid-induced insulin resistance does not impair insulin access to skeletal 
muscle. Am. J. Physiol. - Endocrinol. Metab. 10.1152/ajpendo.00015.2015 
194.  Laine, H., Yki-Jarvinen, H., Kirvela, O., Tolvanen, T., Raitakari, M., Solin, O., 
Haaparanta, M., Knuuti, J., and Nuutila, P. (1998) Insulin resistance of glucose uptake in 
skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in 
obesity. J. Clin. Invest. 101, 1156–62 
195.  Ayala, J. E., Bracy, D. P., Julien, B. M., Rottman, J. N., Fueger, P. T., and Wasserman, D. 
H. (2007) Chronic treatment with sildenafil improves energy balance and insulin action in 
high fat-fed conscious mice. Diabetes. 56, 1025–33 
196.  Bonner, J. S., Lantier, L., Hocking, K. M., Kang, L., Owolabi, M., James, F. D., Bracy, D. 
P., Brophy, C. M., and Wasserman, D. H. (2013) Relaxin treatment reverses insulin 
resistance in mice fed a high-fat diet. Diabetes. 62, 3251–60 
197.  Clark, M. G., Rattigan, S., Clerk, L. H., Vincent, M. A., Clark, A. D., Youd, J. M., and 
Newman, J. M. (2000) Nutritive and non-nutritive blood flow: rest and exercise. Acta 
Physiol. Scand. 168, 519–30 
198.  Berria, R., Wang, L., Richardson, D. K., Finlayson, J., Belfort, R., Pratipanawatr, T., De 
Filippis, E. A., Kashyap, S., and Mandarino, L. J. (2006) Increased collagen content in 
insulin-resistant skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 290, E560-5 
199.  Kang, L., Ayala, J. E., Lee-Young, R. S., Zhang, Z., James, F. D., Neufer, P. D., Pozzi, A., 
Zutter, M. M., and Wasserman, D. H. (2011) Diet-induced muscle insulin resistance is 
associated with extracellular matrix remodeling and interaction with integrin alpha2beta1 
in mice. Diabetes. 60, 416–26 
200.  Kang, L., Lantier, L., Kennedy, A., Bonner, J. S., Mayes, W. H., Bracy, D. P., 
Bookbinder, L. H., Hasty, A. H., Thompson, C. B., and Wasserman, D. H. (2013) 
Hyaluronan accumulates with high-fat feeding and contributes to insulin resistance. 
Diabetes. 62, 1888–96 
201.  Abuissa, H., Jones, P. G., Marso, S. P., O’Keefe, J. H., and O’Keefe, J. H. (2005) 
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention 
of type 2 diabetes: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. 46, 
821–6 
 225 
202.  Taddei, S., Virdis, A., Ghiadoni, L., Mattei, P., and Salvetti, A. (1998) Effects of 
angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in 
essential hypertensive patients. J. Hypertens. 16, 447–56 
203.  Gottlieb, S. S., Dickstein, K., Fleck, E., Kostis, J., Levine, T. B., LeJemtel, T., and 
DeKock, M. (1993) Hemodynamic and neurohormonal effects of the angiotensin II 
antagonist losartan in patients with congestive heart failure. Circulation. 88, 1602–9 
204.  Ghiadoni, L., Virdis, A., Magagna, A., Taddei, S., and Salvetti, A. (2000) Effect of the 
angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with 
essential hypertension. Hypertens. (Dallas, Tex.  1979). 35, 501–6 
205.  Vanhoutte, P. M., Auch-Schwelk, W., Biondi, M. L., Lorenz, R. R., Schini, V. B., and 
Vidal, M. J. (1989) Why are converting enzyme inhibitors vasodilators? Br. J. Clin. 
Pharmacol. 28 Suppl 2, 95S–103S; discussion 103S–104S 
206.  Schindler, C., Bramlage, P., Kirch, W., and Ferrario, C. M. (2007) Role of the vasodilator 
peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc. Health Risk Manag. 3, 
125–37 
207.  Giani, J. F., Mayer, M. A., Muñoz, M. C., Silberman, E. A., Höcht, C., Taira, C. A., 
Gironacci, M. M., Turyn, D., Dominici, F. P., Munoz, M. C., Silberman, E. A., Hocht, C., 
Taira, C. A., Gironacci, M. M., Turyn, D., Dominici, F. P., Muñoz, M. C., Silberman, E. 
A., Höcht, C., Taira, C. A., Gironacci, M. M., Turyn, D., and Dominici, F. P. (2009) 
Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension 
induced by a high-fructose diet in rats. Am. J. Physiol. Endocrinol. Metab. 296, E262-71 
208.  Guimaraes, P. S., Oliveira, M. F., Braga, J. F., Nadu, A. P., Schreihofer, A., Santos, R. A. 
S., and Campagnole-Santos, M. J. (2014) Increasing angiotensin-(1-7) levels in the brain 
attenuates metabolic syndrome-related risks in fructose-fed rats. Hypertension. 63, 1078–
85 
209.  Marcus, Y., Shefer, G., Sasson, K., Kohen, F., Limor, R., Pappo, O., Nevo, N., Biton, I., 
Bach, M., Berkutzki, T., Fridkin, M., Benayahu, D., Shechter, Y., and Stern, N. (2013) 
Angiotensin 1-7 as means to prevent the metabolic syndrome: lessons from the fructose-
fed rat model. Diabetes. 62, 1121–30 
210.  Sjostrand, M., Gudbjornsdottir, S., Holmang, A., Lonn, L., Strindberg, L., and Lonnroth, 
P. (2002) Delayed Transcapillary Transport of Insulin to Muscle Interstitial Fluid in Obese 
Subjects. Diabetes. 51, 2742–2748 
211.  Sandqvist, M., Strindberg, L., Schmelz, M., Lönnroth, P., and Jansson, P.-A. (2011) 
Impaired delivery of insulin to adipose tissue and skeletal muscle in obese women with 
postprandial hyperglycemia. J. Clin. Endocrinol. Metab. 96, E1320-4 
212.  Broussard, J. L., Castro, A. V. B., Iyer, M., Paszkiewicz, R. L., Bediako, I. A., 
Szczepaniak, L. S., Szczepaniak, E. W., Bergman, R. N., and Kolka, C. M. (2016) Insulin 
access to skeletal muscle is impaired during the early stages of diet-induced obesity. 
Obesity. 24, 1922–1928 
213.  Castillo, C., Bogardus, C., Bergman, R., Thuillez, P., and Lillioja, S. (1994) Interstitial 
insulin concentrations determine glucose uptake rates but not insulin resistance in lean and 
obese men. J. Clin. Invest. 93, 10–6 
214.  Szendroedi, J., Frossard, M., Klein, N., Bieglmayer, C., Wagner, O., Pacini, G., Decker, 
J., Nowotny, P., Muller, M., and Roden, M. (2012) Lipid-Induced Insulin Resistance Is 
Not Mediated by Impaired Transcapillary Transport of Insulin and Glucose in Humans. 
Diabetes. 61, 3176–3180 
 226 
215.  Kolka, C. M., Harrison, L. N., Lottati, M., Chiu, J. D., Kirkman, E. L., and Bergman, R. 
N. (2010) Diet-induced obesity prevents interstitial dispersion of insulin in skeletal 
muscle. Diabetes. 59, 619–26 
216.  Ayala, J. E., Bracy, D. P., Malabanan, C., James, F. D., Ansari, T., Fueger, P. T., 
McGuinness, O. P., and Wasserman, D. H. (2011) Hyperinsulinemic-euglycemic clamps 
in conscious, unrestrained mice. J. Vis. Exp. 10.3791/3188 
217.  Kraegen, E. W., James, D. E., Jenkins, A. B., and Chisholm, D. J. (1985) Dose-response 
curves for in vivo insulin sensitivity in individual tissues in rats. Am. J. Physiol. 248, 
E353-62 
218.  Ayala, J. E., Samuel, V. T., Morton, G. J., Obici, S., Croniger, C. M., Shulman, G. I., 
Wasserman, D. H., McGuinness, O. P., and Consortium, N. I. H. M. M. P. C. (2010) 
Standard operating procedures for describing and performing metabolic tests of glucose 
homeostasis in mice. Dis Model Mech. 3, 525–34 
219.  Liu, F., Kohn, W. D., and Mayer, J. P. (2012) Site-specific fluorescein labeling of human 
insulin. J. Pept. Sci. 18, 336–41 
220.  Kohn, W. D., Micanovic, R., Myers, S. L., Vick, A. M., Kahl, S. D., Zhang, L., Strifler, B. 
A., Li, S., Shang, J., Beals, J. M., Mayer, J. P., and DiMarchi, R. D. (2007) pI-shifted 
insulin analogs with extended in vivo time action and favorable receptor selectivity. 
Peptides. 28, 935–948 
221.  Bagher, P., and Segal, S. S. (2011) The mouse cremaster muscle preparation for intravital 
imaging of the microcirculation. J. Vis. Exp. 10.3791/2874 
222.  Baatz, H., Steinbauer, M., Harris, A. G., and Krombach, F. Kinetics of white blood cell 
staining by intravascular administration of rhodamine 6G. Int. J. Microcirc. Clin. Exp. 15, 
85–91 
223.  Mempel, T. R., Scimone, M. L., Mora, J. R., and von Andrian, U. H. (2004) In vivo 
imaging of leukocyte trafficking in blood vessels and tissues. Curr. Opin. Immunol. 16, 
406–17 
224.  Otsu, N. (1979) A threshold selection method from gray-level histograms. IEEE Trans. 
Syst. Man. Cybern. 9, 62–66 
225.  Crank, J. (1975) The mathematics of diffusion, 10.1016/0306-4549(77)90072-X 
226.  McClatchey, P. M., Keller, A. C., Bouchard, R., Knaub, L. A., and Reusch, J. E. B. (2016) 
Fully automated software for quantitative measurements of mitochondrial morphology. 
Mitochondrion. 26, 58–71 
227.  Morgan, C. R., and Lazarow, A. (1963) Immunoassay of Insulin: Two Antibody System: 
Plasma Insulin Levels of Normal, Subdiabetic and Diabetic Rats. Diabetes . 12, 115–126 
228.  Senanayake, P. D., Moriguchi, A., Kumagai, H., Ganten, D., Ferrario, C. M. M., 
Brosnihan, K. B. B., deS. Senanayake, P., Moriguchi, A., Kumagai, H., Ganten, D., 
Ferrario, C. M. M., and Brosnihan, K. B. B. (1994) Increased expression of angiotensin 
peptides in the brain of transgenic hypertensive rats. Peptides. 15, 919–26 
229.  Weibel, E. R. (1969) Stereological principles for morphometry in electron microscopic 
cytology. Int. Rev. Cytol. 26, 235–302 
230.  Steele, R., Wall, J. S., de Bodo, R. C., and Altszuler, N. (1956) Measurement of Size and 
Turnover Rate of Body Glucose Pool by the Isotope Dilution Method. Am J Physiol -- 
Leg. Content. 187, 15–24 
231.  Cherrington, A. D., and Vranic, M. (1973) Effect of arginine on glucose turnover and 
plasma free fatty acids in normal dogs. Diabetes. 22, 537–43 
 227 
232.  Hentz, N. G., Richardson, J. M., Sportsman, J. R., Daijo, J., and Sittampalam, G. S. (1997) 
Synthesis and Characterization of Insulin−Fluorescein Derivatives for Bioanalytical 
Applications. Anal. Chem. 69, 4994–5000 
233.  Jaldin-Fincati, J. R., Pereira, R. V. S., Bilan, P. J., and Klip, A. (2018) Insulin uptake and 
action in microvascular endothelial cells of lymphatic and blood origin. Am. J. Physiol. 
Metab. 10.1152/ajpendo.00008.2018 
234.  Chen, A. K., Cheng, Z., Behlke, M. A., and Tsourkas, A. (2008) Assessing the sensitivity 
of commercially available fluorophores to the intracellular environment. Anal. Chem. 80, 
7437–44 
235.  Berlier, J. E., Rothe, A., Buller, G., Bradford, J., Gray, D. R., Filanoski, B. J., Telford, W. 
G., Yue, S., Liu, J., Cheung, C.-Y. C.-Y., Chang, W., Hirsch, J. D., Beechem, J. M., 
Haugland, R. P. R. P., Haugland, R. P. R. P., Beechem Rosaria P. Haugland, J. M., and 
Haugland, R. P. R. P. (2003) Quantitative Comparison of Long-wavelength Alexa Fluor 
Dyes to Cy Dyes: Fluorescence of the Dyes and Their Bioconjugates. J. Histochem. 
Cytochem. 51, 1699–1712 
236.  Poole, D. C., Musch, T. I., and Kindig, C. A. (1997) In vivo microvascular structural and 
functional consequences of muscle length changes. Am. J. Physiol. - Hear. Circ. Physiol. 
237.  Lee, J.-F., Gordon, S., Estrada, R., Wang, L., Siow, D. L., Wattenberg, B. W., Lominadze, 
D., and Lee, M.-J. (2009) Balance of S1P1 and S1P2 signaling regulates peripheral 
microvascular permeability in rat cremaster muscle vasculature. Am. J. Physiol. Heart 
Circ. Physiol. 296, H33-42 
238.  Magidson, V., and Khodjakov, A. (2013) Circumventing photodamage in live-cell 
microscopy. Methods Cell Biol. 114, 545–60 
239.  Majumdar, S., Genders, A. J., Inyard, A. C., Frison, V., and Barrett, E. J. (2012) Insulin 
entry into muscle involves a saturable process in the vascular endothelium. Diabetologia. 
55, 450–6 
240.  Huxley, V. H., Curry, F. E., and Adamson, R. H. (1987) Quantitative fluorescence 
microscopy on single capillaries: alpha-lactalbumin transport. Am. J. Physiol. 252, H188-
97 
241.  Baxter, L. T., and Jain, R. K. (1989) Transport of fluid and macromolecules in tumors. I. 
Role of interstitial pressure and convection. Microvasc. Res. 37, 77–104 
242.  Renkin, E. M. (1988) Transport Pathways and Processes. in Endothelial Cell Biology in 
Health and Disease, pp. 51–68, Springer US, Boston, MA, 10.1007/978-1-4613-0937-6_3 
243.  Schäffer, L., Brand, C. L., Hansen, B. F., Ribel, U., Shaw, A. C., Slaaby, R., and Sturis, J. 
(2008) A novel high-affinity peptide antagonist to the insulin receptor. Biochem. Biophys. 
Res. Commun. 376, 380–3 
244.  Sjöstrand, M., Gudbjörnsdottir, S., Holmäng, A., Lönn, L., Strindberg, L., and Lönnroth, 
P. (2002) Delayed transcapillary transport of insulin to muscle interstitial fluid in obese 
subjects. Diabetes. 51, 2742–8 
245.  Lee, W. L., and Klip, A. (2016) Endothelial Transcytosis of Insulin: Does It Contribute to 
Insulin Resistance? Physiology. 31, 336–345 
246.  Bendayan, M., and Rasio, E. A. (1996) Transport of insulin and albumin by the 
microvascular endothelium of the rete mirabile. J. Cell Sci. 109 ( Pt 7, 1857–64 
247.  Vincent, M. A., Dawson, D., Clark, A. D. H., Lindner, J. R., Rattigan, S., Clark, M. G., 
and Barrett, E. J. (2002) Skeletal muscle microvascular recruitment by physiological 
hyperinsulinemia precedes increases in total blood flow. Diabetes. 51, 42–8 
 228 
248.  Kang, L., Mokshagundam, S., Reuter, B., Lark, D. S., Sneddon, C. C., Hennayake, C., 
Williams, A. S., Bracy, D. P., James, F. D., Pozzi, A., Zent, R., and Wasserman, D. H. 
(2016) Integrin-Linked Kinase in Muscle Is Necessary for the Development of Insulin 
Resistance in Diet-Induced Obese Mice. Diabetes. 65, 1590–1600 
249.  Kolka, C. M., and Bergman, R. N. (2012) The barrier within: endothelial transport of 
hormones. Physiology (Bethesda). 27, 237–47 
250.  Ellmerer, M., Hamilton-Wessler, M., Kim, S. P., Huecking, K., Kirkman, E., Chiu, J., 
Richey, J., and Bergman, R. N. (2006) Reduced Access to Insulin-Sensitive Tissues in 
Dogs With Obesity Secondary to Increased Fat Intake. Diabetes. 55, 1769–1775 
251.  Wallis, M. G., Wheatley, C. M., Rattigan, S., Barrett, E. J., Clark, A. D. H., and Clark, M. 
G. (2002) Insulin-mediated hemodynamic changes are impaired in muscle of Zucker 
obese rats. Diabetes. 51, 3492–8 
252.  Williams, I. M., Valenzuela, F. A., Kahl, S. D., Ramkrishna, D., Mezo, A. R., Young, J. 
D., Wells, K. S., and Wasserman, D. H. (2018) Insulin exits skeletal muscle capillaries by 
fluid-phase transport. J. Clin. Invest. 128, 699–714 
253.  Lacorre, D.-A., Baekkevold, E. S., Garrido, I., Brandtzaeg, P., Haraldsen, G., Amalric, F., 
and Girard, J.-P. (2004) Plasticity of endothelial cells: rapid dedifferentiation of freshly 
isolated high endothelial venule endothelial cells outside the lymphoid tissue 
microenvironment. Blood. 103, 4164–4172 
254.  Yen, T. T., Stienmetz, J., and Simpson, P. J. (1970) Blood volume of obese (ob-ob) and 
diabetic (db-db) mice. Proc. Soc. Exp. Biol. Med. 133, 307–8 
255.  Cassuto, J., Dou, H., Czikora, I., Szabo, A., Patel, V. S., Kamath, V. V., Belin de 
Chantemele, E., Feher, A., Romero, M. J., and Bagi, Z. (2013) Peroxynitrite Disrupts 
Endothelial Caveolae Leading to eNOS Uncoupling and Diminished Flow-Mediated 
Dilation in Coronary Arterioles of Diabetic Patients. Diabetes. 63, 1381–1393 
256.  Armstrong, S. M., Khajoee, V., Wang, C., Wang, T., Tigdi, J., Yin, J., Kuebler, W. M., 
Gillrie, M., Davis, S. P., Ho, M., and Lee, W. L. (2012) Co-Regulation of Transcellular 
and Paracellular Leak Across Microvascular Endothelium by Dynamin and Rac. Am. J. 
Pathol. 180, 1308–1323 
257.  McClatchey, P. M., Frisbee, J. C., and Reusch, J. E. B. (2017) A conceptual framework 
for predicting and addressing the consequences of disease-related microvascular 
dysfunction. Microcirculation. 24, e12359 
258.  Yang, Y., Smith, D. L., Keating, K. D., Allison, D. B., Nagy, T. R., and Nagy, T. R. 
(2014) Variations in body weight, food intake and body composition after long-term high-
fat diet feeding in C57BL/6J mice. Obesity (Silver Spring). 22, 2147–55 
259.  Sader, M., and Celermajer, D. S. (2002) Endothelial function, vascular reactivity and 
gender differences in the cardiovascular system. Cardiovasc. Res. 53, 597–604 
260.  Huxley, V. H., and Wang, J. (2010) Cardiovascular sex differences influencing 
microvascular exchange. Cardiovasc. Res. 87, 230–42 
261.  Jackson, W. F., Boerman, E. M., Lange, E. J., Lundback, S. S., and Cohen, K. D. (2008) 
Smooth muscle alpha1D-adrenoceptors mediate phenylephrine-induced vasoconstriction 
and increases in endothelial cell Ca2+ in hamster cremaster arterioles. Br. J. Pharmacol. 
155, 514–24 
262.  Gurney, A. M., and Allam, M. (1995) Inhibition of calcium release from the sarcoplasmic 
reticulum of rabbit aorta by hydralazine. Br. J. Pharmacol. 114, 238–44 
263.  Bursztyn, M., Raz, I., Mekler, J., and Ben-Ishay, D. (1997) Effect of acute N-nitro-L-
 229 
arginine methyl ester (L-NAME) hypertension on glucose tolerance, insulin levels, and 
[3H]-deoxyglucose muscle uptake. Am. J. Hypertens. 10, 683–6 
264.  House, L. M., Morris, R. T., Barnes, T. M., Lantier, L., Cyphert, T. J., McGuinness, O. P., 
Otero, Y. F., and Otero, Y. F. (2015) Tissue inflammation and nitric oxide-mediated 
alterations in cardiovascular function are major determinants of endotoxin-induced insulin 
resistance. Cardiovasc. Diabetol. 14, 56 
265.  Boesen, E. I., and Pollock, D. M. (2007) Effect of chronic IL-6 infusion on acute pressor 
responses to vasoconstrictors in mice. Am. J. Physiol. Circ. Physiol. 293, H1745–H1749 
266.  Robinson, M. A., Welsh, D. C., Bickel, D. J., Lynch, J. J., and Lyle, E. A. (2003) 
Differential effects of sodium nitroprusside and hydralazine in a rat model of topical 
FeCl3-induced carotid artery thrombosis. Thromb. Res. 111, 59–64 
267.  Griffith, O. W., and Kilbourn, R. G. (1996) Nitric oxide synthase inhibitors: amino acids. 
Methods Enzymol. 268, 375–92 
268.  Kvietys, P. R., and Granger, D. N. (2012) Role of reactive oxygen and nitrogen species in 
the vascular responses to inflammation. Free Radic. Biol. Med. 52, 556–592 
269.  Rumbaut, R. E., Wang, J., and Huxley, V. H. (2000) Differential effects of l -NAME on 
rat venular hydraulic conductivity. Am. J. Physiol. Circ. Physiol. 279, H2017–H2023 
270.  O’Callaghan, C. J., Komersova, K., and Louis, W. J. (1998) Acute effects of blood 
pressure elevation on insulin clearance in normotensive healthy subjects. Hypertens. 
(Dallas, Tex.  1979). 31, 104–9 
271.  Deibert, D. C., and DeFronzo, R. A. (1980) Epinephrine-induced insulin resistance in 
man. J. Clin. Invest. 65, 717–21 
272.  Beyer, A. M., Guo, D.-F., and Rahmouni, K. (2013) Prolonged treatment with angiotensin 
1-7 improves endothelial function in diet-induced obesity. J. Hypertens. 31, 730–8 
273.  Andrade, J. M. O., Lemos, F. de O., da Fonseca Pires, S., Millán, R. D. S., de Sousa, F. B., 
Guimarães, A. L. S., Qureshi, M., Feltenberger, J. D., de Paula, A. M. B., Neto, J. T. M., 
Lopes, M. T. P., Andrade, H. M. de, Santos, R. A. S., and Santos, S. H. S. (2014) 
Proteomic white adipose tissue analysis of obese mice fed with a high-fat diet and treated 
with oral angiotensin-(1–7). Peptides. 60, 56–62 
274.  Winzell, M. S., Ahrén, B., and Ahren, B. (2004) The High-Fat Diet-Fed Mouse: A Model 
for Studying Mechanisms and Treatment of Impaired Glucose Tolerance and Type 2 
Diabetes. Diabetes. 53 Suppl 3, S215-9 
275.  Echeverría-Rodríguez, O., Del Valle-Mondragón, L., and Hong, E. (2014) Angiotensin 1-
7 improves insulin sensitivity by increasing skeletal muscle glucose uptake in vivo. 
Peptides. 51, 26–30 
276.  Gironacci, M. M., Adamo, H. P., Corradi, G., Santos, R. A., Ortiz, P., and Carretero, O. A. 
(2011) Angiotensin (1-7) Induces Mas Receptor Internalization. Hypertension. 58, 176–
181 
277.  Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., and Polonsky, K. S. (1997) Treatment 
with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in 
subjects with impaired glucose tolerance. J. Clin. Invest. 100, 530–537 
278.  Zinker, B. A., Lacy, D. B., Bracy, D. P., and Wasserman, D. H. (1993) Role of glucose 
and insulin loads to the exercising limb in increasing glucose uptake and metabolism. J. 
Appl. Physiol. 74, 2915–2921 
279.  Abdul-Ghani, M. A., Williams, K., DeFronzo, R., and Stern, M. (2006) Risk of 
Progression to Type 2 Diabetes Based on Relationship Between Postload Plasma Glucose 
 230 
and Fasting Plasma Glucose. Diabetes Care. 29, 1613–1618 
280.  Lorenzo, C., Wagenknecht, L. E., Hanley, A. J. G., Rewers, M. J., Karter, A. J., and 
Haffner, S. M. (2010) A1C Between 5.7 and 6.4% as a Marker for Identifying Pre-
Diabetes, Insulin Sensitivity and Secretion, and Cardiovascular Risk Factors: The Insulin 
Resistance Atherosclerosis Study (IRAS). Diabetes Care. 33, 2104–2109 
281.  Laakso, M., and Kuusisto, J. (2014) Insulin resistance and hyperglycaemia in 
cardiovascular disease development. Nat. Rev. Endocrinol. 10, 293–302 
282.  Henriksen, E. J., and Prasannarong, M. (2013) The role of the renin-angiotensin system in 
the development of insulin resistance in skeletal muscle. Mol. Cell. Endocrinol. 378, 15–
22 
283.  Coimbra, C. C., Garofalo, M. A., Foscolo, D. R., Xavier, A. R., and Migliorini, R. H. 
(1999) Gluconeogenesis activation after intravenous angiotensin II in freely moving rats. 
Peptides. 20, 823–7 
284.  Takeda, M., Yamamoto, K., Takemura, Y., Takeshita, H., Hongyo, K., Kawai, T., 
Hanasaki-Yamamoto, H., Oguro, R., Takami, Y., Tatara, Y., Takeya, Y., Sugimoto, K., 
Kamide, K., Ohishi, M., and Rakugi, H. (2013) Loss of ACE2 exaggerates high-calorie 
diet-induced insulin resistance by reduction of GLUT4 in mice. Diabetes. 62, 223–33 
285.  Prasannarong, M., Santos, F. R., and Henriksen, E. J. (2012) ANG-(1-7) reduces ANG II-
induced insulin resistance by enhancing Akt phosphorylation via a Mas receptor-
dependent mechanism in rat skeletal muscle. Biochem. Biophys. Res. Commun. 426, 369–
73 
286.  Kang, L., Mayes, W. H., James, F. D., Bracy, D. P., and Wasserman, D. H. (2014) Matrix 
metalloproteinase 9 opposes diet-induced muscle insulin resistance in mice. Diabetologia. 
57, 603–13 
287.  Tran, L. T., Yuen, V. G., and McNeill, J. H. (2009) The fructose-fed rat: a review on the 
mechanisms of fructose-induced insulin resistance and hypertension. Mol. Cell. Biochem. 
332, 145–59 
288.  Leto, D., and Saltiel, A. R. (2012) Regulation of glucose transport by insulin: traffic 
control of GLUT4. Nat. Rev. Mol. Cell Biol. 13, 383–96 
289.  Shiuchi, T., Cui, T.-X. T.-X. T.-X., Wu, L., Nakagami, H., Takeda-Matsubara, Y., Iwai, 
M., and Horiuchi, M. (2002) ACE Inhibitor Improves Insulin Resistance in Diabetic 
Mouse Via Bradykinin and NO. Hypertension. 40, 329–34 
290.  Sano, H., Kane, S., Sano, E., Mı̂inea, C. P., Asara, J. M., Lane, W. S., Garner, C. W., and 
Lienhard, G. E. (2003) Insulin-stimulated Phosphorylation of a Rab GTPase-activating 
Protein Regulates GLUT4 Translocation. J. Biol. Chem. 278, 14599–14602 
291.  Muñoz, M. C., Giani, J. F., Burghi, V., Mayer, M. A., Carranza, A., Taira, C. A., and 
Dominici, F. P. (2012) The Mas receptor mediates modulation of insulin signaling by 
angiotensin-(1-7). Regul. Pept. 177, 1–11 
292.  Muñoz, M. C., Giani, J. F., and Dominici, F. P. (2010) Angiotensin-(1-7) stimulates the 
phosphorylation of Akt in rat extracardiac tissues in vivo via receptor Mas. Regul. Pept. 
161, 1–7 
293.  Santos, S. H. S., Giani, J. F., Burghi, V., Miquet, J. G., Qadri, F., Braga, J. F., Todiras, M., 
Kotnik, K., Alenina, N., Dominici, F. P., Santos, R. A. S., and Bader, M. (2014) Oral 
administration of angiotensin-(1-7) ameliorates type 2 diabetes in rats. J. Mol. Med. 
(Berl). 92, 255–65 
294.  Larance, M., Ramm, G., Stöckli, J., van Dam, E. M., Winata, S., Wasinger, V., Simpson, 
 231 
F., Graham, M., Junutula, J. R., Guilhaus, M., and James, D. E. (2005) Characterization of 
the role of the Rab GTPase-activating protein AS160 in insulin-regulated GLUT4 
trafficking. J. Biol. Chem. 280, 37803–13 
295.  Santos, R. A. (2014) Angiotensin-(1-7). Hypertension. 63, 1138–47 
296.  Mendes, A. C. R., Ferreira, A. J., Pinheiro, S. V. B., and Santos, R. A. S. (2005) Chronic 
infusion of angiotensin-(1–7) reduces heart angiotensin II levels in rats. Regul. Pept. 125, 
29–34 
297.  Passos-Silva, D. G., Verano-Braga, T., and Santos, R. A. S. (2013) Angiotensin-(1–7): 
beyond the cardio-renal actions. Clin. Sci. 124, 443–456 
298.  Simionescu, N., Siminoescu, M., and Palade, G. E. (1975) Permeability of muscle 
capillaries to small heme-peptides. Evidence for the existence of patent transendothelial 
channels. J. Cell Biol. 64, 586–607 
299.  WAGNER, R., MODLA, S., HOSSLER, F., and CZYMMEK, K. (2012) Three-
Dimensional Analysis and Computer Modeling of the Capillary Endothelial Vesicular 
System with Electron Tomography. Microcirculation. 19, 477–484 
300.  Prager, R., Wallace, P., and Olefsky, J. M. (1986) In vivo kinetics of insulin action on 
peripheral glucose disposal and hepatic glucose output in normal and obese subjects. J. 
Clin. Invest. 78, 472–81 
301.  Erdei, N., Tóth, A., Pásztor, E. T., Papp, Z., Édes, I., Koller, A., and Bagi, Z. (2006) High-
fat diet-induced reduction in nitric oxide-dependent arteriolar dilation in rats: role of 
xanthine oxidase-derived superoxide anion. Am. J. Physiol. Circ. Physiol. 291, H2107–
H2115 
302.  Pacher, P., Beckman, J. S., and Liaudet, L. (2007) Nitric Oxide and Peroxynitrite in 
Health and Disease. Physiol. Rev. 87, 315–424 
303.  Ghosh, K. K., Burns, L. D., Cocker, E. D., Nimmerjahn, A., Ziv, Y., Gamal, A. El, and 
Schnitzer, M. J. (2011) Miniaturized integration of a fluorescence microscope. Nat. 
Methods. 8, 871–878 
304.  Llewellyn, M. E., Barretto, R. P. J., Delp, S. L., and Schnitzer, M. J. (2008) Minimally 
invasive high-speed imaging of sarcomere contractile dynamics in mice and humans. 
Nature. 454, 784–8 
305.  Levick, J. R., and Michel, C. C. (2010) Microvascular fluid exchange and the revised 
Starling principle. Cardiovasc. Res. 87, 198–210 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 232 
APPENDIX 
 
ImageJ Image Analysis Scripts 
 
 For the scripts below, commands are bolded and comments describing each step are 
italicized. These scripts were developed for specific image file types. While the analysis 
procedures will work on any images, slight adjustments to the scripts may need to be made to 
handle different file types. 
 
Automated CD31+ structure quantification with ImageJ 
 
//define a function called action which can be looped over for each image in a directory 
function action(input, filename){ 
 open(input + filename); 
  
//improve contrast by histogram stretching 
run("Enhance Contrast", "saturated=0.35"); 
 
//de-convolve hematoxylin, eosin, and DAB stains  
 run("Colour Deconvolution", "vectors=[H&E DAB] hide"); 
 
//CD31+ structures are stained by DAB which is Colour 3 by this plugin  
selectWindow(filename+"-(Colour_3)"); 
 
//use Intermodes thresholding method to identify CD31+ structures, thresholding method 
determined empirically 
 setAutoThreshold("Intermodes"); 
 run("Threshold..."); 
 selectWindow(filename+"-(Colour_3)"); 
 
//use particle analysis to count thresholded structures, criteria for determining a structure 
determined empirically  
run("Analyze Particles...", "size=100-Infinity display summarize"); 
 run("Close All"); 
} 
 
//use batch mode to improve the speed of the macro 
setBatchMode(true); 
 
//ask user to choose an input directory 
input=getDirectory("Choose a Directory"); 
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//set a variable that contains the list of files in the directory 
list=getFileList(input); 
 
//run function defined above for every file in the directory 
for(i=0; i < list.length; i++) 
 action(input, list[i]); 
setBatchMode(false); 
 
 
 
Automated vascular and interstitial segmentation with Image J 
 
//use batch mode to improve the speed of the macro 
setBatchMode(true); 
 
//store title of image as a variable called ‘”name”’ 
name=getTitle(); 
 
//determine the measurements you will eventually make on the vessels 
run("Set Measurements...", "area mean redirect=None decimal=3"); 
 
//split stack into separate channels for rho-dex and ins-647 
run("Split Channels"); 
 
//determine properties of the image stack 
Stack.getDimensions(width, height, channels, slices, frames); 
 
//set up loop for all frames and slices 
for (i=1; i<frames+1; i++) { 
 for (j=1; j<slices+1; j++){ 
 
//make sure you are on the right slice and frame; start with the rho-dex channel 
selectWindow("C1-"+name+""); 
 setSlice(j); 
 selectWindow("C2-"+name+"");  
 setSlice(j); 
 selectWindow("C1-"+name+""); 
 Stack.setFrame(i); 
 selectWindow("C2-"+name+""); 
 Stack.setFrame(i); 
  
//use Otsu-thresholding to demarcate vessels 
run("Auto Threshold", "method=Otsu white"); 
  
//create a mask of these thresholded vessels 
run("Create Mask"); 
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//perform some basic morphometric operations on these vessels to make them smoother and 
more continuous 
run("Close-"); 
 run("Open"); 
 run("Median...", "radius=4"); 
  
//have ImageJ only choose vessels with certain characteristics (determined empirically) 
run("Analyze Particles...", "size=50.00-Infinity circularity=0.00-0.50 
show=Masks"); 
  
//create new mask of the vessels 
selectWindow("Mask of mask"); 
 run("Create Selection"); 
 
//apply mask to insulin-647 channel 
selectWindow("C1-"+name+""); 
 run("Restore Selection"); 
  
//measure insulin-647 in the vessels 
run("Measure"); 
  
//go back to original vascular mask and dilate it to segment interstitial spaces 
selectWindow("Mask of mask"); 
 run("Enlarge...", "enlarge=1"); 
 selectWindow("C1-"+name+""); 
  
//move dilated mask back to insulin-647 channel 
run("Restore Selection"); 
  
//measure insulin-647 in this interstitial segment 
run("Measure"); 
  
//repeat this procedure for additional interstitial spaces out to 3µm from the vessel 
selectWindow("Mask of mask"); 
 run("Enlarge...", "enlarge=0.5"); 
 selectWindow("C1-"+name+""); 
 run("Restore Selection"); 
 run("Measure"); 
 selectWindow("Mask of mask"); 
 run("Enlarge...", "enlarge=0.5"); 
 selectWindow("C1-"+name+""); 
 run("Restore Selection"); 
 run("Measure"); 
 selectWindow("Mask of mask"); 
 run("Enlarge...", "enlarge=0.5"); 
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 selectWindow("C1-"+name+""); 
 run("Restore Selection"); 
 run("Measure"); 
 selectWindow("Mask of mask"); 
 run("Enlarge...", "enlarge=0.5"); 
 selectWindow("C1-"+name+""); 
 run("Restore Selection"); 
 run("Measure"); 
  
//close all open windows 
selectWindow("Mask of mask"); 
 close(); 
 selectWindow("mask"); 
 close(); 
 } 
 } 
run("Close All"); 
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MATLAB Mathematical Modeling Scripts and Functions 
 For MATLAB scripts, comments are in green and follow ‘%’ signs. The optimization 
script and “lack of fit” functions change slightly depending on the specific mathematical model 
the imaging data are being fit to. The optimization script and “lack of fit” function shown below 
were used for fitting data to the fluid-phase transport model.  
 
Optimization Script 
 
%Optimization script for regressing simulated data against experimental measurements.  
 
clear; %clears workspace 
close all; %closes any figures that are open 
D=1; F=0.1; k=0.00001; t0=0.25; %initial parameter guesses for fluid-phase transport 
%model. Initial parameter values are different for diffusion and Michaelis-Menten 
%models. 
folder = uigetdir;%prompt user to select directory where data files are 
cd(folder) %change folder to this new folder 
files=dir('*.xlsx'); %pull out the excel files into a structure 
files=extractfield(files, 'name'); %pull the filenames out of the structure 
% and into a cell array 
len=length(files); 
 
fit_start = 1; %distance at which you want to start fitting data (µm from 
%capillary) 
fit_end = 3; %end fitting distance (µm from capillary) 
 
 
%Read in data from excel files and format 
for i = 1:len, 
    [data{i}, txt, raw{i}] = xlsread(files{i});%read excel file; store numerical 
    % data and text headers in separate cell arrays 
    [x_length, t_length] = size(txt); %get dimensions of data set 
    data{i} = cell2mat(raw{i}([2,2*fit_start+1:2*fit_end+1],2:t_length))'; %transpose 
%numerical data and create matrices with experimental measurements 
 
end 
 
%Pull out information from the headers in the excel spreadsheets 
[tok,rem]=strtok(txt); %takes the string data from the header and splits it 
% into 2 cell arrays, tok and rem. tok is the 1st part of the header 
%(the numeric value) and rem is the 2nd part of the header (units) after 
% some kind of delimiter (i.e. space). 
 
t = str2double(tok(1,2:end)'); %construct time vector by selecting the 
% numeric values of the time heading, converting them from a string to a 
% double-precision value (number) and then transposing this matrix 
 
x = str2double(tok([1+2*fit_start:2*fit_end+1],1)); %construct position 
% vector by selecting the numeric values of the position heading and 
% converting them from a string to a double-precision value (number) 
 
tunit=rem{1,2}; %store time units as a character 
xunit=rem{2,1}; % store position units as a character 
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data = cat(3,data{:}); %create measurement matrix by concatenating data from 
%each of the files along the third dimension (z). Each matrix is a 2D 
%matrix (space by time). In order to operate on all of the data at the same 
%time, you stack these matrices on top of each other in the 3rd dimension 
%(i.e. in z). 
 
sd = std(data,0,3); %create standard deviation matrix by taking the standard 
%deviation of the data sets with no weighting factor (0) along the 3rd 
%dimension (3) 
 
sdbar = nanmedian(sd(:)); %find median of standard deviation matrix and store 
%it as sdbar 
 
sd(:) = sdbar; %new standard deviation matrix is a standard deviation matrix 
%fully populated by the median sd. We decided to give all the points equal weight by 
%using the median SD value points with high SD will essentially get ignored during the 
%fitting process and the points with low SD will dominate. The measurements with the 
%highest SD in our case are the very early time points near the capillary, which are 
%our most important measurements. 
 
datanan = data(:,:,any(all(isnan(data),2))); %move data sets with NaNs (missing  
%values) to a new list. This list contains only data sets with NaNs 
 
data(:,:,any(all(isnan(data),2)))=[]; %remove data sets with NaNs from 
%original list. This list of matrices is now only matrices with no NaNs 
 
[m,n,len] = size(data); %get dimensions of non-NaN data set 
 
pout = zeros(5+m,len); %initialize parameter matrix - memory pre-allocation. 
%It's good practice in MATLAB to specify the end dimensions of a matrix 
%that will grow as more calculations are made 
 
chi2 = zeros(1,len); %initialize chi^2 vector, the sum of squares of the weighted 
%residuals. 
 
p0=[D;F;k]; %set up initial parameter vector;  
 
%Randomize initial parameter guesses 
lb = log10(p0) - 3; 
ub = log10(p0) + 3; 
p0a = 10.^(lb + rand(size(p0)).*(ub-lb)); 
 
%Optimization 
for i=1:len,%loop through all the non-NaN files you read in 
    cp=data(:,1,i); %get plasma ins-647 intensity by calling the first column 
    %of data from each matrix 
    p0=[p0a;t0;cp(1);cp]; %include plasma ins-647 values as an adjustable parameter           
%because the time at which they were measured is not known exactly; we will also    
%let the initial time (t0) vary because there is a slight delay between the time of 
%injection and the time at which the first image is collected 
    plb=zeros(size(p0)); %set lower bounds on parameters 
    pub=inf(size(p0)); %set upper bounds on parameters 
    pub(4) = 1; % set max t0 to 0.25 min 
    cdata = data(:,:,i); %pick ith data set 
    cwt = sd; %this is the standard deviation matrix used for weighting residuals 
    options = optimoptions(@lsqnonlin, 'MaxFunctionEvaluations', 50000, 
'MaxIterations',5000); 
    [pout(:,i),chi2(i),r] = 
lsqnonlin(@(p)lof_conv(p,x,t,cdata,cwt),p0,plb,pub,options); 
%This is the optimizer, it will find the best-fit parameter estimates which minimize 
%the difference between experimental measurements and simulated data. The optimizer 
%uses a gradient descent algorithm. The first input is @(p)lof(p,x,t,cdata,cwt). This 
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% ‘lof’ function (‘lack of fit’) is the function to be minimized. The outputs of this 
%function (parameters) are stored to the parameter matrix, the norm of the residual is 
%stored to the chi2 vector, and the residuals are stored to the r vector 
 
    r=reshape(r,m,n); %reshape residual vector into a matrix 
 
    [cout,xout,tout]=sim_conv(x,t,pout(:,i)); %use parameters estimated from 
    %optimization to feed to the model equation to simulate a c(x,t) profile 
     
 
%%%Optimization for data sets with missing values 
 
 
[m2, n2, len2]=size(datanan); %get dimensions of NaN-containing matrix 
[num_nan_total] = size(find(any(isnan(datanan),2)),1); %find total number of NaNs 
 
 
 poutb_final = zeros(m+5, len2); %initialize final parameter matrix for 
 %NaN-containing matrices. This matrix is the same size as the one used for 
 %matrices without NaNs so that they can be merged later 
 chi2b=zeros(1,len2); % initialize chi square array for matrices w NaNs 
 
for i=1:len2,%loop through all the files you read in 
    cdata = datanan(:,:,i); %pick ith data set 
    [num_nan_ind] = size(find(any(isnan(cdata),2)),1); %find number of NaNs in the 
%specific matrix 
    [timenan] = zeros(1, num_nan_total); %initialize vector to store location of NaNs 
    timenan(i:i + num_nan_ind-1) = find(any(isnan(cdata),2)); %locate NaNs and store 
%them inpre-specified vector from step above 
    t = str2double(tok(1,2:end)'); %original time vector 
    t(timenan(i:i+num_nan_ind-1))=[]; %remove time point that's missing from 
%experimental data from the time vector. This will tell the simulation function only 
%to simulate at time points for which we have data 
 
    cdata(any(isnan(cdata),2),:) = []; % Trim NaNs from matrices 
    [m3, n3, len3] = size(cdata); % get size of matrix after removing NaNs 
    poutb = zeros(5+m3,len3);%initialize parameter array for matrices with 
    %NaNs. This parameter matrix only accounts for the size of the 
    %trimmed matrix. This allows lsqnonlin to work. Will resize later after 
    %fitting. 
    cp=cdata(:,1);  
    p0=[p0a;t0;cp(1);cp]; 
    plb=zeros(size(p0));  
    pub=inf(size(p0)); 
    pub(4) = 1;  
    cwt = sd;  
 
%Optimization 
    options = optimoptions(@lsqnonlin, 'MaxFunctionEvaluations', 50000, 
'MaxIterations',5000); 
    [poutb(:,i),chi2b(i),r] = 
lsqnonlin(@(p)lof_conv(p,x,t,cdata,cwt),p0,plb,pub,options); 
     
 
%Parameter matrix formation for NaN-containing matrices 
    poutb_size=zeros(m+5, 1); 
    poutb_sizeb=zeros(m+5, 1); %similar to step above but has NaNs instead of 
    %zeros. Explanation to follow 
    poutb_size(timenan(i:i+num_nan_ind-1)+5)=true; %indicate the place in the re-sized 
    %parameter matrix where there will be a missing value 
    poutb_size = logical(poutb_size); %turn poutb_size into a logical array 
    poutb_sizeb(poutb_size)=nan; %populate the place specified in the step 
    %above with NaN 
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    poutb_sizeb(~poutb_size) = poutb(:,i); %populate the rest of the matrix 
    %with the rest of the parameters 
    poutb_final(:,i)=poutb_sizeb; %add this single parameter array to the 
    %total parameter array for all the NaN-containing matrices; 
 
 
    r=reshape(r,m3,n3); %reshape residual vector into a matrix 
 
    [cout,xout,tout]=sim_conv(x,t,poutb(:,i)); %use parameters estimated from 
    %lsqnonlin to get c(x,t) profile 
 
     
pout_final=cat(2,pout,poutb_final); %concatenate parameter matrices 
chi2f = cat(2, chi2, chi2b); %concatenate chi2 matrices 
 
pav = nanmean(pout_final,2); % average parameter estimates 
psd = nanstd(pout_final,0,2); % standard deviation of parameter estimates 
dof = m*n - length(p0); % degrees of freedom 
disp(''); 
disp(['chi2 = ',mat2str(chi2f,5)]); % display outputs 
disp(['Expected chi2 (95% confidence) = 
',mat2str(chi2inv([0.025,0.975],dof),5)]);%computes the chi-square inverse cumulative 
%distribution function for a certain number of degrees of freedom. This is the 
%expected residual errors for the number of variables we have.  
 
%Display mean and standard deviation of parameter estimates 
disp(['D = ',num2str(pav(1)),' ',char(177),' 
',num2str(psd(1)),xunit,'^2/',tunit(2:end),'; cv=', num2str(psd(1)/pav(1)*100),'%']); 
disp(['F = ',num2str(pav(2)),' ',char(177),' 
',num2str(psd(2)),xunit,'/',tunit(2:end),'; cv=', num2str(psd(2)/pav(2)*100),'%']); 
disp(['k = ',num2str(pav(3)),' ',char(177),' ',num2str(psd(3)),' 1/',tunit(2:end),'; 
cv=', num2str(psd(3)/pav(3)*100),'%']); 
disp(['t0 = ',num2str(pav(4)),' ',char(177),' ',num2str(psd(4)),tunit]); 
disp(['% within range = 
',num2str(nnz(chi2f<chi2inv([0.975],dof))/size(chi2f,2)*100),'%']); 
 
Lack of fit function 
 
%Lack of fit function. Calculate lack-of-fit between experimental and simulated 
measurements. 
 
function r = lof_conv(p,x,t,cdata,cwt) 
 
[n1 n2] = size(cdata); n3=n2-1; %Get size of the experimental data matrix 
%being passed in from lsqnonlin (optimizer). 
t=t(1:n1); x=x(1:n3); %Reshape time and space vectors accordingly. 
cpred = sim_conv(x,t,p); %Simulate intensity-space-time profile from model equation 
%(in this case fluid-phase transport model) based on parameters passed from lsqnonlin. 
 
cwt2 = cwt(1:n1, 1:n2); %Reshape weighting matrix according to size of 
%incoming data matrix. 
 
r = (cpred(:)-cdata(:))./cwt2(:);% Simulated data (cpred) minus experimental 
%measurements (cdata)divided by the weigthing (median standard deviation) matrix. 
%These weighted residuals will then be passed back to the optimizer. 
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Diffusion model simulation 
%Simulate insulin concentration as a function of distance from capillary (x) and time 
%following injection (t) using the diffusion model equation and parameters from 
%optimizer. 
 
function [cout,xout,tout] = sim_dif(x1,t1,p) %Create a function called 
% 'sim_dif' which takes space, time, and model parameters as inputs and generates an 
%insulin concentration-space-time matrix. 
 
D = p(1); P = p(2); k = p(3); t0 = p(4); cp1 = p(5:end); %Unpack parameters from 
%parameter vector. 
 
L=max(x1); T=L^2/D; C=max(cp1); %Define scaling factors. 
 
x = x1/L; t=[0;t1+t0]/T; cp=cp1/C; %Scale data by the scaling factors defined above. 
 
b = P*L/D; d = k*L^2/D; %Combine parameters and scaling factors in such a way that 
$non-dimensionalizes the parameters (i.e. their units cancel). 
 
dt=diff(t)'; %Time interval. 
 
[x,t] = meshgrid(x,t); %Create coordinate system over which you can evaluate and 
$visualize a function of two variables with different ranges. 
 
[m,n] = size(x); % Get dimensions of the coordinate system you just created. 
 
cp=cp(:,ones(1,n)); %Make cp vector match the size of both x and t. In order to later 
%computed the integrand the arrays must be the same size. 
 
c=zeros(m-1,n); %Pre-allocate memory by initializing insulin concentration vector. 
 
 
for i = 2:m  %Loop over time points greater than zero. 
 
    z=t(i(ones(i,1)),:) - t(1:i,:); %Calculate the convolution integral time shift(t-
%tau. 
 
f = b*exp(-d*z).*(exp(-x(1:i,:).^2./(4*z))./sqrt(pi*max(z,eps))... 
   -b*exp(b*x(1:i,:)+b^2*z).*erfc(0.5*x(1:i,:)./sqrt(z)+b*sqrt(z))); 
%Evaluate the exponential terms of the final non-dimensionalized solution to the 
%diffusion model. 
 
y = cp(1:i,:).*f; %Compute full integrand. 
 
c(i-1,:) = 0.5*dt(1:i-1)*(y(1:i-1,:) + y(2:i,:)); %Use trapezoidal integration to 
%evaluate the integral. 
 
end 
 
[xout,tout] = meshgrid([0;x1],t1+t0); %Create an output matrix for the data you just 
%simulated.  
 
cout = [cp1(2:end) C*c]; %Populate output concentration matrix with simulated data. 
 
 
 
 241 
Michaelis-Menten model simulation 
%Simulate insulin concentration as a %function of distance from capillary (x) and time 
following injection (t) using the %Michaelis-Menten model equation and parameters from 
optimizer. 
 
function [cout,xout,tout] = sim_mm(x1,t1,p) %Create a function called 
% 'sim_dif' which takes space, time, and model parameters as inputs and generates an 
%insulin concentration-space-time matrix. 
 
D = p(1); Vmax = p(2); Km = p(3); k = p(4); t0=p(5); cp1 = p(6:end); %Unpack 
$parameters from %parameter vector. 
 
L=max(x1); T=L^2/D; C=max(cp1); %Define scaling factors. 
 
x = x1/L; t=[0;t1+t0]/T; cp=cp1/C; %Scale data by the scaling factors defined above. 
 
g = (Vmax*L)/(D*C); r = Km/C; d = k*L^2/D; %Combine parameters and scaling factors in 
%such a way that $non-dimensionalizes the parameters (i.e. their units cancel). 
 
dt=diff(t)'; %Time interval. 
 
[x,t] = meshgrid(x,t); %Create coordinate system over which you can evaluate and 
$visualize a function of two variables with different ranges. 
 
[m,n] = size(x); % Get dimensions of the coordinate system you just created. 
 
cp=cp(:,ones(1,n)); %Make cp vector match the size of both x and t. In order to later 
%computed the integrand the arrays must be the same size. 
 
c=zeros(m-1,n); %Pre-allocate memory by initializing insulin concentration vector. 
 
for i = 2:m  %Loop over time points greater than zero. 
 
    z=t(i(ones(i,1)),:) - t(1:i,:); %Calculate the convolution integral time shift(t-
%tau. 
 
f = (g./(pi*z)).*exp((d.*z)+ (-x(1:i,:).^2./(4*z))); 
   f(isnan(f))=0; 
%Evaluate the exponential terms of the final non-dimensionalized solution to the 
%Michaelis-Menten model. 
 
y = cp(1:i,:)./(r+cp(1:i,:)).*f; %Compute the full integrand.  
 
c(i-1,:) = 0.5*dt(1:i-1)*(y(1:i-1,:) + y(2:i,:)); %Use trapezoidal integration to 
evaluate the integral. 
 
end 
 
[xout,tout] = meshgrid([0;x1],t1+t0); %Create an output matrix for the data you just 
%simulated. 
 
cout = [cp1(2:end) C*c]; %Populate output concentration matrix with simulated data. 
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Fluid-phase transport model simulation 
%Simulate insulin concentration as a function of distance from capillary (x) and time 
%following injection (t) using the fluid-phase transport model equation and parameters 
%from optimizer. 
 
function [cout,xout,tout] = sim_conv(x1,t1,p) %Create a function called 
% 'sim_conv' which takes space, time, and model parameters as inputs and generates an 
%insulin concentration-space-time matrix. 
 
D = p(1); F = p(2); k = p(3); t0 = p(4); cp1 = p(5:end); %Unpack parameters from 
%parameter vector. 
 
L=max(x1); T=L^2/D; C=max(cp1); %Define scaling factors.  
 
x = x1/L; t=[0;t1+t0]/T; cp=cp1/C; %Scale data by the scaling factors defined above. 
 
b = F*L/D; d = k*T; %Combine parameters and scaling factors in such 
% a way that non-dimensionalizes the parameters (i.e. their units cancel 
% out. 
 
dt=diff(t)'; %Time interval. 
 
[x,t] = meshgrid(x,t); %Create coordinate system over which you can evaluate and 
%visualize a function of two variables with different ranges. 
 
[m,n] = size(x); % Get dimensions of the coordinate system you just created. 
 
cp=cp(:,ones(1,n)); %Make cp vector match the size of both x and t. In order to later 
%computed the integrand the arrays must be the same size. 
 
c=zeros(m-1,n); %Pre-allocate memory by initializing insulin concentration vector.  
 
for i = 2:m  %Loop over time points greater than zero. 
 
    z=t(i(ones(i,1)),:) - t(1:i,:); %Calculate the convolution integral time shift(t-
%tau. 
 
f = b*exp(-d*z).*(exp(-x(1:i,:).^2./(4*z))./sqrt(pi*max(z,eps))); 
 
%Evaluate the exponential terms of the final non-dimensionalized solution to the 
%fluid-phase transport model. 
 
y = cp(1:i,:).*f; %Compute full integrand. 
 
c(i-1,:) = 0.5*dt(1:i-1)*(y(1:i-1,:) + y(2:i,:)); %Use trapezoidal integration to 
%evaluate the integral. 
 
end 
 
[xout,tout] = meshgrid([0;x1],t1+t0);%Create an output matrix for the data you just 
%simulated.  
 
cout = [cp1(2:end) C*c]; %Populate output concentration matrix with simulated data. 
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Intravital insulin-647 imaging protocol 
Imaging materials checklist 
1. Fasting buckets 
2. Large white absorbent pad and 1 small one (per mouse) 
3. Tools: fine-tipped forceps, scissors, hemostats (with and without silicone tubing) 
4. Styrofoam pad for taking tissues 
5. Kimwipes and gauze 
6. Gloves 
7. Blunted injection needles (at least 5 per mouse)  
8. 8 cm micro-renathane tubing with connector for injections 
9. Alcohol swabs  
10. Ketamine/xylazine/acepromazine cocktail 
11. Razor 
12. Custom stage mount 
13. Duct tape 
14. Tetramethylrhodamine-dextran 
a. Make 5 mg/ml stock solution in 0.9% NaCl 
b. Sonicate and spin down to get rid of aggregates 
c. Aliquot and freeze at -20°C 
d. Dilute 5X in 50uL 0.9% saline (10 uL dextran into 40uL saline) 
15. Insulin-647 
a. Make 1mg/ml stock solution in insulin storage buffer + 1% TX (insulin storage 
buffer: 16mg/ml glycerol, 2.5mg/ml m-cresol, 20mM Tris Hcl, pH 7.5) 
b. Add 34 µL 10% TX-100 to 306µL insulin storage buffer 
c. Add 170µL ins storage buffer + TX to 1 vial of insulin-647 (should be 0.17mg 
mass) 
d. Wrap in aluminum foil and shake for 30 minutes 
e. Transfer to Eppendorf tube, transfer label, sonicate in water bath sonicator for 1 
hour 
f. Spin down for 10 min @ 13,000rpm to ensure no aggregation 
g. Dilute 1:100 in 0.9% saline and check absorbance  
i. Use quartz cuvette 
ii. Blank should be 1:100 ins storage buffer + 1% TX in 0.9% NaCl 
iii. Absorbance should be in the 0.25 – 0.35 range 
iv. Calculate insulin concentration in U/ml using the equation: 
Abs*100/239,000*10^6/6 
1. This is just Beer’s law; 100 – dilution factor, 239,000 – molar 
absorptivity coefficient of Alexa Fluor-647; 10^6/6 – unit 
conversion 
h. Check fluorescence on fluorometer with an emission scan (Ex: 633, Em: 650-750) 
i. Emission intensity peak should be over 1 million 
i. Dilute insulin-647 to appropriate concentration based on dose and mouse body 
weight using spreadsheet 
16. [14C]2DG 
a. Dry down tracers 
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17. 0.1% BSA in saline 
18. 0.9% injectable saline 
19. Peristaltic pump 
20. 5% CO2/95%N2 
21. Bicarbonate-buffered physiological saline solution (PSS; make working solution day of 
experiments – 250mL per mouse) 
a. Stock 1 20x (2.638M NaCl, 94mM KCl, 40mM MgSO4, 23.4 mM CaCl2) 
b. Stock 2 20X (360mM NaHCO3) 
c. Mix 12.5ml Stock 1, 12.5ml Stock  2,  225ml H20 per mouse filter 
22. Beaker + stir bar 
23. Heating block 
24. Vacuum setup (Sidearm flask, tubing) 
25. Electric blanket/temperature device 
26. LN2  
27. Styrofoam LN2 bucket 
28. Labeled tubes for tissues (Soleus, gastrocnemius, vastus, liver, epidydimal fat, heart, 
brain) 
29. Labeled tubes for probes/samples (rhodamine dextran, insulin-647, 2DG standard, 
plasma, treatment)  
30. Heparinized capillary tubes for blood collection 
31. Sharps box 
32. Glucose strips 
33. Timer 
34. Lab notebook 
35. ddH2O water bottle 
36. Other potential items depending on the study: hematocrit tubes / clay, syringe pump, 3 
ways, syringes with red tops, additional micro-renathane tubing 
 
Room set-up 
1. Set up body temperature on top shelf of cart control unit and turn on 
2. Put peristaltic pump on top of temperature unit 
3. Put heating block just to the left of the peristaltic pump 
4. Heat PSS to 37°C on heating block and mix 
5. Put influent line of peristaltic pump into PSS 
6. Hook up tubing to 95%N2/5%CO2; put pipette tip end into PSS and bubble for ~5 
minutes before starting experiment 
a. Tape gas tubing to PSS bottle 
7. Set-up vacuum trap 
a. Sidearm connected to vacuum line with tubing 
b. Vertical arm (serological pipette) connected to port on stage mount with tubing 
c. Turn on vacuum 
8. Clean coverglass with water, sparkle, water, then dry with kimwipes 
9. Take off condenser with screwdriver and set to the left 
10. Move objective to lowest position (rotate focus knob towards you) 
11. Clean 20X W 0.8NA lens gently with lens paper and cotton-tipped applicator 
12. Put custom stage mount in the correct holder on the microscope 
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13. Tape effluent line to stage mount so that pipette tip releases PSS at the bottom right 
corner of coverglass 
14.  Put everything for mouse preparation and tissue collection on table 
a. Plug in razor 
15.  Put liquid nitrogen, Styrofoam bucket, and freezer clamps under table 
 
Probe preparation 
1. Dilute 2Mda tetramethylrhodamine-dextran (5mg/ml) 5x in 50uL saline (10 uL dex into 
40 uL saline) 
2. Make insulin-647 in 0.1% BSA according to dilution spreadsheet 
3. Store on ice and covered in tinfoil until use 
 
Microscope set-up 
1. Turn on switches in the order that they are labeled:  
a. Main power source (1) 
b. Main power key (2) 
c. Argon laser control  (3a) 
d. Argon laser power supply (3b)  
e. Components power supply (4) 
f. PC power supply (5) 
g. Argon laser – turn from standby to on, turn knob to the right until red light comes 
on then turn back down until it becomes green (6) 
h. Mercury lamp (7) 
2. Use touch pad to ensure that 20X W 0.8NA lens is selected 
3. Move objective to lowest Z position 
4. Open Zen software 
a. Have to also click “Start System” 
5. Turn on lasers 
a. Acquisition tab ® Laser dialog box ® switch DPSS-561 and HeNe633 to “on” 
6. Load settings 
a. Depends on the experiment being run (either 1, 2, or 4U/kg insulin-647) 
 
Syringes 
1. Fill up 2 syringes with 0.9% NaCl 
a. Connect 1 to 8 cm microrenathane tubing with connector (flush line) 
2. Fill up rhodamine-dextran syringe 
3. Fill up insulin-647/2DG syringe - combined 
 
Mouse preparation and mounting 
1. Hook up micro-renathane tubing + connector to venous catheter; check to see if it is 
drawing/infusing with saline 
2. Anesthetize mouse with ketamine/xylazine/acepromazine cocktail 
a. Inject ~40ul (obese) or ~30ul (lean) per mouse to start  
b. Give 20µL before putting mouse on stage 
c. Give 20µL ~3 minutes before experiment 
d. Give additional boosters as necessary 
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3. Lay mouse on heating blanket 
a. Try to keep mouse on heating pad as much as possible but may have to take off 
for certain procedures 
4. Shave right leg 
a. Wipe away hair with gauze / alcohol swabs 
b. Very important to make sure there is absolutely no hair anywhere near the prep 
5. Expose lateral gastrocnemius on left leg 
a. Make notch in skin near Achilles tendon 
b. Grab notch with hemostat and pull skin off of the leg 
c. Cut away skin 
d. The muscle you are looking for is lateral to the tibia (lateral gastroc); it forms a 
triangular region on the side of the leg 
e. Remove fascia with fine tipped forceps and scissors so that fibers are exposed 
(check under dissecting microscope if necessary) 
i. Pull up fascia and make an incision, there is a pocket underneath 
ii. Cut out the fascia from the entire lateral gastrocnemius 
iii. Be sure not to nick blood vessel towards the bottom of the exposed tissue 
region 
f. During gastrocnemius preparation, keep leg hydrated with 0.9% saline 
6. Situate mouse on coverslip platform 
a. Start superfusion 
b. Lay mouse on its side so the exposed lateral gastrocnemius is flush against the 
coverslip 
c. You want as much of the body of the mouse off the stage mount as possible (helps 
with breathing-induced motion artifacts 
d. Try to get the heel situated so that it is fully on the coverslip; trap the toes against 
the side of the coverglass so that the leg can’t raise up 
i. Can tape down leg if necessary 
7. Insert rectal probe 
a. Grab by the flexible part; run down at the same angle as the tail to insert into 
rectum 
b. Tape down 
8. Put heating blanket on top of the mouse 
a. Get nice wrap around mouse by fitting the edge of the heating blanket into the 
back of the stage mount 
b. Put ~1/2-filled water glove (not too heavy) on top of heating blanket to further 
stabilize mouse 
 
Locating vessels 
1. Select Locate tab in the top left 
2. Select the GFP filter  
3. Turn on reflected light to desired intensity (12%) 
4. Bring objective down away from the mouse and look underneath the coverglass to get in 
the approximate area of the tissue (will look whitish under the blue light) 
5. Bring objective close to the coverslip 
6. Use eyepieces to ensure quality of preparation and mouse situation 
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a. Exposed tissue should be in the same focal plane (roughly) 
b. Not too much movement 
c. If you don’t meet either of these criteria, I would recommend re-situating the 
mouse to get its leg pressed and held down more securely against the coverslip 
7. Turn off reflected light 
8. Inject rhodamine-dextran and chase with saline 
9. Select FS43 HE filter to view the red dextran and turn on reflected light 
10. Focus up and down and select a region with parallel capillaries that can be seen clearly 
a. Capillaries should be sharp – should be able to see blood flowing 
b. Go above and below the focus plane to make sure there are no large feeder vessels 
in the vicinity 
c. Make sure there are no hairs 
d. Region with vessels in several different focal planes is ideal 
11. A good area for lots of clear vessels can be found by going to the far left of the exposed 
gastrocnemius, locating some big post-capillary venules and then looking below them 
and to the right 
 
 
 
 
 
 
 
 
 
 
 
Imaging  
1. Switch to Acquisition tab 
2. There are at least 3 different imaging settings saved (depends on dose of insulin-647 you 
use) 
a. For any given experiment, use the same imaging settings for all the mice in that 
experiment 
3. In the “channels” dialog box uncheck the AF647 track, leaving only the Rhod channel 
checked 
4. Scan Rhod channel in Live mode to view vessels 
5. Set up z-stack 
a. Focus up to the coverslip (focus knob towards you) and then back down to the 
first vessels (focus knob away from you) that appear; click set first 
b. Move down (focus knob away from you) 16µm and click set last - this will 
depend on the specific experiment – some experiments will have larger depths 
than others 
a. Interval should be set to half of the pinhole width (usually 4µm) 
b. Make sure you have 4 slices (depends on experiment) 
12.  Click Start experiment to acquire dextran image + insulin-647 background 
 
Region to 
image 
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Imaging 
1. Inject insulin-647/2DG slowly; chase with ~30uL of saline 
2. Manually acquire z-stack every minute for 15 minutes 
a. Acquire image ~ 10 seconds before the minute (i.e. 50 sec, 1min 50 sec, etc) – 
Start Experiment,  
b. Split, Save, Close previous point, open new blank image 
c. Make sure sufficient “New Acquisition Documents” are open and ready at all 
times 
d. Make sure you are saving the correct image in the right hand panel 
e. Can scan in live mode to make sure focal plane hasn’t drifted. This is done by 
finding a distinctive feature in the image and keeping that in focus throughout the 
time course 
 
Taking tissues and plasma 
1. Take ~ 200-300 uL whole blood from tail vein into microvettes 
2. Excise soleus, gastrocnemius, vastus, liver, epididymal fat, heart, and brain 
a. Freeze clamp and place in LN2 
 
Cleaning up prior to next experiment 
1. Wrap up mouse carcass in absorbent pad and put in fasting bucket 
2. Wipe off tools with alcohol swab 
3. Clean off coverglass with water, sparkle, water 
 
